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ABSTRACT 
 
Abigail H. Turner: Intracellular Epidermal Growth Factor Receptor Tyrosine Kinase 
Assays at the Single Cell Level Using Capillary Electrophoresis 
(Under the direction of Nancy L. Allbritton)
 
Quantification of abnormal Epidermal Growth Factor Receptor (EGFR) 
tyrosine kinase activity is critical to the clinical success of targeted inhibitors used to 
treat EGFR-dependent cancers. Current selection criteria based on the presence or 
absence of activating mutations in the EGFR gene need to be supplemented with 
complementary assays which quantify EGFR biochemical activity in intact living 
cells. While in cellulo EGFR activity can be measured to great success in tissue 
cultured cells using genetically encoded reporters, such techniques are incompatible 
with small, highly heterogeneous tumor samples. A chemical cytometry approach to 
direct EGFR activity measurements is presented which consists of an in cellulo 
peptide reporter-based kinase assay coupled to ultrasensitive microelectrophoretic 
analysis. The major challenge to such a measurement is biological assay interference 
from off-target enzymes. A novel approach to minimizing selectivity-based assay 
interference and its application in single intact cells is presented.
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CHAPTER 1: IMPORTANCE OF EGFR KINASE ACTIVITY MEASUREMENTS 
AT THE SINGLE CELL LEVEL 
1. Introduction 
1.1 Enzymes and Their Role in Oncogenic Transformation 
 Enzymes are protein catalysts that enable the chemical reactions necessary for 
cellular function. The chemical reactions catalyzed vary widely, including 
oxidation/reductions, structural rearrangements, and hydrolyses. The basic model of 
an enzymatic reaction is outline in Equation (1). 
 E + S  E + P (1) 
In this model, the enzyme E recognizes the substrate S and catalyzes its conversion 
to the product P. The activity of an enzyme, defined as moles of product generated 
per unit time, is a complex function of protein conformation, protein-protein 
interactions, substrate and product concentrations, and the presence of co-factors, 
activators, and inhibitors.1 In healthy cells, enzyme activity levels are dynamic and 
tightly controlled, poised to respond to a stimulus and subsequently to return to 
basal levels.2,3 Disease phenotypes can often be traced to one or more abnormal 
enzyme activities. Perhaps the best understood example of this is the hyper- 
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-activation of protein kinases in cancer.4 
Protein kinases effect the phosphorylation of protein or peptide substrates by 
catalyzing the transfer of the γ-phosphoryl of ATP to the hydroxyl of functional 
serine, threonine, or tyrosine residues. Protein phosphorylation functions to 
modulate enzyme activity and is a primary mechanism of information propagation 
in intracellular signaling networks.5,6 Abnormally high activity of some protein 
kinases can lead to dysregulated signaling in key networks governing such cellular 
functions as growth, proliferation, and survival, ultimately leading to malignant 
cellular transformation and disease.4 
1.2 Oncogenic EGFR Activity 
The Epidermal Growth Factor Receptor (EGFR) is a receptor tyrosine kinase 
that promotes growth and proliferation in response to growth factor binding.7 EGFR 
is comprised of three domains, represented in Figure 1A: an extracellular ligand-
binding domain, a transmembrane domain, and an intracellular tyrosine kinase 
domain with an unstructured C-terminal tail. EGFR is one of a family of four 
structurally related transmembrane receptor tyrosine kinases (RTKs) that make up 
the Human Epidermal Growth Factor Receptor (HER) Family. These kinases are 
highly homologous in the kinase domain,8 but differ significantly in their ligand 
selectivity.9 Ligand binding to EGFR, HER3, or HER4 induces a conformational 
change in the extracellular domain and promotes receptor dimerization with one of 
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the other HER family members.10 Homo- or hetero-dimerized receptors then 
perform reciprocal trans-phosphorylation of tyrosine residues in the intracellular tail 
region of the kinase domain.11 These phosphotyrosine residues serve as docking 
sites for downstream signaling proteins, which bind at these sites through their SH2 
domains and are recruited to the kinase domain for phosphorylation and activity 
modulation.7  
The identity of the activating ligand and the composition of the receptor 
dimer determines which tyrosine residues within the tail are phosphorylated and, 
therefore, which intracellular signaling pathways are activated.5 EGFR-containing 
dimers initiate four key signaling pathways controlling growth and proliferation: 
PI3K/Akt/mTor, Ras/MEK/ERK, JAK/STAT, and PLC (Figure 1B).12 In healthy cells, 
EGFR signaling is kept in check by protein phosphatases, which catalyze 
dephosphorylation, and by the cell’s protein metabolism machinery, which recycle 
proteins into their constituent amino acids.5 Uncontrolled EGFR signaling can lead 
to inappropriate hyperactivation of EGFR-dependent signaling networks, resulting 
in uncontrolled proliferation and oncogenesis. Aberrant EGFR signaling has been 
documented in a range of epithelium-derived cancers including non-small cell lung, 
breast, colorectal, pancreatic, head-and-neck, and some gliomas.9 Oncogenic EGFR 
signaling typically results either from overexpression of the EGFR protein or from 
one or more activating mutations in the EGFR gene, leading to constitutive, growth 
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factor-independent activation of the EGFR kinase domain and unregulated signaling 
in downstream networks. 
1.3 Targeting EGFR in the Clinic  
In a healthy cell, loss of activity in one signaling network is compensated by 
redundant parallel pathways to maintain homeostasis.13 Tumor cells, in a 
phenomenon termed oncogene addiction, rely so heavily on one aberrant activity 
that inhibition of that activity results in cell death.14,15 This constitutes an important 
therapeutic opportunity in tumors where the oncogene can be identified. For EGFR-
reliant tumors, a set of targeted EGFR inhibitors is routinely employed in the clinic. 
These drugs fall into two classes: monoclonal antibodies and small molecule 
tyrosine kinase inhibitors.16 Anti-EGFR monoclonal antibodies bind the EGFR 
extracellular domain to prevent receptor dimerization and activation, whereas the 
small molecule TKIs dock in the kinase domain (KD) ATP binding site to directly 
inhibit EGFR kinase activity. Theoretically, these targeted inhibitors should 
selectively induce apoptosis in EGFR-dependent tumor cells, leaving normal cells 
(with normal signaling redundancies) unharmed and resulting in fewer deleterious 
side effects compared with cytotoxic chemotherapy. In reality, while they are 
accompanied by fewer and less severe side effects compared with untargeted 
cytotoxic chemotherapy, these drugs fail to live up to their full potential.17 A review 
of studies of a small-molecule EGFR inhibitor found that 32% of patients with 
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advanced EGFR mutation-positive non-small cell lung cancer failed to respond to 
treatment.18  
The variable clinical success of EGFR inhibitors can in part be attributed to 
inadequate selection criteria when determining patient eligibility for anti-EGFR 
therapy. The most recent guidelines for clinical EGFR testing recommend analysis of 
primary tissue with PCR amplification followed by mutation specific sequencing 
(e.g. Sanger, capillary electrophoresis, real-time PCR) to test for the presence of 
activating mutations in the EGFR gene.18 Despite a positive correlation between 
detection of EGFR mutations and response to EGFR TKIs, a subpopulation of 
patients who are EGFR-positive fail to benefit from targeted therapy. Additionally, a 
small number of patients receive a survival benefit from anti-EGFR therapy despite 
testing negative for EGFR mutations.18  
A major flaw of the current testing methodology is the use of genetic 
information as a proxy for actual enzyme activity. Abnormal EGFR signaling driven 
by hyperactivation of the kinase is not directly related to the presence of an 
activating mutation; rather, many layers of regulation exist between genetic 
mutation and observed activity including transcriptional and translational 
mechanisms and functional post-translational processing of the protein. Therefore, 
the simple presence of an activating EGFR mutation in a tumor genome is a 
potentially inaccurate gauge of abnormal kinase activity and, consequently, an 
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inadequate predictor of response to anti-EGFR therapy. Genetic analyses need to be 
supplemented with complementary assays that directly quantify EGFR kinase 
activity in patient samples. Additionally, the determinants of kinase activity can 
differ in each cell, resulting in highly heterogeneous signaling even in apparently 
homogeneous samples. Therefore, activity measurements need to be adaptable to 
the single cell level so that rare drug- sensitive or drug-resistant populations are not 
obscured.  
1.4 Overview of Kinase Activity Assays 
 In this section, the basic theory of kinase activity measurements is explored. 
Practical considerations for experimental design and implementation are discussed, 
followed by a brief treatment of the theoretical foundations underpinning current 
modeling and interpretation of kinase activity data. 
1.4.1 Basic Requirement for Kinase Activity Measurements  
Direct measurements of kinase activity, or kinase assays, can be accomplished 
by an impressive range of technologies developed over the course of the last century. 
Fundamentally, these technologies measure either the consumption of substrate (dS) 
or the evolution of phosphorylated substrate (dP), typically as a function of time (-
dS/dt = dP/dt). Kinase assay design is a complex bioanalytical goal, the pursuit of 
which has resulted in the development of an enormous variety of assay platforms. 
The components of a kinase assay depend on the sample matrix and assay platform; 
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a brief summary of common assay platform components is presented in Table 1. The 
minimum requirements for any kinase assay are as follows: 
 Kinase 
 Phosphorylatable substrate 
 ATP 
 Divalent metal cation (Mg2+ or Mn2+) 
 Buffer/stabilizers 
 Detection method 
The source of the kinase to be assayed will largely determine the assay sample 
matrix and the available detection platforms. Many assay platforms are not 
compatible with physiological samples (cell lysates, intact cells) because endogenous 
species in the sample matrix interfere either with the kinase reaction itself or with 
the detection method. Therefore assay platforms are generally divided into three 
classes: in vitro assays with purified kinase, in cellulo assays in cellular lysates, and in 
cellulo assays in living cells.  
1.4.2 Source of Kinase and Sample Matrix 
 In choosing a source of kinase and assay platform, the biological relevance of 
the experiment must be balanced against the need for experimental transparency, as 
well as practical considerations of difficulty, cost, and available instrumentation. 
Clearly, if true biological kinase activity needs to be measured, an in cellulo or in vivo 
model is the best option. However, in cellulo assays are highly complex, not only in 
their implementation, but also in interpretation of results. Additionally, control of 
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experimental variables is limited, thereby limiting the precision of the hypotheses 
that may be explored. Often, in vitro assays with purified kinase prove to be the 
most practicable choice for routine biochemical analyses such as kinetic experiments 
and inhibitor screens because they afford the researcher full control over sample 
matrix, assay conditions, and assay variables.  
1.4.3 Kinase Substrate Choice  
The kinase substrate may be chosen from a range of options, depending upon 
the particular assay format and other experimental requirements and constraints. 
These include: 1) full-length or partial protein, 2) random amino acid polymers,19 
and 3) short tryptic or synthetic peptides.20-22 Early kinase assays employed full-
length proteins such as histone as the kinase substrate20; where the protein used is an 
endogenous substrate for the kinase of interest, native specificity can be 
approximated. Specificity is particularly an important consideration in complex 
sample matrices such as cellular lysates where the substrate is subject to interference 
from off-target enzymatic activities such as phosphorylation by off-target kinases, 
dephosphorylation by protein phosphatases, and metabolism by proteolytic 
enzymes. Where specificity is not a consideration or is undesirable, random amino 
acid polymers can be an inexpensive and robust alternative. These are large 
macromolecular polymers containing a fixed percentage of phosphorylatable 
residues in a simple background of nonreactive amino acids. The most popular 
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example of this is poly-Glu(Tyr) (4:1), a random polymer containing one mole of 
tyrosine for every 4 moles of glutamic acid. Such polymers show very broad 
specificity profiles due to a lack of refined structural characteristics. However, prior 
to the availability of inexpensive peptide substrates, poly-Glu(Tyr) and similar 
polymers were commonly employed when protein substrates were cost or time-
prohibitive.  
Macromolecular substrates have generally fallen out of favor as technology 
has progressed, particularly for in vitro work. First, advances in peptide synthesis, 
specifically the invention of solid phase peptide synthesis by Merrifield in the 
1960s,23,24 have made custom peptide substrates widely commercially available and 
affordable. Second, whereas the macromolecular kinase substrates often contain 
multiple phosphorylation sites which make kinetic analyses difficult,25 peptide 
substrates have user-defined sequences with any desired number of 
phosphoacceptors. Peptide substrates are usually quite small, containing 15 or fewer 
amino acids. This size regime is advantageous because it results in excellent 
solubility and very high stability over the course of the assay, improving 
experimental robustness. Perhaps the most important advantage of peptide 
substrates over other classes of substrates is the ease with which peptides can be 
customized to suit both the target kinase and the experimental technique. For 
example, labeling of synthetic peptides with fluorophores or other moieties to 
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enable detection has become a trivial task for which most labs are sufficiently 
equipped. Importantly, the wide availability of fluorophore-labeled peptide 
substrates has precipitated the development of a host of fluorescence and 
luminescence-based assay platforms and greatly facilitated massively high 
throughput screening assays that have become foundational in academic and 
industrial drug discovery labs. 
1.4.4 Basic Kinetic Theory 
A theoretical understanding of kinase activity is grounded in measurements 
of reaction rate. Consequently, most kinase assays incorporate some temporal 
component, whether by continuously monitoring the kinase reaction over time, or 
by taking measurements at multiple fixed time points. A robust kinetic model of a 
kinase’s activity allows perturbations to that activity to be accurately assessed. This 
is particularly important when evaluating potential therapeutic interventions such 
as kinase agonists and inhibitors. The Michaelis-Menten model of enzyme kinetics26 
is often invoked to model kinase reactions. Dating to the early twentieth century, the 
Michaelis-Menten model describes the kinetics of an enzymatic reaction of the form: 
 𝐸 + 𝑆
𝑘1
⇔𝐸𝑆
𝑘𝑐𝑎𝑡
→  𝐸 + 𝑃 (2) 
Here the enzyme E and substrate S form a reversible complex ES, followed by the 
conversion of substrate to product P and dissolution of the ES complex. The 
k-1 
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Michaelis-Menten model assumes that the enzymatic reaction conforms to the 
standard quasi-steady state assumption (sQSSA), which requires that the 
concentration of the enzyme substrate complex is essentially constant in time.27 In 
the traditional treatment, this is interpreted as a requirement that the consumption 
of substrate is negligible (≤ 5 %) over the course of the experiment. An additional 
requirement for this treatment is that the initial reaction rate must increase linearly 
with enzyme concentration. Invoking the sQSSA with regard to (2), the following 
equation describing the reaction rate v can be derived: 
 𝑣 =
𝑑𝑃
𝑑𝑡
=
𝑘𝑐𝑎𝑡[𝐸]0[𝑆]
𝐾𝑀 + [𝑆]
=
𝑉𝑚𝑎𝑥[𝑆]
𝐾𝑀 + [𝑆]
 (3) 
where [E]0 is the total enzyme concentration. Two derived parameters are used to 
describe reactions conforming to the Michaelis-Menten model. The Vmax is the 
maximal rate of reaction, equivalent to the kcat (2) multiplied by the total enzyme 
concentration and corresponding to the maximal rate limited by the number of 
available enzyme active sites. The KM is a ratio of kinetic constants that is often 
treated analogously to a binding equilibrium constant, although it is not in fact an 
equilibrium constant unless the system being modeled is at equilibrium under the 
experimental conditions used. It is more correct to interpret the KM as the substrate 
concentration at which the enzyme’s catalytic power is most efficiently utilized. It is 
therefore a good approximation of the endogenous intracellular substrate 
concentration. Generally speaking, a substrate of a given enzyme is considered 
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“good” if the KM describing their interaction is in the low micromolar or smaller. The 
parameters KM and kcat are useful for comparing enzyme and substrate behavior 
under varied conditions. The ratio kcat/ KM is commonly invoked to directly compare 
multiple substrates of one enzyme or the efficiency of phosphorylation of one 
substrate by multiple enzymes. For this reason, the ratio is often referred to as the 
“specificity constant”. A large specificity constant implies that the substrate is 
phosphorylated rapidly and with a good degree of selectivity. When comparing one 
substrate and two enzymes, the substrate is said to be selective for one enzyme over 
another when the specificity constant for that enzyme is significantly larger.  
 Perturbations to an enzymatic reaction, e.g. addition of agonists or inhibitors, 
will affect the measured kinetic parameters. This allows the experimenter to derive 
mechanistic information about the perturbing species. This is particularly useful 
when evaluating kinase inhibitors because the mechanism of inhibition will affect 
the inhibitor’s behavior and efficacy in vivo. A competitive inhibitor, one that 
competes with endogenous substrates for binding to the enzyme active site, will 
diminish the measured Vmax and increase the measured KM. A non-competitive 
inhibitor, on the other hand, will reduce the measured Vmax, but will not affect the 
measured KM. An uncompetitive inhibitor, one that binds and inactivates the ES 
complex, will decrease both the measured KM and Vmax.28 Clearly, robust kinetic 
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assays interpreted through the appropriate model can yield a wealth of information 
about enzymatic behavior and response to perturbation. 
 The classical approach to estimating Michaelian kinetic parameters requires 
measuring initial reaction rate at a series of substrate concentrations to generate a 
Michaelis-Menten kinetic curve (Figure 2). The experimental points are then fit using 
nonlinear regression to (3), using KM and Vmax as fit parameters. The kcat is derived 
from Vmax and the total concentration of enzyme. In order to satisfy the sQSSA with 
this approach, the experiment must be engineered such that the total substrate 
present is approximately equal to the amount of free substrate available: 
 [𝑆]0 = [𝑆] + [𝐸𝑆] + [𝑃] ≈ [𝑆] (4) 
Consequently, the reaction should only be followed to ≤5% completion in order to 
ensure that the rate measured is truly an initial rate. The initial rates method is the 
gold standard because it is mathematically straightforward and experimentally 
simple to implement. Additionally, because product formation is only followed over 
a very small portion of the reaction course, or “progress curve”, confounding 
experimental problems such as reagent instability and product inhibition are 
avoided.29 However, the initial rate method is costly in terms of time, labor, and 
reagents, and it cannot exploit the information contained in the discarded 95% of the 
progress curve. Furthermore, since this approach essentially involves taking the 
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derivative of progress curve data, it is fundamentally prone to magnifying 
experimental error. 
 Efforts to derive KM and kcat by fitting complete progress curves date back to 
the seminal report by Michaelis and Menten in 1913, in which the authors integrated 
equation (3) to describe time-dependent formation of product. The integrated or 
time-dependent Michaelis-Menten (5) comprises a linear term describing product 
formation at high [S] (e.g. >> KM), and a logarithmic term which models product 
formation at low [S] (<< KM). 
 𝐾𝑀 ∙ 𝑙𝑛 (
[𝑆]0
[𝑆]0 − [𝑃](𝑡)
) + [𝑃](𝑡) = 𝑉𝑚𝑎𝑥 ∙ 𝑡 (5) 
This equation is difficult to fit accurately because the independent variable cannot be 
isolated from the dependent variable. Attempts to derive KM and Vmax from 
linearized plots of equation (5) have been made but are error-prone and unpopular. 
An alternative solution to the integration of (5) is given in (6).30,31 
 [𝑃](𝑡) = [𝑆]0 − 𝐾𝑀 ∙ 𝑊 {
[𝑆]0
𝐾𝑀
𝑒𝑥𝑝 (
[𝑆]0 − 𝑉𝑚𝑎𝑥 ∙ 𝑡
𝐾𝑀
)} (6) 
where W is the Lambert function, such that: 
 𝐹𝑜𝑟 𝑦 + 𝑙𝑛(𝑦) = 𝑙𝑛(𝑥) (7) 
 𝑦 = 𝑊(𝑥)  
Use of the Lambert function allows the dependent variable P(t) to be isolated from 
the independent variable, thus reducing error in modeling. Few non-linear 
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regression programs are equipped to solve the Lambert function, but several useful 
analytical approximations have been published which are simple to implement in 
common software such as OriginLab or GraphPad.30-35 Because progress curve 
analysis takes into account the entire reaction course, an individual progress curve 
experiment contains >90% more information than a corresponding initial rates 
experiment. Theoretically, this means that fewer progress curve experiments should 
be needed, compared with initial rates experiments, to obtain the same information. 
The shape of a kinase reaction curve describes not only the phosphorylation event, 
but also contributions from activators, inhibitors, interferents, competing enzymatic 
reactions, substrate inhibition, reagent instability, and any other phenomena 
observable by the assay technique employed. This leads to fewer overall 
experiments performed, less reagent consumption, and less time and labor 
expenditure. The barrier to widespread implementation of progress curve analysis 
has undoubtedly been the need for complex mathematical models to describe the 
shape of the observed reaction curves, accompanied by the requirement for 
considerable computational resources. However, technological advances in the last 
decade have made essentially negligible the computational burden for progress 
curve analysis. Concomitantly, many specialized software packages have been made 
available, with varying degrees of user-friendliness, to facilitate complex model 
development for progress curve analysis.29,36-40 Nevertheless, progress curve analysis 
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takes time to implement successfully—time which many laboratories are not willing 
to expend in order to “fix what isn’t broken”. Progress curve analysis has remained 
largely a niche technique, applied in situations where the benefits of the technique 
sufficiently outweigh the inertial burden of supplanting initial rates analyses.  
 Most in vitro assay platforms will support either initial rates or progress curve 
analyses, although continuous assays are particularly well-suited to progress curve 
analysis because a large number of data points can be collected with minimal effort 
on the part of the researcher. The majority of in vitro assays are fixed time-point 
assays, which are compatible with kinetic and mechanistic studies as described 
provided that it is possible to make measurements at multiple time points. The 
following sections describe the common assay platforms employed to measure 
EGFR kinase activity in vitro using purified kinase, in cellulo using cellular extracts or 
fixed cells, and in cellulo in live cells.  
1.5 Assay Platforms for Direct Measurement of EGFR Kinase Activity 
In the following sections, a brief review of EGFR kinase activity assays is 
provided. The review focuses on how these assays are practically utilized and aims 
to illustrate the types of experimental questions each technique is useful to answer. 
Assay limitations are also discussed. Table 2 summarizes the assays discussed. 
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1.5.1 In Vitro Radiometric Assays  
 In vitro EGFR assays fall into two classes based on the detection method used: 
radiometric assays using radiolabeled ATP and fluorescence/luminescence-based 
assays. Radiometric assays have historically been the preferred platform for kinase 
activity assays due to their simplicity, robustness, and sensitivity, and are 
considered the gold standard for measuring EGFR kinase activity.25 However, 
radiometric assays are expensive and hazardous to human health and to the 
environment. Therefore, non-hazardous assays using fluorescence or luminescence 
readouts have supplanted radiometric assays in recent years, particularly for high 
throughput applications.  
 Radiometric kinase assays measure the incorporation of 32P or 33P from 
radiolabeled ATP into peptide or protein substrates. In a typical assay, kinase, 
substrate, ATP, and radiolabeled ATP are co-incubated in solution, followed by 
spotting of the assay mixture onto a negatively-charged phosphocellulose 
membrane. The anionic membrane captures the protein or peptide substrate, which 
either natively or by design contains a cationic binding sequence. The membrane can 
then be extensively washed to remove excess radiolabeled ATP before treating the 
membrane with scintillant and detecting the emitted photons. This approach was 
applied by Rusnak and colleagues to characterization of an EGFR/Her2 inhibitor 
GW2016 (lapatinib, Tykerb®, GlaxoSmithKline).41 Radiometric assays using peptide 
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substrates were used to compare inhibition of a panel of kinases by GW2016 and 
explore inhibitor selectivity. GW2016 has since become a successful targeted drug 
used to treat various forms of metastatic breast cancer.  
 More recently, Anastassiadis and colleagues42 reported the use of a 
radiometric “HotSpot” assay to generate a comprehensive map of kinase inhibitor 
selectivity. The authors assayed a panel of 300 kinases including EGFR for inhibition 
by nominally selective targeted inhibitors using an automated radiometric assay 
platform. The authors compared the inhibitor selectivity scores obtained with their 
radiometric assays to similar studies using kinase-inhibitor binding assays and 
found that the binding assays were prone to both false positives and false negatives. 
The authors were also able to comprehensively profile the selectivity of 178 kinase 
inhibitors with good coverage across the kinome and to generate selectivity maps to 
guide future use of these inhibitors. Interestingly, the authors found that a 4,6-
dianilinopyrimidine EGFR inhibitor displayed the greatest degree of “uni-
specificity,” inhibiting substrate phosphorylation by EGFR by more than 94% while 
inhibiting the next most susceptible target by only 22%. Because the authors used 
radiometric assays, they were able to directly quantify substrate turnover by the 
kinase panel. Therefore they were able to unambiguously and accurately assess the 
influence of the inhibitor panel on kinase-mediated substrate turnover with minimal 
interference to confound results and generate false positives or negatives.  
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1.5.2 In Vitro Fluorescence/Luminescence-Based Assays 
 Use of radiometric assays for high-throughput studies such as that described 
above are uncommon because disposal of such a large quantity of hazardous waste 
can become cost prohibitive. More commonly, fluorescence/luminescence based 
platforms are employed. An impressive variety of such platforms have been 
reported25,43,44—far too many to be described here. The reader is referred to a series of 
reviews which comprehensively cover in vitro measurement of kinase activity using 
fluorescence or luminescence-based platforms. Here, selected examples of the most 
common assay platforms that have been applied to measurement of EGFR activity 
are recommended to the reader’s attention. 
 Generally, fluorescence/luminescence kinase assays are divided into those 
that use phospho-specific antibodies to detect phosphorylation and antibody-free 
methods. Of these, the antibody-dependent methods are the most common. Li and 
colleagues applied a commercially available homogeneous time-resolved 
fluorescence (HTRF) assay (KinEASE, CisBio) to the in vitro characterization of novel 
EGFR inhibitors.45 Here, a short peptide substrate, biotinylated at the N-terminus, is 
phosphorylated by EGFR. Streptavidin labeled with a specialized FRET acceptor 
binds the biotinylated peptide, while an anti-phosphotyrosine antibody binds only 
phosphorylated peptide. The antibody is labeled with a Europium cryptate FRET 
donor. Excitation of the Eu complex around 320 nm leads to short-range energy 
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transfer (< 9 nm) to the FRET acceptor, which emits long-lived fluorescence at 665 
nm. Because the emission lifetime is comparatively long, time-resolved 
measurements which allow for decay of short-lived background fluorescence are 
possible. This significantly improves the signal-to-background ratio of the assay. Li 
and colleagues applied the HTRF assay to determine IC50 values for a large panel of 
novel EGFR inhibitors coupled to bioprobes and were able to show improved 
potency of bioprobe-coupled inhibitors compared with their uncoupled parent 
compounds. Because the HTRF assay is homogeneous and highly miniaturizeable, it 
is well suited to such large-scale studies where reagent consumption and laborious 
wash steps can be prohibitively resource expensive. Nevertheless, antibody-
dependent kinase assays are limited by the availability of selective detection 
antibodies. Furthermore, these assays are generally endpoint-only, so kinetic 
experiments are laborious. 
 The Imperiali lab has published a variety of continuous kinase activity assays 
based on chelation-enhanced fluorescence (CHEF).46-48 The technology, 
commercialized as the Omnia® assay by Life Technologies, has recently been 
applied to mechanistic studies of irreversible EGFR inhibitors.49 The Omnia EGFR 
assay uses a specially-designed peptide sensor consisting of a kinase recognition 
sequence, including phosphorylation site, a beta-turn motif, and a specialized Sox 
fluorophore. Phosphorylation of the peptide leads to chelation of a Mg2+ cation, 
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bridging the phosphoryl with the Sox label to enhance fluorescence 2-10 fold. The 
Sox sensor provides a direct, kinetic readout of EGFR kinase activity. Schwartz and 
colleagues determined the mechanism of covalent EGFR inhibition by modeling 
changes in time-dependent in vitro Sox sensor phosphorylation as a function of 
EGFR inhibition.49 
 Chang and colleagues applied another popular continuous EGFR assay to 
screen for irreversible EGFR inhibitors.50 The Z’-Lyte assay, available from Life 
Technologies, is an in vitro FRET-based platform. A peptide substrate is engineered 
with a phosphorylation site located proximal to a protease cleavage site. The peptide 
is labeled at N- and C-termini with a FRET dye pair. Phosphorylation of the peptide 
by EGFR inhibits proteolytic cleavage in a coupled reaction, while the non-
phosphorylated peptide is cleaved. Therefore, FRET is allowed to occur only when 
the peptide is phosphorylated, generating a signal that is directly proportional to 
substrate turnover by EGFR. The authors applied the Z’-Lyte assay to determine IC50 
values for a series of EGFR inhibitors and to compare inhibitor potency against 
several clinically important EGFR mutants.  
 A common feature of the Omnia and Z’-Lyte assays is the need to design 
peptide substrates that are both efficiently phosphorylated by the target kinase and 
highly compatible with the assay platform. Because substrate design is non-trivial, 
fairly promiscuous substrates which are suitable for multiple kinases are desirable. 
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Therefore, selectivity is problematic, limiting the use of these assays in more 
complex matrices such as cellular extracts.  
1.5.3 In Vitro Mobility Shift Assay 
 Caliper’s mobility shift assay platform stands out among in vitro kinase 
assays because it quantifies both phosphorylated and non-phosphorylated 
substrates by incorporating an analytical separation step.25 The kinase reaction is 
typically carried out off-line, followed by analysis on a specialized microfluidic chip. 
The key to this technology is the ability separate non-phosphorylated and 
phosphorylated peptide substrates based on differential mobility in an electric field. 
The substrates are pre-labeled with a fluorophore to permit on-chip fluorescence 
detection. Automated sampling of the off-line kinase reaction at regular intervals 
enables essentially continuous assay monitoring. Because this approach measures 
both substrate and product, no calibration curve is required to quantify either 
species. Rather, the absolute quantity of phosphorylated substrate can be calculated 
from the fraction of substrate turnover and the known quantity of total substrate in 
the reaction. Xie and colleagues took advantage of the capability for continuous 
assay monitoring afforded by the Caliper chip to acquire progress curves of peptide 
phosphorylation by EGFR with and without a novel EGFR inhibitor or a control 
inhibitor.51 They demonstrated based on the shape of the progress curves that the 
novel EGFR inhibitor binds and irreversibly inhibits the kinase, while the control 
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inhibitor binds but eventually dissociates from the kinase, allowing it to recover 
activity.51   
1.5.4 In Cellulo Assay Platforms for Cell Lysates 
 Undoubtedly the most common and popular assay of EGFR activity in cell 
lysates is the classical Western blot; here, proteins from a cellular extract are pre-
separated by denaturing gel electrophoresis, transferred to an ionic membrane, and 
probed with phospho-specific antibodies. Typically, phosphorylation of several 
endogenous EGFR substrates in the sample of interest is compared to controls to 
qualitatively assess the activity of the EGFR signaling pathway. The phosphorylated 
substrates measured typically include autophosphorylation sites within the EGFR 
kinase domain and EGFR-dependent phosphorylation sites in downstream signaling 
proteins such as members of the MAPK and PI3K/Akt pathways.52,53 Western 
blotting is the gold standard biochemical EGFR assay for cellular lysates. 
 Yu, et al. reported a mass spectrometry-based method for monitoring EGFR-
mediated signaling in a massively parallel manner.54 The KAYAK (Kinase ActivitY 
Assay for Kinome profiling) was used to monitor phosphorylation of 90 unique 
peptide substrates covering a broad range of kinase activities downstream of EGFR. 
Peptide substrates were incubated individually with cell lysate and ATP, then the 
quenched reactions mixed with heavy isotope standards for each phosphopeptide. 
The 90 assays were then combined into two pools and separated by nano-LC prior to 
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MS analysis; inclusion of heavy isotope standards for each substrate enabled 
quantitative analysis of substrate phosphorylation. The authors were able to monitor 
pathway-specific changes in phosphorylation in response to targeted EGFR 
inhibition in immortalized tumor cell lines. KAYAK is a promising approach to 
studying network behavior downstream of EGFR, particularly in response to 
stimulation and inhibition. It provides information similar to large-scale western 
blotting, but does not require antibodies and requires only two LC-MS experiments 
to analyze 90 pathway components. A drawback of this method is the use of heavy 
isotope internal standards required for quantitation by mass spectrometry, which 
significantly increases the cost of the assay.  
 Ghosh and colleagues at the University of Wisconsin, Madison, published a 
novel and sensitive peptide-based EGFR assay designed to quantify EGFR activity in 
lysates of primary cells.55 The authors modified magnetic beads with a set of EGFR 
peptide substrates and incubated the beads in 96-well plates with inhibitor-treated 
lysates of immortalized triple negative breast cancer cells lines. Following the kinase 
reaction, the beads were washed and phosphorylated peptide labeled with an HRP-
conjugated anti-phosphotyrosine antibody. After further washing, the 
phosphorylation was detected by monitoring HRP-mediated conversion of Amplex 
Red to Resorufin in the presence of H2O2. The authors demonstrated reasonable 
selectivity of their assay for EGFR by showing differential assay response in lysates 
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of cell lines with known high or low expression of EGFR. The authors also showed 
good sensitivity of the assay, successfully measuring peptide phosphorylation with 
only 10 µg of lysate protein, or about 500 cancer cells.55 This assay has yet to be 
validated in primary cells, but the possibility of easily measuring kinase activity in 
small numbers of cells is intriguing. It should be noted, however, that assay 
performance in primary cells is unlikely to match performance in tissue cultured cell 
lines where the cell populations are comparatively homogenous and EGFR activity 
is artificially high. It is probable that much larger primary cell populations will be 
required to reliably generate quantifiable signal. Furthermore, a major concern in the 
analysis of primary cancer cells is intratumoral heterogeneity which, undetected, can 
lead to disease relapse. Any technique measuring EGFR activity in a bulk lysate 
risks averaging out and obscuring rare or small subpopulations, missing critical 
therapeutic information. Therefore, techniques which measure EGFR activity in 
single cells are highly desirable.  
 Shi, et al. reported a microfluidic “single cell barcode chip” which can be used 
essentially to perform multiplexed ELISA assays in single cell lysates generated in 
situ.56 One or a few EGFR-positive cultured glioblastoma cells were captured in 
wells of a two-layer microfluidic chip. Each well contained a spatially-defined array 
of eleven capture antibodies directed against EGFR and downstream signaling 
proteins. Cells in each well were lysed in situ using lysis buffer containing protease 
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and phosphatase inhibitors to minimize interference from off-target enzymes. After 
an incubation period to allow analyte proteins to bind to their respective capture 
antibodies and subsequent wash steps, biotinylated primary antibodies (e.g. 
directed against specific phosphorylation sites) were introduced to complete the 
ELISA “sandwich”. Detection was accomplished by labeling the biotinylated 
antibodies with fluorophore-labeled streptavidin, followed chip reading in a high 
resolution fluorescence scanning instrument.  
1.5.5 In Cellulo Assay Platforms for Fixed Cells 
Leuchowius and colleagues developed a flow cytometry-based method for 
quantifying EGFR dimer formation and phosphorylation in single cells using a novel 
in situ proximity ligation method.57 Fixed and permeabilized cells were labeled with 
EGFR-specific antibodies conjugated to oligonucleotides. Treatment with DNA 
ligase to create a cDNA bridge between co-localized antibodies was followed by 
DNA amplification and labeling with fluorophores. The fluorescence intensity, 
proportional either to EGFR dimer formation or EGFR phosphorylation depending 
on the detection antibodies chosen, was then quantified by flow cytometry. This 
method is very sensitive compared to traditional immunostaining because the DNA 
amplification step allows many fluorophores to bind to each antibody pair. The 
authors successfully applied this method to measure EGF-dependent EGFR 
phosphorylation in tissue-cultured cells.  
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 Intercellular heterogeneity in EGFR expression and activation is of particular 
interest for clinical samples. Generally, cells of interest are obtained as fixed tissue 
slices that have been prepared by a clinical pathologist for immunohistochemistry. 
Tissue fixatives covalently crosslink intracellular proteins, essentially freezing the 
tissue in time. The tissue may then be stained with antibodies directed against EGFR 
or phosphorylated EGFR to qualitatively assess kinase overexpression and/or 
hyperactivation. Sonnweber and colleagues performed such immunostaining on 
tumors obtained from patients with early stage non-small cell lung cancer (NSCLC) 
and showed that EGFR phosphorylation, but not overexpression, correlated with 
poor prognosis.58 
 A serious drawback of immunohistochemical analyses is the subjective nature 
of the actual data analysis. Skilled pathologists assign a numerical score based on 
their assessment of the stained tissue; because each pathologist has different 
experience and qualifications, this leads to variable results. Kong and colleagues 
sought to provide a reliable alternative to IHC by developing a quantitative, 
automated fluorescence lifetime imaging (FLIM) method for determining EGFR 
phosphorylation in fixed tissue microarrays.59 The authors converted fixed, paraffin 
embedded malignant tissue into rehydrated tissue microarrays, then stained the 
arrays with an anti-EGFR antibody and an anti-phosphotyrosine antibody. The 
antibodies were labeled with a cyanine (“Cy”) dye pair that, when co-localized, 
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could undergo FRET upon excitation of one of the dyes. Automated FLIM imaging 
of the tissue arrays allowed the authors to quantify EGFR phosphorylation in the 
primary tissues. The authors showed that the mean FRET efficiency from the 
brightest 10% of cells from biopsy cores correlated significantly with reduced 
disease-free survival, but did not correlate with overall survival. The authors were 
also able to demonstrate that total EGFR expression did not significantly correlate 
with either disease-free survival or overall survival. This finding was in agreement 
with other non-quantitative studies using immunostaining and western blot 
analyses. 
  Use of fixed tissue for single cell analysis of clinical samples is standard 
because fixation and subsequent processing allows tissue to be preserved for storage 
and pathological analysis at a convenient time. However, fixation terminates 
intracellular reactions by cross-linking intracellular proteins. Since the timescale of 
fixation may not match with the timescale of the biochemical reaction to be 
measured, measurement artifacts may be introduced that would be avoided if 
measurements were taken in intact living cells. Therefore, assay platforms have been 
developed for quantification of EGFR activity in single living cells. 
1.5.3 In Cellulo Assay Platforms for Live Cells 
 Approaches to monitoring EGFR activity in living cells vary widely. A 
particularly elegant approach was presented by Roger Tsien’s lab, where a FRET 
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sensor comprised of an EGFR substrate peptide and a phosphotyrosine-binding SH2 
domain separating a FRET pair of fluorescent proteins was genetically encoded in a 
cell line of interest.60 Upon phosphorylation of the substrate region, the SH2 domain 
binds the phosphorylation site, bringing the fluorescent proteins into proximity and 
causing an increase in measured FRET that is proportional to the degree of 
phosphorylation. This approach enabled the authors to image the dynamics of 
sensor phosphorylation in response to EGFR stimulation. Other examples of 
genetically encoded FRET sensors of EGFR activity in living cells have been 
published61, inspired by Tsien’s design. These sensors are invaluable research tools, 
but are poorly compatible with real clinical samples, which are heterogeneous and 
small, usually consisting of tens of thousands of cells or fewer and heavily 
contaminated with stromal cells, fibroblasts, and other cells from the tumor 
microenvironment. Furthermore, sensor encoding and validation can take days or 
weeks to complete; ideally, activity measurements in clinical specimens should be 
performed as soon as possible after collection to minimize changes in activity due to 
ex vivo sample handling and culture. 
This work details the development of a single cell EGFR kinase assay which is 
compatible with small, heterogeneous populations of live cells. The assay is based 
on a microelectrophoretic chemical cytometry platform, described in subsequent 
sections, coupled to a capillary electrophoresis-based EGFR biochemical assay in 
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which a rationally designed peptide substrate is employed to directly report kinase 
activity at the single cell level. 
1.6 Chemical Cytometry with Single Cell Capillary Electrophoresis 
1.6.1 Definition and Applications of Chemical Cytometry 
 Dovichi defines “chemical cytometry” as the application of analytical 
chemistry to quantify the contents of single cells.62 This requires highly specialized 
instrumentation capable of handling minute sample volumes (typical mammalian 
cell ≈ 10-12 L) coupled to ultrasensitive detection methods. Chemical cytometry 
methods involve a separation component for multiplexed analysis of cellular 
contents. The separation technique best suited to handling the contents of single 
cells is capillary electrophoresis (CE). CE was first applied to chemical cytometry by 
Jorgenson in 1989.63 In that early work, single giant neurons were manually lysed 
and their contents labeled with a fluorescent tag prior to separation by CE coupled 
to an arc lamp fluorescence detector. Shortly thereafter, Ewing demonstrated the use 
of CE to directly sample portions of the cytoplasm from large neurons by inserting 
the etched inlet of the capillary directly into the cell.64 Ewing used electrochemical 
detection to quantify neurotransmitters from the neuronal cytoplasm. In recent years, 
significant advancements in detection sensitivity have enabled CE-based chemical 
cytometry of primary mammalian cells, including undirected (e.g. proteomics) and 
directed (target-specific) analyses. Dovichi’s group has demonstrated ultrasensitive 
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two-color CE-LIF analysis of lipid metabolism in single cells using fluorescent lipid 
reporters, with limits of detection as low as 10-22 mol.65 Sweedler’s group has applied 
CE-MS to quantitation of > 100 small molecule metabolites in single neurons, with 
detection limits in the high attomole range (10-16 mol).66 Mass spectrometry detection 
has yet to catch up with LIF detection in terms of sensitivity, but has the advantage 
of being label-free. The Allbritton group has developed a toolbox of fluorescent 
enzyme activity reporters for single cell biochemical assays in mammalian cells, 
using an ultrasensitive CE-LIF chemical cytometry platform with detection limits in 
the range of 10-19-10-20 mol, depending upon the reporter used. Single cell 
biochemical assays reported by the Allbritton group include those for protein 
serine/threonine kinases, 67,68 intracellular proteases,69-71 lipid kinases,72,73 and protein 
tyrosine phosphatases.74,75 In all cases, these technologies rely heavily on the 
exceptional separation power of CE to resolve analytes of interest in a highly 
complex sample matrix. The following section provides an overview of the 
theoretical aspects of CE and its figures of merit. 
1.6.2. Theoretical Overview of Capillary Electrophoresis76,77 
 CE is an analytical separation technique in which analytes are resolved based 
on differential mobility in an electric field which is generated by applying a voltage 
across an electrolyte-filled capillary (Figure 3). The rate of migration, v, of a given 
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analyte is determined by the product of the analyte’s effective mobility, µeff, and the 
applied field E:  
 𝑣 = µ𝑒𝑓𝑓𝑬 (8) 
The effective mobility of an analyte is the sum of its electrophoretic (µep) and 
electroosmotic (µeo) mobilities (9). 
 µ𝑒𝑓𝑓 = µ𝑒𝑝 + µ𝑒𝑜 (9) 
The electrophoretic mobility depends upon properties of the analyte itself within the 
context of the separation background electrolyte (BGE) being employed. It is directly 
proportional to the charge on the analyte and indirectly proportional to drag forces 
experience by the analyte. While the analyte charge is a function of the chemistry of 
the analyte and BGE, the drag forces are related to the size and shape of the analyte 
in solution. The electrophoretic mobility can be written as 
 µ𝑒𝑝 =
𝑞
𝑓
 (10) 
where q is the net charge on the analyte and f describes the drag forces experienced 
by the analyte. For a spherical analyte, the mobility is written 
 µ𝑒𝑝 =
𝑞
6𝜋𝜂𝑎
 (11) 
where η is the viscosity of the BGE and a is the hydrodynamic radius of the analyte. 
For many analytes, particularly biopolymers such as DNA and proteins, the 
relationship of molecular weight to electrophoretic mobility is of interest. Several 
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models, based on geometric parameters associated with various solvated polymer 
conformations, have been proposed to predict the effect of molecular weight on 
mobility. No “one size fits all” model has emerged which can reliably predict 
mobility, particularly for peptides. For small spherical analytes, the electrophoretic 
mobility is proportional to (MW)-1/3. The relationship for proteins, described by the 
Offord model, predicts the mobility to vary with (MW)-2/3. The MW-mobility 
relationship for peptides of moderate length (< 40 a.a.) lies somewhere between 
these two extremes.78 
 The electroosmotic mobility is the mobility of an analyte with a net charge of 
zero. It is due to the phenomenon of electroosmosis: bulk fluid flow based on 
mobility of BGE ions in the electrical double layer (Figure 3B). In typical capillary 
zone electrophoresis (CZE), the separation capillary is an open tubular column made 
of unmodified fused silica, which presents ionizable silanol groups at the surface of 
the capillary wall. Deprotonation of surface silanol groups gives the capillary wall a 
net anionic charge (Figure 3C). Cationic components of the BGE specifically adsorb 
at the capillary surface, forming an immobile, cationic layer called the Stern layer. 
The local concentration of cations extends into the mobile (“diffuse”) layer. The 
Stern and diffuse layers together comprise the electrical double layer at the capillary 
surface, forming a potential gradient extending from the surface into the bulk 
solution. The potential at the outer edge of the diffuse layer is called the zeta 
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potential (ζ). In an applied field, cations in the diffuse layer migrate in the direction 
of the cathode. Cohesive forces in the BGE cause the bulk solution to migrate with 
the mobile layer, inducing bulk flow with a characteristic flat flow profile which 
facilitates the exceptional separation efficiencies for which CE is known. The 
electroosmotic flow (EOF) depends upon the surface chemistry of the capillary wall 
and the composition and pH of the BGE. The electroosmotic mobility can be written 
as 
 µ𝑒𝑜 =
𝜖
4𝜋𝜂
𝜁𝑬 (12) 
where � is the dielectric constant of the BGE. The electroosmotic mobility (µeo) is 
inversely proportional to the natural logarithm of the ionic strength of the BGE.79 
 For CZE in open tubular columns in the absence of hydrodynamic or 
convective flow, band broadening depends only on molecular diffusion of the 
analyte as described by the Einstein equation: 
 𝜎 = √2𝐷𝑡 (13) 
Therefore, the number of theoretical plates N achievable in CZE is given by 
 𝑁 =
𝐿2
𝜎2
=
𝜇𝑒𝑓𝑓𝑉
2𝐷
 (14) 
where L is the length of the capillary column and V is the applied voltage. In terms 
of the Van Deemter model of theoretical plate height (H), H in CE depends only on 
the longitudinal diffusion (B) term and is inversely proportional to migration rate. 
   
35 
Since rate is proportional to the applied voltage, it is apparent that the separation 
efficiency in CZE benefits from the highest possible applied voltage. Maximizing the 
applied voltage also has the benefit of increasing the resolution RS between analyte 
bands: 
 𝑅𝑠 = 0.177(µ𝑒𝑝,1 − µ𝑒𝑝,2) [
𝑉
?̅?(µ̅𝑒𝑝 + µ𝑒𝑜)
]
1/2
 (15) 
From this equation, one may infer that maximal resolution is achieved when the 
electroosmotic mobility perfectly counterbalances the average electrophoretic 
mobility of the analytes (RS  ∞). Obviously, both the applied voltage and factors 
governing µeo and µep (BGE chemistry, capillary treatment) should be optimized to 
provide acceptable resolution in the shortest separation time possible to maximize 
separation efficiency. The upper limit of V in most cases is efficient heat dissipation 
across the capillary to prevent radial temperature gradients which cause band 
broadening and convective effects leading to nonlinearity of the voltage-current 
relationship (Joule heating). The Joule heating limit for a given capillary length and 
internal diameter depends strongly on the BGE used and varies widely for different 
buffer systems at the same concentration. Best practice for achieving a highly 
efficient CZE separation is to develop an optimized BGE system (buffer composition, 
pH, additives) permitting acceptable resolution of all analytes in the shortest 
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possible time, and to operate under the highest applied voltage allowed by the 
optimized BGE.  
 CE is amenable to a variety of operation modes determined by the BGE and 
capillary modifications. CE in open tubular columns with typical homogeneous BGE, 
termed CZE as previously discussed, is the most versatile CE mode. Other 
specialized modes have been developed which introduce different mechanisms of 
selectivity to the separation. Micellar electrokinetic chromatography (MEKC), 
introduced by Terabe in the early 1980s80, is a useful CE variant in which the normal 
BGE is supplemented with a surfactant at concentrations well above the surfactant’s 
critical micelle concentration (CMC). The micelles act as a pseudostationary phase 
which is usually engineered to migrate in the opposite direction of the EOF. 
Analytes partition in and out of the micellar phase, such that their effective mobility 
is influenced by their affinity for the pseudostationary phase. MEKC is viewed as a 
hybrid electrophoretic/chromatographic technique and has been proposed as a 
flexible, economical and environmentally-friendly alternative to traditional 
analytical HPLC.81 This mode adds an orthogonal dimension of selectivity to CZE 
and can significantly augment separation power, particularly in the case of analytes 
with similar charge-to-mass ratios.  
 Capillary isoelectric focusing (cIEF) is an important CE mode widely applied 
to biological macromolecule characterization. In cIEF, the capillary is filled with a 
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pH gradient-forming BGE. Charged analytes migrate in the applied field until they 
reach a pH zone corresponding to their isoelectric point; at this point, the analyte’s 
net charge is zero, causing its mobility to go to zero. Bands can be detected either in 
situ by whole-column imaging, or conventionally at a detection window or flow cell 
following analyte mobilization. CIEF is a powerful technique for high resolution 
determination of protein charge variants, for example due to post-translational 
modification.82,83 It has therefore increased in popularity with the recent growth in 
the therapeutic protein market.  
 Exceptional separation efficiencies can routinely be achieved in CE analyses, 
with theoretical plates in excess of 106/m in many cases.84 Since N is independent of 
capillary length (14), increasing this parameter leads to very large peak capacities, 
theoretically without sacrificing separation quality. Thus, CE is ideal for analysis of 
complex samples such a biologic cells. CE supports very small sample volumes (< 1 
µL); the minute sample consumption facilitates analysis of precious/rare samples, 
such as small populations of primary cells from tumor biopsies. Achieving limits of 
detection suitable to such small sample sizes has been a major challenge in 
developing CE instrumentation. Many detectors have been successfully coupled to 
CE, including UV, fluorescence, and mass spectrometry.85,86 Laser-induced 
fluorescence (LIF) has been employed to achieve the lowest limits of detection (5 x 
10-23 mol) of any CE detector.87 The caveat to LIF is the need for fluorescent analytes. 
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Since most analytes of interest, particularly in biological matrices, are not natively 
fluorescent, derivatization may be required. Mass spectrometry is label-free, but is 
difficult to couple to CE due to electric field issues and BGE constraints and is only 
sufficiently sensitive to detect the most abundant species in the cell (e.g. ATP). 
Electrochemical detection has been coupled to single cell CE and is suitable for 
sensitive detection of electroactive analytes such as dopamine88 and nitric oxide89. In 
general, however, CE-LIF is employed for single cell analysis of low-abundance 
species.62 
1.6.3 Single Cell Capillary Electrophoresis Assay of EGFR Kinase Activity 
 The following chapters detail the development and implementation of a 
single-cell biochemical assay of EGFR activity optimized for use with chemical 
cytometry by CE-LIF. Figure 4A and B provides a diagrammatic overview of the 
assay. Briefly, a carboxyfluorescein-labeled peptide substrate (“reporter”) of EGFR is 
loaded into a population of cells of interest, followed by an incubation period to 
allow any EGFR in the cell to phosphorylate the reporter. The cells are seeded on a 
glass coverslip coated with extracellular matrix to promote rapid adhesion. To 
analyze an individual cell, the cell chamber is mounted in a flow chamber over the 
objective of an inverted microscope, flushed for a few minutes with 37 C 
extracellular buffer, and a cell chosen for analysis by microscopy. The cell is then 
lysed very rapidly (< 5 ms) by a pulse from a Nd:YAG laser focused adjacent to the 
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cell. The laser forms a plasma in the buffer near the cell, which generates a cavitation 
bubble. Collapse of the cavitation bubble creates shear forces which rapidly disrupt 
the cellular membrane and terminate intracellular biochemical reactions through 
dilution. The cellular contents are loaded electrokinetically into the lumen of the 
separation capillary, positioned a few microns above the cell. The capillary inlet is 
moved from the cell chamber to the inlet BGE reservoir and separation initiated by 
application of a high voltage. The unmodified reporter is separated from 
phosphorylated reporter and any other metabolic products by CE and detected by 
ultrasensitive LIF. The EGFR kinase activity is calculated from the ratio of 
phosphorylated to total peptide in the electropherograms; this ratiometric readout is 
very robust to experimental variability and allows absolute quantification by 
comparison to a standard. 
 The described assay is ideal for single cell analysis of primary cells. The single 
cell CE platform supports very small and/or very heterogeneous cell populations 
and is easily coupled to immunofluorescence microscopy to allow identification of 
cells of interest based on surface markers. For example, staining with fluorophore-
labeled anti-EpCAM facilitates differentiation of epithelium-derived tumor cells 
from fibroblasts and stromal cells that can comprise the bulk of biopsy samples. The 
exceptional separation power of CE allows reporter multiplexing to measure 
multiple signaling pathways simultaneously. The combination of very small sample 
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volumes for CE and excellent mass sensitivity for LIF detection results in limits of 
detection on the order of 10-20 mol. For a typical mammalian cell with a volume of 1 
pL, this corresponds to an intracellular reporter concentration of 10 nM. This 
exquisite sensitivity allows reporter loading into cells to be kept to a minimum to 
prevent measurement artifacts due to reporter interference in native signaling 
interactions. The single cell CE system is amenable to automation and high-
throughput analysis. While the best published throughput for such a system does 
not rival massively high throughput techniques such as FACS, it is nevertheless 
possible to analyze hundreds of cells per hour.90 Further increasing throughput is an 
area of active investigation in the Allbritton lab. With higher throughput it is 
possible to analyze populations of cells large enough to allow statistical analyses to 
tease apart relevant biochemical subpopulations. This is a particularly pressing need 
in the clinical treatment of EGFR-dependent solid tumors, where single cell analysis 
is essential to provide information about clinically relevant heterogeneity affecting 
response to targeted inhibitors. Flow cytometry is not suitable in general for biopsies 
from solid tumors because the technique requires millions of cells for robust analysis, 
while biopsies from solid tumors may contain as few as ten thousand cells. Of this 
small population, tumor cells may comprise only a small fraction. Single cell CE can 
address each cell in the small population with minimal waste or information loss to 
provide a holistic picture of biochemical heterogeneity in clinical samples.  
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The foundation of a successful single cell biochemical assay is the activity 
reporter. For EGFR and other tyrosine kinases, this is a fluorophore-labeled, acidic 
peptide with a tyrosine phosphoacceptor surrounded by recognition elements 
tailored to the kinase of interest. The reporter peptide is synthesized and 
characterized in vitro under controlled conditions, providing a robust reference for 
behavior in cellulo. This stands in stark contrast to genetically encoded reporters that 
must be characterized in cellulo with very limited control over experimental 
variables. The exogenous reporter can be introduced into the cytosol of intact cells 
by any of a variety of methods, including pinocytosis, electroporation, or 
microinjection. The reporter may alternatively be conjugated to a lipid or cell 
penetrating peptide to promote passive transport into the cytosol. The reporter 
sequence may be easily optimized to suit experimental needs. For example, native 
amino acids within the reporter may be replaced with unnatural analogs to increase 
selectivity for the target kinase and improve reporter stability in the cytosol. Finally, 
the separation component of the assay permits direct detection of the reporter in all 
its forms, including the unmodified reporter, its phosphoform, and any proteolytic 
products. Importantly, since both the unmodified and phosphorylated reporter are 
detected in the same experiment, the assay directly quantifies EGFR biochemical 
activity in each cell. It is therefore complementary to existing clinical EGFR assays 
which measure aberrancies in the EGFR pathway in single primary cells at the 
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genetic or protein expression level. The single cell EGFR kinase assay may be 
implemented in conjunction with these existing clinical assays to provide a holistic 
picture of EGFR activation in primary cells and to improve identification of patients 
likely to respond targeted EGFR inhibitors. 
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Table 1. Common Components of Kinase Assays 
Source of Kinase Substrate Sample Matrix 
Components 
Assay Format Detection Mode 
 Recombinant 
purified enzyme 
 Cell lysate 
 Immuno-precipitated 
enzyme from cell 
lysate 
 Intact cell 
 Full-length protein 
 Protein domain 
 Tryptic fragment 
peptide 
 Random amino 
acid polymer 
 Synthetic peptide 
 γ-32P-ATP 
 Unlabeled ATP 
 Buffer (HEPES, 
MOPS, Tris-HCl) 
 Salt (high 
concentration NaCl) 
 Surfactants (SDS, NP-
40, Tween-20) 
 Stabilizers (BSA, 
glycerol) 
 Divalent cations 
(Mg2+, Mn2+) 
 Reducing agents 
(DTT, 2-
mercaptoethanol) 
 Cell components 
(lipids, nucleotides,  
proteins, ions, small 
molecules) 
 Inhibitors (protease, 
phosphatase, kinase) 
 Homogeneous 
with in situ 
detection (mix-and-
read) 
 Homogeneous 
with ex situ 
detection 
(separations-based 
methods) 
 Heterogeneous 
(liquid and solid 
phase with wash 
steps, e.g. ELISA) 
 Live cell and/or 
live tissue 
(genetically 
engineered) 
coupled to 
microscopy or flow 
cytometry 
 Live cell coupled to 
separation 
technique 
 Fixed, 
permeabilized cell 
coupled to 
cytometry 
 Radiometric 
 Luminescence 
(chemiluminescence, 
fluorescence) 
 TR-FRET 
 Fluorescence 
Polarization 
 Absorbance 
 Mass spectrometry 
Label Instrumentation 
 32P 
 Fluorophore 
 Biotin 
 Quantum dot 
 Lanthanide-, metal 
cation-, or 
fluorophore- doped 
nanoparticle 
 Anti-phospho 
antibody 
 Plate reader 
(fluorescence, 
absorbance) 
 Spectrophotometer 
 Gel electrophoresis + 
Western blotting 
 HPLC/UV/ 
Fluorescence/MS 
 CE-LIF 
 Mass Spectrometry 
 Flow cytometry 
 Mass cytometry 
 Fluorescence 
microscopy 
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Table 2. Assay Platforms for Measuring EGFR Tyrosine Kinase Activity 
IN VITRO ASSAY PLATFORMS    
ASSAY REFERENCES CLASS MECHANISM APPLICATIONS/COMMENTS 
radiometric filter-binding  41,42 radiometric kinase-mediated transfer of 33P-phosphate 
to protein or peptide substrate; 
heterogeneous 
in vitro; kinetics and mechanistic 
studies; gold standard  
HTRF  45 fluorescence/ 
luminescence, 
Ab-dependent 
FRET between labeled peptide and anti-
phosphotyrosine antibody; FRET signal 
proportional to phosphopeptide 
in vitro; homogeneous, mix-and-
read; high throughput; popular in 
drug discovery setting; usually 
peptide substrates only due to 
acceptable distance for FRET 
ELISA   fluorescence/ 
luminescence, 
Ab-dependent 
capture antibody isolated phosphorylated 
substrate, secondary detection antibodies 
allow assessment of phosphorylation by 
fluorescence, chemiluminescence or UV 
in vitro or bulk in cellulo; high 
throughput 
Z'-LYTE  50 fluorescence/ 
luminescence, 
Ab-independent 
engineered peptide substrate contains 
FRET pair, phosphorylation site, and 
proteolytic cleavage site; phosphorylation 
protects from cleavage, leading to high 
FRET 
in vitro; high throughput; antibody-
independent; substrate design is 
non-trivial 
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Omnia  49 fluorescence/ 
luminescence, 
Ab-independent 
Chelation-Enhanced Fluorescence 
(CHEF); engineered peptide substrate 
labeled with Sox fluorophore chelates 
divalent cation when phosphorylated, 
enhancing Sox fluorescence 
in vitro; high throughput; progress 
curves; substrate design is non-
trivial 
Caliper Mobility Shift  51 fluorescence/ 
luminescence, 
Ab-independent 
phosphorylated peptide substrate 
separated from non-phosphorylated 
substrate by differential mobility in a 
microfluidic chip 
in vitro; high throughput; progress 
curves; substrate design is non-
trivial 
BULK IN CELLULO ASSAY PLATFORMS    
western blot  52,53 fluorescence/ 
luminescence, 
Ab-dependent 
proteins transferred to membrane, 
washed, and probed with primary and 
detection Abs; low throughput 
phosphorylation of endogenous 
substrates 
magnetic bead  55 fluorescence/ 
luminescence, 
Ab-dependent 
peptide substrate appended to magnetic 
bead; detection with phospho-specific Ab; 
beads permit miniaturization higher 
throughput 
miniaturizeable for HT applications 
or small numbers of cells (e.g. 
clinical tissue samples) 
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KAYAK  54 mass 
spectrometry 
label-free; massively parallel 
multiplexing; high throughput; large 
sample consumption 
proteomics/research applications; 
network biology 
IN CELLULOASSAYS IN SINGLE CELL LYSATES   
SC barcode chip  56 fluorescence/ 
luminescence, 
Ab-dependent 
single cell; essentially on chip ELISA single cell version of western 
blot/ELISA type data; potentially 
applicable to clinical samples 
IN CELLULO ASSAYS IN SINGLE FIXED CELLS      
immunohistochemistry 
(IHC) 
 58 fluorescence/ 
luminescence, 
Ab-dependent 
single cell; non-quantitative; poor 
reproducibility; usually not for 
phosphoproteins 
accessible to clinical pathologists, 
widely used and accepted for 
primary clinical specimens 
Flow proximity ligation  57 fluorescence/ 
luminescence, 
Ab-dependent 
nucleotide-labeled detection antibodies 
bind EGFR and/or phosphorylated 
EGFR; co-localized antibodies joined by 
cDNA after treatment with DNA ligase; 
amplified cDNA labeled with 
fluorophore; many mol of fluorophore 
for each mol of Ab pair results in high 
sensitivity 
single cell; quantitative; high 
throughput; requires large cell 
numbers; suitable for clinical 
samples 
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FRET/FLIM for pEGFR  59 fluorescence/ 
luminescence, 
Ab-dependent 
co-immunostaining for EGFR and pTyr 
with Ab labeled with FRET pair; high 
throughput; requires capability for 
FLIM imaging; complex sample prep 
requires specialized imaging; tissue 
preparation is laborious 
IN CELLULO ASSAYS IN SINGLE LIVE CELLS     
genetically encoded FRET 
sensor 
 60 fluorescence/ 
luminescence, 
Ab-independent 
phosphorylation of peptide substrate 
forces intermolecular binding of SH2 
domain, bringing CFP and YFP into 
proximity for FRET 
requires genetic engineering; 
suitable for research purposes; 
provides dynamic spatial and 
temporal information 
chemical cytometry  17-20 fluorescence/ 
luminescence, 
Ab-dependent 
fluorescent peptide reporter is loaded 
into single cells; phosphorylated and 
non-phosphorylated reporter are 
separated by single cell CE-LIF 
following individual cell lysis 
exquisitely sensitive; requires very 
few cells; suitable to multiplexing 
and automation 
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Figure 1. Overview of EGFR biology. (A) Structure of EGFR in its unbound, 
inactive state and its ligand-bound, dimerized active state. Ligand binding and 
dimerization induce structural changes in the intracellular kinase domain which 
activate EGFR kinase activity. (B) The major EGFR-dependent intracellular signaling 
pathways.  
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Figure 2. Kinetic curve based on the Michaelis-Menten model of enzyme kinetics. 
Initial reaction rate varies characteristically with substrate concentration. The Vmax is 
the maximum rate of reaction, reached when the substrate concentration equals or 
exceeds the concentration of available enzyme active sites. The substrate 
concentration at ½ Vmax is defined as the Michaelis-Menten constant, KM. 
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Figure 3. Overview of capillary electrophoresis (A) Diagram of a typical CE-LIF 
instrument. The ends of a buffer-filled glass capillary are immersed in buffer 
reservoirs connected to a high-voltage power supply. A window burned in the 
capillary coating is aligned with an excitation laser and a ball lens, oriented at right 
angles to each other, to allow excitation of fluorescent analytes and orthogonal 
collection of emission. (B) Schematic representation of the electrical double layer at 
the surface of a fused silica capillary. The anionic surface charge on the capillary 
wall attracts an immobile layer of cations from the BGE. Further out in solution, a 
mobile layer of net cationic character is responsible for bulk BGE flow in an electric 
field. Charge neutrality is re-established in the bulk solution. (C) Ion separation in 
normal mode capillary electrophoresis. Cations migrate ahead of the EOF toward 
the anode at the outlet, while neutral species migrate with the EOF. Anion migration 
opposes the EOF, so these species will only reach the detector if the electroosmotic 
mobility is greater than the electrophoretic mobility. (D) Net mobility in capillary 
zone electrophoresis is the vector sum of the electrophoretic and electroosmotic 
mobilities.  
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Figure 4. Overview of single cell EGFR assay. (A) Detection of EGFR reporter and 
its enzymatic products by CE-LIF. Optimal separation conditions allow all 
metabolites to be resolved from the parent reporter. (B) Schematic of the single-cell 
EGFR biochemical assay. Reporter is loaded into intact cells. After incubation, the 
cells are analyzed by single-cell CE-LIF, and reporter modification is quantified to 
yield a direct readout of EGFR kinase activity. (C) Fluorescence microscopy of intact 
cells loaded with a fluorescein-labeled EGFR reporter.  
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CHAPTER 2: CONFORMATIONAL CONSTRAINT AS A SOLUTION TO 
PROTEIN TYROSINE PHOSPHATASE INTERFERENCE IN INTRACELLULAR 
PEPTIDE-BASED KINASE ASSAYS 
2.1 Background 
Protein tyrosine kinases (PTKs) propagate intracellular signaling through 
selective phosphorylation of regulatory tyrosine residues within protein substrates.1-
3 Abnormal activation of one or more PTKs represents an important phenotype in a 
variety of cancers, and, increasingly, clinically efficacious anti-cancer treatment 
regimens include some form of targeted PTK inhibition.4-6 Successful treatment with 
targeted PTK inhibitors clearly presupposes the presence of cells whose malignancy 
is driven by the PTK to be inhibited. In practice, direct assessment of PTK activity in 
clinical specimens is a daunting analytical challenge, in particular because the 
inherent heterogeneity of clinical samples necessitates that measurements be taken 
at the level of the individual cell7. Bulk population measurements are much simpler 
to implement analytically, but may miss rare druggable subpopulations, ultimately 
resulting in disease relapse.7,8Direct measurement of PTK activity involves 
monitoring phosphorylation of a substrate of the PTK of interest, typically via some 
kind of fluorescence readout. For activity measurements in intact cells, the “reporter” 
substrate must either be genetically encoded and expressed in the cell, or must be 
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synthesized exogenously and introduced into the cytosol prior to measurement. The 
first approach is advantageous because endogenous protein substrates may be used 
as reporters, preserving native structural and spatiotemporal regulatory 
mechanisms.9 However, genetic encoding is experimentally difficult to implement,10 
particularly in small, heterogeneous clinical samples, and may not permit reliable 
quantitative analyses in all samples.11 In contrast, short phosphorylatable peptide 
substrates, which have traditionally been used to monitor PTK activity in vitro, are 
efficiently and cost-effectively synthesized exogenously, can be introduced into 
intact cells through a wide range of techniques, and are adaptable to ultrasensitive, 
quantitative analytical platforms.12,13 Peptide reporters have been successfully 
coupled to ultrasensitive single-cell microelectrophoresis to quantify a variety of 
enzymatic activities in intact single cells, including peptide metabolism,14-17 
serine/threonine kinase activity,18 and protein tyrosine phosphatase activity.19,20 
However, this platform has been difficult to adapt to PTK activity measurements 
due to the susceptibility of PTK peptide reporters to interference from protein 
tyrosine phosphatase (PTP) activity. PTPs catalyze the hydrolysis of the 
phosphotyrosine phosphate monoester and are some of the most efficient and 
fastest-acting enzymes currently known.21-23 The ability of PTPs to act rapidly and 
comparatively indiscriminately upon phosphorylated peptide substrates often 
results in peptide reporters being overwhelmed by PTP activity. The practical 
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implication of this phenomenon is that the lifetime of phosphoreporter in 
biologically relevant systems (cell lysates, intact cells) is typically too short to 
capture experimentally. Where the phosphoreporter is the species of interest (e.g. 
PTK activity assays), this short lifetime is a serious analytical obstacle. While it is 
common to overcome this challenge in cell lysates by employing one or more 
chemical PTP inhibitors, this approach is not ideal for assays in intact cells because 
PTP inhibition is likely to disrupt the delicate signaling architecture being studied. 
An inhibitor-free solution to PTP interference would be ideal. 
We report that substitution of a constrained tyrosine analog, 7-hydroxy-(S)-
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Htc), in the place of natural 
tyrosine within a validated EGFR kinase activity reporter reduces PTP assay 
interference by three orders of magnitude while retaining comparable capacity to 
monitor EGFR activity and response to inhibition in vitro. We further apply this 
enhanced reporter to quantify EGFR activity in single, intact A431 epidermoid 
carcinoma cells using ultrasensitive single cell microelectrophoresis. We 
demonstrate that the Htc-containing reporter, but not the native tyrosine reporter, is 
suitable for quantifying EGFR biochemical activity in single intact cells.  
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2.2 Materials and Methods 
2.2.1 Peptide Synthesis and Purification 
 
Peptides were prepared using Fmoc Solid Phase Peptide Synthesis (SPPS) 
protocols, either by hand or using a Protein Technologies, Inc. PS3 automated 
peptide synthesizer (Tucson, AZ). Standard Fmoc amino acids were purchased from 
NovaBiochem as the t-Butyl-protected forms where appropriate, with the exception 
of aspartic acid. The peptide sequences in this report were highly susceptible to 
aspartic acid racemization via aspartimide hydrolysis. Therefore, the OMpe-
protected form of aspartic acid was employed where economically feasible.24 The 
solid phase was chosen for increased hydrophilicity to promote peptide chain 
solvation.25 Either Nova-PEG Amide (AnaSpec, Fremont, CA) or CLEAR Amide 
(Peptides International, Louisville, KY) resin was used. Before use, resin was 
allowed to reach room temperature and was rinsed sequentially with methanol, 
isopropyl alcohol, dichloromethane, and DMF to remove as much water as possible 
and reduce aspartic acid racemization. Fmoc removal was achieved with 20% (v/v) 
piperidine in DMF supplemented with 0.1 M HOBt to further combat aspartic acid 
racemization.26 Native Fmoc-amino acids were coupled using HCTU in 0.4 M N-
methylmorpholine in DMF. Complete coupling was verified using a Ninhydrin test 
(AnaSpec, Fremont, CA) for primary amines or a chloranil/acetaldehyde test for 
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secondary amines. Special attention was required for the coupling of the constrained 
tyrosine analog Htc (Fmoc-7-hydroxy-(S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic 
acid, Sigma, St. Louis, MO). Best results were obtained using the DIC/Oxyma 
coupling system in DMF, using a slight excess of DIC and Oxyma with respect to the 
amino acid and reacting at least 18 h. After successful Htc coupling, the hydroxyl at 
the 7 position of the tetrahydroisoquinoline moiety was protected by 2 h or 
overnight treatment with excess 2-chlorotrityl chloride in DIEA/DMF. Addition of 
the subsequent glutamic acid required overnight coupling with a large excess of 
amino acid and use of HATU/Oxyma in NMM/DMF. All peptides were labeled at 
the N-terminus with 6-carboxyfluorescein (Anaspec) using an overnight treatment 
in DIC/Oxyma in N-methylpyrrolidonone. Labeled peptides were treated briefly 
with 20% (v/v) piperidine + 0.1 M HOBt in DMF prior to cleavage to remove 
fluorescein esters. Peptides were cleaved from the resin and side chain protecting 
groups were removed in 95% trifluoroacetic acid with 2.5% triisopropylsilane and 
2.5% water as scavengers. TFA was removed via evaporation under a gentle stream 
of N2(g), and peptides were either isolated by precipitation in cold diethyl ether or 
directly reconstituted in water following TFA removal. All products were purified 
by reversed phase HPLC with a 2-3.33 %/min water-acetonitrile gradient. Mobile 
phases were supplemented with 0.1% TFA. Purified products were verified by mass 
spectrometry, using either ESI ionization coupled to a quadrupole mass analyzer or 
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by MALDI-TOF MS. Purified peptides were isolated by lyophilization and 
reconstituted in pH 7.5 Tris buffer prior to concentration determination by UV-Vis. 
2.2.2 Cell Culture 
All cell lines were maintained at 37 °C in a humidified atmosphere with 5% 
CO2 in the recommended medium supplemented with 10% FBS, 100 mg/mL 
penicillin, and 100 U/mL streptomycin. A431: DMEM (Cellgro, Manassas, VA); 
SKBR3: McCoy’s 5A (Cellgro, Manassas, VA); NCI-N87: RPMI 1640 (Cellgro, 
Manassas, VA). For stimulation experiments in single A431 cells, cells were starved 
overnight in low serum (0.2% FBS) DMEM. Immediately prior to analysis, cells were 
stimulated 20-30 min with 200 ng/mL EGF (Life Technologies, Carlsbad, CA) in low 
serum media.  
2.2.3 In Vitro EGFR Assays 
Purified EGFR kinase domain was purchased from EMD Millipore (catalog # 
14-431, Billerica, MA) and was used at 2-5 ng/µL in EGFR dilution buffer (20 mM 
MOPS, pH 7.5; 1 mM EDTA; 0.01% Brij 35; 0.1% β-mercaptoethanol; 1 mg/mL BSA; 
5% glycerol). Reactions were carried out at 30 °C in kinase reaction buffer (5 mM 
MOPS, pH 7.2; 0.4 mM EDTA; 1 mM EGTA; 10 mM MnCl2; 4 mM MgCl2; 8 µg/mL 
BSA) with 1 mM ATP and the indicated concentrations of peptide. Time points were 
terminated by 1:5 dilution in 0.2 M HCl (aq) and stored at -20 °C until analysis by 
CE-LIF. 
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2.2.4 Phosphopeptide Preparation 
The phosphorylated forms of Tyr-tide and Htc-tide were prepared 
enzymatically using EGFR under the conditions indicated above, but with a high 
concentration of EGFR. Peptide phosphorylation was monitored by CE-LIF; 
reactions were quenched with EDTA after the peptides reached approximately 90% 
phosphorylation. Phosphopeptide mixtures were inactivated by incubation for 4 
min at 90 °C to denature the EGFR, aliquoted at working volumes, and stored at -
20 °C.  
2.2.5 In Vitro PTP Assays 
Purified recombinant PTP1B and TCPTP were purchased from EMD 
Millipore (Billerica, MA). PTP reactions were carried out at room temperature in 
PTP reaction buffer (60 mM HEPES, pH 7.2; 150 mM NaCl; 1 mM EDTA; 0.17 mM 
DTT; 0.83% glycerol; 0.017% BSA; 0.002% Brij-35); time points were quenched, stored, 
and analyzed as above. 
2.2.6 Cell Lysate Preparation 
A431 cell lysates were prepared by rinsing confluent monolayers 3X with 
phosphate-buffered saline (PBS, pH 7.4) and scraping the cells into fresh lysis buffer 
(20 mM HEPES, pH 7.4; 5 mM β-glycerophosphate; 200 mM NaCl; 1% NP-40; 10% 
glycerol with 1X Roche cOmplete EDTA-Free protease inhibitor) over ice. Cell 
suspensions were transferred to low-retention microcentrifuge tubes and incubated 
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on ice 20 min with occasional gentle mixing, followed by a 15 min clarification at 
14000 rcf (4 °C). Supernatants were reserved, aliquoted at working volumes, and 
stored up to 6 months at -20 °C. The total protein content of the lysates was 
determined using a fluorescamine assay.17  
2.2.7 Lysate Phosphorylation Assays 
To measure reporter phosphorylation in cell lysates, A431 lysates were 
thawed on ice and diluted to 4 mg/mL (4X) in fresh lysis buffer with 0.1 mM sodium 
pervanadate prior to mixing with kinase reaction buffer and peptide reporter (final 
concentration 10 µM). Lysates were treated with 10 µM EGF for 5 min prior to assay 
initiation. Assays were initiated by adding ATP to a final concentration of 1 mM. For 
inhibitor studies, lysates were pre-treated 10 min with indicated concentrations of 
gefitinib or lapatinib, followed by stimulation and assay initiation. All assays were 
performed at 37 °C; time points were collected, quenched, and analyzed as above.  
2.2.8 Lysate Dephosphorylation Assays 
Stock cell lysates were thawed on ice and diluted to 10 mg/mL with fresh 
lysis buffer. 10 mg/mL lysates were diluted to 1.25 mg/mL (1.25X) in PTP reaction 
buffer (above) supplemented with 3.3X Sigma protease inhibitor cocktail in DMSO 
and with or without 150 µM fresh sodium pervanadate. Lysates were incubated 20 
min on ice with inhibitors prior to addition of phosphoreporter to a final 
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concentration of 10 µM and incubation at 37 °C. Time points were collected, 
quenched, and analyzed as indicated above. 
2.2.9 Lysate Peptidolysis Assays 
To quantify reporter degradation in cell lysates, confluent monolayers of 
A431 cells were harvested with trypsin, pelleted, washed 2X with PBS, resuspended 
in a small volume of PBS and lysed by multiple rounds of freezing in liquid nitrogen 
and rapidly thawing at 37 °C. Lysate concentrations were determined as indicated 
above and diluted to a final concentration of 18 mg/mL in PBS prior to addition of 10 
µM reporter to initiate the reaction. Reactions were carried out at 37 °C and 
quenched as above.  
2.2.10 Capillary Electrophoresis 
Capillary electrophoretic analyses were performed using commercial 
Beckman Coulter (Pasadena, CA) automated PA800 CE-LIF instruments outfitted 
with 488 nm solid state lasers (Coherent, Santa Clara, CA). Separations were carried 
out in 30 µm internal diameter bare silica capillaries filled with electrophoretic 
buffer (0.2 M boric acid/NaOH, pH 9.5) under a 600 V/cm applied electric field. Prior 
to analysis, samples were diluted to 100-200 nM in 50% electrophoretic buffer/50% 
water to promote sample stacking.  
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2.2.11 In Vitro Data Analysis 
Electropherograms were integrated using commercial software (32Karat, 
Beckman Coulter, Pasadena, CA). For kinase assays, percent phosphorylation was 
calculated from the corrected area under the phosphoreporter peak divided by the 
total reporter corrected area multiplied by 100%. For phosphatase assays, the 
percent phosphorylation was normalized to the initial percent phosphorylation at 
time zero. Percent dephosphorylation was calculated as the normalized percent 
phosphorylation at a given time subtracted from the normalized percent 
phosphorylation at time zero. For phosphorylation and dephosphorylation in cell 
lysates, values are given with respect to intact reporter. 
To estimate Michaelis-Menten kinetic constants KM and kcat, progress curves of 
reporter phosphorylation by EGFR or of phosphoreporter dephosphorylation by 
PTP1B or TCPTP were generated by treating as above with recombinant enzyme 
followed by CE-LIF. Progress curves were fit to the time-dependent Michaelis-
Menten equation (Eq 1) using an analytical approximation of the Lambert function.27 
Curves at 2-3 substrate concentrations were fit globally in OriginLab (Northampton, 
MA). In the case of EGFR, multiple replicates were fit globally, as this resulted in 
better fits than weighted fitting of averaged data with standard deviations. In all 
cases, the standard errors reported are those generated by OriginLab’s non-linear 
regression tool. Fits and residual plots are available in the supporting information. 
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The KM and kcat for pHtc-tide dephosphorylation by recombinant phosphatases was 
measured by traditional initial rates analysis due to economic constraints on enzyme 
consumption. A plot of initial rate versus substrate concentration was fit to the 
Michaelis-Menten equation using OriginLab’s nonlinear regression tool.  
2.2.12 Pinocytic Loading for Single Cell EGFR Activity Assays 
Monolayers of A431 cells were serum starved overnight in DMEM medium 
containing 0.2% serum. Immediately before pinocytic loading with peptide reporter, 
the monolayers were stimulated 10 min with 200 ng/mL EGF to initiate high levels 
of EGFR activity. Monolayers were then disadhered using 0.05% trypsin with EDTA 
and suspended in complete medium. Approximately 1x106 cells were isolated in a 
1.5 mL tube and loaded with Htc-tide or Tyr-tide by pinocytosis. The cells were 
incubated for 10 min with hypertonic loading solution (InfluxTM, Life Technologies) 
containing 100 µM peptide reporter (20 µL per 106 cells), followed by pinosome lysis 
in hypotonic DMEM to release reporter into the cytosol and initiate the EGFR 
biochemical assay. Cells were washed once with complete medium and immediately 
plated on custom glass chambers coated with CellTakTM (Corning, Corning, NY). 
Viability, assessed by trypan blue staining immediately after loading, was 81%. Cells 
were plated at a low density resulting in approximately 30 adherent cells/mm2 after 
rinsing. Cells were allowed to adhere at 37 C for approximately 35 min, followed by 
single cell analysis. 
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2.2.12 Single Cell Analysis with Microelectrophoresis 
 Single cell microelectrophoresis was performed as previously described.17-20 
Cell chambers containing loaded A431 cells adhered to CellTak were placed on the 
stage of an inverted microscope. Extracellular buffer (33-37 C) was flowed over the 
cells for several minutes to remove weakly adhered or non-adherent cells. Cells 
were chosen for individual analysis based on acceptable morphology (round shape, 
intact membrane, lack of blebbing) and absence of other cells in the field of view. 
Selected cells were lysed individually by a rapid pulse from an Nd:YAG laser as 
previously described, then the contents electrokinetically loaded into the lumen of a 
30 µm i.d. fused silica capillary positioned directly above the cell. The cellular 
contents including unmodified and modified peptide reporter were separated by 
capillary electrophoresis under a field strength of 200 V/cm and detected by laser-
induced fluorescence. The optimal separation buffer for single cell analysis was 0.2 
M boric acid/NaOH with 2 mM SDS, pH 9.5. The number of moles of reporter 
loaded into each cell was calculated based on the response from a known standard 
run at the beginning of each day.  
2.3 Results and Discussion 
2.3.1 Mitigation of Phosphoreporter Dephosphorylation in vitro via 
Conformational Constraint 
In previous efforts to develop native tyrosine-containing peptide reporters for 
single-cell PTK assays, our lab has consistently observed the rapid 
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dephosphorylation of these peptides upon phosphorylation, both in vitro and in vivo. 
In all cases, we observed that phosphoreporter dephosphorylation occurs on a 
significantly shorter time scale than phosphorylation of the corresponding tyrosine 
reporter (Table 3). In vitro dephosphorylation of the phosphorylated EGFR kinase 
reporter pTyr-tide (6FAM-EDDEYEEV-NH2) by recombinant TCPTP occurs with a 
rate constant kcat 168X greater than that of Tyr-tide phosphorylation by EGFR. Based 
on the observation that introduction of conformational constraint to a peptide 
substrate can impede its interaction with certain enzymes,28-31 we hypothesized that 
substitution of the native tyrosine (Figure 5A) within the reporter sequence with a 
conformationally constrained, phosphorylatable analog would slow 
dephosphorylation by PTPs, increasing phosphoreporter lifetime in the cytosol to 
measureable levels. The constrained tyrosine analog L-Htc (Figure 5B) has 
previously been included in an efficient substrate of spleen tyrosine kinase (SYK) 
and is variably tolerated by other PTKs.28,30 We observed that substitution of L-Htc 
into our EGFR reporter Tyr-tide resulted in comparable phosphorylation by EGFR 
(Table 3). Similar to tyrosine, the Htc molecule contains a phosphorylatable 
hydroxyl positioned on a rigid conjugated 6-member ring. In contrast to tyrosine, 
however, this ring is cyclized via a methylene bridge to the α-nitrogen, forming a 
fused bicyclic system with limited flexibility. NMR studies of L-Htc in the context of 
similar peptides have shown that this residue can adopt either a gauche (+) or 
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gauche (-) conformation about the χ1 torsional angle formed by the Nα—Cα—Cβ—
Cγ, with the gauche (+) being preferred.28 This cyclization severely restricts the 
flexibility of the entire residue, limiting the conformations that the peptide is able to 
adopt within the enzyme active site. To test the hypothesis that decreased flexibility 
of the phosphorylated reporter would discourage dephosphorylation by PTPs, we 
performed a series of in vitro dephosphorylation assays with the model PTPs PTP1B 
and TCPTP, which have been shown to preferentially recognize highly acidic 
peptide substrates such as pTyr-tide.32,33 The data in Figure 5C illustrate the different 
timescales of dephosphorylation of pTyr-tide and pHtc-tide (6FAM-EDDE-Htc-EEV-
NH2) by PTP1B at a range of enzyme concentrations. We observed very little 
dephosphorylation of pHtc-tide, even at the highest enzyme concentration. In 
contrast, pTyr-tide is fully dephosphorylated within 5 min at this enzyme 
concentration. This differential susceptibility to PTP interference is further 
illustrated in Figure 5D and E. Phosphoreporter dephosphorylation in 10 min was 
monitored as a function of increasing PTP1B or TCPTP concentration. While it is 
possible by using large quantities of either enzyme to force dephosphorylation of 
pHtc-tide, it is significantly less susceptible to dephosphorylation compared with 
the native phosphotyrosine peptide.  
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2.3.2 Phosphoreporter Lifetime in Epithelial Tumor Lysates 
We next verified that this phenomenon was not limited to the two 
recombinant PTPs tested by comparing dephosphorylation of pHtc-tide and pTyr-
tide in lysates of a panel of model tumor lines overexpressing one or more of the 
EGFR family kinases. A431 cells, derived from an epidermoid carcinoma of the 
vulva and overexpressing full length wild type EGFR, have previously been used to 
study PTP1B activity in cell lysates.34,35 The data in Figure 6A clearly demonstrate 
that, while pTyr-tide is completely dephosphorylated within 5 min, approximately 
90% of pHtc-tide remains even after 30 min. We verified that the decrease in 
phosphoreporter in both cases was due to dephosphorylation and not to 
peptidolysis or another competing process by pre-treating the lysates with 0.1 mM 
sodium pervanadate, a pan-PTP inhibitor that irreversibly oxidizes the catalytic 
cysteine within the PTP active site.36 Loss of both reporters was nearly eliminated 
upon pervanadate treatment, confirming that this phenomenon is due to PTP 
activity. The resistance of pHtc-tide to dephosphorylation is not limited to A431 
lysates. We observed similar rates of dephosphorylation of both pTyr-tide and pHtc-
tide in A431 epidermoid carcinoma, SKBR3 breast carcinoma, and NCI-N87 gastric 
carcinoma cell lysates (Figure 6B), suggesting that Htc-tide can be generally applied 
to measure EGFR kinase activity in cell lysates.  
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2.3.3 Kinetics of Phosphoreporter Dephosphorylation 
We further investigated the mechanism of Htc reporter resistance to PTP 
interference by comparing the kinetics of dephosphorylation of the two 
phosphoreporters by recombinant PTP1B and TCPTP. The interaction of both 
phosphoreporters with PTP1B and TCPTP can be modeled according to the 
standard Michaelis-Menten model of enzyme kinetics.32,37 We used a combination of 
progress curve analysis and initial rate measurements to estimate the kinetic 
parameters KM and kcat from dephosphorylation time courses. For both PTPs studied, 
the kcat for pTyr-tide dephosphorylation was 3 orders of magnitude larger than the 
corresponding value for pHtc-tide. Interestingly, the KM values for pTyr-tide and 
pHtc-tide were very similar for both PTPs, suggesting that the differential 
dephosphorylation observed is primarily driven by differences in the rate of 
phosphate monoester hydrolysis, rather than in the ability of the two reporters to 
bind to the phosphatase active site. Examining the vacuum electrostatics of the 
substrate binding surfaces of published X-Ray crystal structure of PTP1B38 in 
PyMol39 indicates large patches of enriched positive charge near the phosphate 
monoester binding pocket (Figure 7). We posit that the overwhelming acidity of the 
peptide reporters drives electrostatic interactions with the substrate binding regions 
of the phosphatases; this electrostatic affinity is reflected in the low measured KM 
values. This hypothesis is supported by recent work demonstrating the 
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overwhelming preference of common PTPs for acidic substrates.33 We speculate that 
the introduction of conformational constraint into the backbone of pHtc-tide 
positions the phosphate monoester unfavorably with respect to the conserved PTP 
catalytic residues, thus significantly decreasing the rate of phosphate monoester 
hydrolysis. The ability of EGFR to recognize Htc-tide may be a function of a more 
balanced surface charge distribution near the substrate binding cleft of the EGFR 
KD38 (Figure 7A), resulting in a greater number of accessible binding modes for Htc-
tide and a higher probability of catalytically favorable reporter binding. X-Ray 
crystallographic or NMR studies would be required to verify this hypothesis and 
may be an interesting avenue for future research.  
2.3.4 Increased Resistance to Peptidolysis in Cell Lysates 
 It has been previously reported that modification of short peptides with 
unnatural amino acids discourages peptidolysis and increases intact peptide lifetime 
in cell lysates and intact cells.31,40-42 We hypothesized that substitution of tyrosine 
with L-Htc would confer the additional advantage of improved stability in the face 
of peptidolysis in cell lysates. To test this possibility, we first synthesized standards 
of the 6FAM-labeled fragments of Tyr-tide and verified that no fragments co-
migrated with intact unmodified or phosphorylated Tyr-tide or Htc-tide. Tyr-tide 
and Htc-tide share four fragments N-terminal to the phosphorylation site. The three 
Htc-containing fragments of Htc-tide were not synthesized because similarities in 
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electrophoretic mobility between Htc-tide and Tyr-tide allow us to infer 
approximate migration times for the remaining Htc-containing fragments. Given the 
excellent separation between the intact reporters and all fragments (Figure 8A), it is 
improbable that the Htc-containing fragments would co-migrate with either intact 
reporter. Having demonstrated the ability to separate intact reporter from its 
metabolic products by CE-LIF, we evaluated breakdown of these reporters in high-
concentration, inhibitor-free A431 lysates (Figure 8B). As expected, replacement of 
natural tyrosine with the constrained analog increased the stability of the reporter 
almost 2-fold, increasing the half-life of intact reporter from 193 (± 53) min to 328 (± 
87) min in 18 mg/mL cell lysates. 
2.3.5 Quantifying Response to EGFR Inhibition 
 Having demonstrated comparable in vitro phosphorylation of Tyr-tide and 
Htc-tide by recombinant EGFR kinase domain, we proceeded to compare the utility 
of the two reporters to monitor EGFR activity in a more biologically relevant system. 
We therefore explored the capacity of Htc-tide and Tyr-tide to act as reporters of 
EGFR kinase activity in A431 cell lysates (Figure 9). We monitored reporter 
phosphorylation in lysates of A431 cells that had been serum starved overnight, 
treated with EGFR TKI, and stimulated with the EGFR ligand EGF immediately 
prior to assay initiation. The reporters respond equivalently to selective EGFR 
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perturbation, indicating that Htc-tide may be used in place of Tyr-tide to monitor 
EGFR activity in cellulo.  
2.3.6 Single Cell Analysis  
 The ultimate goal of this work is to develop a peptide reporter suitable for 
single cell analysis of EGFR biochemical activity in intact cells. To that end, the 
compatibility of Htc-tide versus Tyr-tide for single cell EGFR kinase assays was 
assessed (Figure 10). Either Htc-tide or Tyr-tide was loaded by pinocytosis into 
serum-starved, stimulated A431 cells and incubated for 35-45 min at 37 C. 
Individual loaded cells were lysed and analyzed by single cell microelectrophoresis 
as previously described.17-20 Both reporters were successfully loaded into the cytosol, 
as confirmed by fluorescence microscopy (data not shown). In keeping with 
previous work, both reporters underwent variable peptidolysis. Figure 10B shows a 
linear increase in intracellular Htc-tide metabolism with the amount of Htc-tide 
loaded into the cells. Consistent with lysate data, Htc-tide showed marginally better 
resistance to peptidolysis compared with Tyr-tide. This improved stability is likely 
due to the increased rigidity of the peptide backbone of Htc-tide compared with 
Tyr-tide.  
 While Tyr-tide was successfully loaded into cells and underwent expected 
levels of peptidolysis, it was not detectably phosphorylated in any of the cells 
analyzed (Figure 10A). This result is in keeping with previous observations of rapid 
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dephosphorylation of phosphotyrosine peptides in intact single cells.19,20 In contrast, 
Htc-tide was measurably phosphorylated in all of the cells analyzed, indicating 
excellent resistance to assay interference from PTPs. Quantification of Htc-tide 
phosphorylation in single A431 cells shows a linear increase in moles of pHtc-tide 
detected in response to increased total Htc-tide loaded (Figure 10B). This is 
consistent with estimated intracellular Htc-tide concentrations (0.001-0.1 µM) well 
below the in vitro measured KM of 18 µM.  
2.4 Conclusions 
 This work presents a novel solution to protein tyrosine phosphatase 
interference in peptide reporter-based intracellular EGFR kinase assays whose 
efficacy does not depend on use of inhibitors or any other intervention beyond 
chemical modification of the peptide reporter. Simply replacing natural tyrosine 
with the conformationally constrained analog Htc sufficiently altered reporter 
recognition by PTPs to enable intracellular reporter phosphorylation. This approach 
to mitigating assay interference is minimally invasive to the cell. To the best of our 
knowledge, the data presented here comprise the first examples of direct 
measurement of tyrosine kinase activity in intact single cells using a short synthetic 
peptide reporter. Future work will explore the broader applicability of 
conformationally constrained tyrosine analogs in reducing PTP interference in a 
range of intracellular PTK assays. Conformational constraint of the reporter may 
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prove to be a general solution to assay interference for chemical cytometry of PTK 
activity. 
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Figure 5. Differential in vitro dephosphorylation of EGFR reporters. A) Line 
structure of phosphorylated tyrosine. B) Line structure of phosphorylated L-Htc. C) 
Time course of phosphorylated EGFR reporter dephosphorylation by PTP1B at a 
range of concentrations. D)-E) Bar graphs comparing phosphoreporter 
dephosphorylation as a function of increasing PTP1B (D) or TCPTP (E). N = 3. 
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Figure 6. In cellulo dephosphorylation of phosphorylated EGFR reporters. A) 
Dephosphorylation of phosphorylated Htc-tide (blue) or Tyr-tide (red) in A431 
lysates with and without pervanadate treatment. B) Dephosphorylation of the 
phosphoreporters is independent of cell line. A431: epidermoid carcinoma; SKBR3: 
breast carcinoma; NCI-N87: gastric carcinoma. N = 3. 
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Figure 7. Vacuum electrostatic potential maps of EGFR kinase domain (A) and 
PTP1B (B) bound to substrates. The structure in (A) was obtained from the NCBI 
structure database and first published in Yun, et al. (PDB 2ITX). The structure in (B) 
was obtained from the same database and was published in Sarmiento, et al. (PDB 
1EEO).  
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Figure 8. Assessment of reporter proteolysis in cell lysates. A) Standard separation 
of Htc-tide, Tyr-tide, and their phosphoforms from the fragments of Tyr-tide. Htc-
tide shares four fragments with Tyr-tide (i-iv). i: 6FAM-E-OH; ii: 6FAM-ED-OH; iii: 
6FAM-EDD-OH; iv: 6FAM-EDDE-OH; v: 6FAM-EDDEY-OH; vi: 6FAM-EDDEYE-
OH; vii: 6FAM-EDDEYEE-OH. B) Reporter breakdown in A431 lysates as a function 
of time. N = 3. 
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Figure 9. EGFR reporter phosphorylation in A431 cell lysates under perturbation. 
Both Htc-tide and Tyr-tide phosphorylation faithfully report EGF-induced kinase 
activity stimulation and EGFR TKI-induced inhibition. N = 3. 
 
 89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Single cell analysis using Tyr-tide and Htc-tide. A) Tyr-tide is not 
phosphorylated (left panel), but undergoes proteolysis (right panel) in single intact 
A431 cells loaded by pinocytosis (N = 6). Htc-tide is both phosphorylated and 
metabolized in intact A431 cells (N = 11). B) Htc-tide phosphorylation and 
proteolysis is dose-dependent.  
 
A 
B 
Total Htc-tide (zmol) 
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CHAPTER 3: TOWARD HIGH THROUGHPUT EGFR ACTIVITY 
MEASUREMENTS IN SINGLE TUMOR CELLS 
3.1 Introduction 
 In previous chapters the necessity of measuring oncogenic EGFR kinase 
activity in single intact cells has been extensively discussed. This chapter focuses on 
validation of the Htc-tide-based single cell EGFR assay developed in Chapter 2, with 
the aim of adapting the assay to an automated CE-LIF system designed for high 
throughput serial analysis of single cells. An overarching goal of this dissertation is 
to create a tool which can be used to explore intercellular heterogeneity in EGFR 
signaling. Intercellular heterogeneity is a well-established feature of cancer1,2 and has 
been proposed as a mechanism underlying disease relapse in cancer patients treated 
with targeted kinase inhibitors.3 Tumor cell populations are rapidly evolving in 
response to Darwinian selection pressures comprising their local microenvironment. 
1,4-6 Because the microenvironment of, and therefore the selection pressures 
experienced by, each cell are unique, intratumoral heterogeneity can be extremely 
high. 
 The practical consequence of intratumoral, or intercellular, heterogeneity 
from a clinical standpoint, is that a tumor may contain subpopulations with a wide 
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range of responses to targeted drugs.7,8 The ability to quantify drug target activity in 
each cell from a tumor biopsy would provide clinicians with a holistic view of 
aberrant signaling across individual tumors, thus enabling design of more 
efficacious treatment regimens targeting each subpopulation within the tumor. 
Statistically robust detection of intratumoral subpopulations is to some extent 
limited by the number of cells that can be accurately analyzed. Importantly, this 
number depends not only upon the number of usable cells present in the biopsy 
sample, but also on the throughput of the single cell analysis platform used. 
 The Htc-tide-based single cell EGFR assay described in the previous 
chapter can be adapted to high throughput serial analysis on automated 
instrumentation developed in the Allbritton lab. 9,10 The highest throughput 
achieved on this system to date is 3.5 cells/min (210 cells/h), separating fluorescent 
dyes loaded into non-adherent cells.9 This chapter details the in cellulo validation of 
the Htc-tide assay and preliminary work on its adaptation to the high throughput 
serial analysis system.  
 A three-dimensional (3D) cell culture model was chosen as a model 
system for assay validation. 3D culture is a convenient research tool that more 
closely mimics in vivo tumor structure and nutrient gradients compared with 
traditional 2D culture systems, while retaining the convenience and ready 
availability of 2D systems. 11,12 3D cultures, or spheroids, generally are composed of 
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three regions based on nutrient and oxygen permeation across the spheroid 
diameter.13 In the outer region, where cells have most access to nutrients, cells are 
proliferative. As growth factor penetration decreases, cells become quiescent. The 
core of the spheroid is inaccessible to nutrients, resulting in cell necrosis. 11,13 
Interestingly, differences have been reported in EGFR-family kinase activity and 
response to targeted inhibitors in 3D compared with 2D cultures. Luca and 
colleagues surveyed EGFR expression and pathway activation in a series of 
colorectal cancer models, and showed that decreased EGFR expression in 3D culture 
models using quantitative RT-PCR and immunoblotting.14 Weigelt, et al. found that 
3D cultures of breast cancer cell lines overexpressing the EGFR family kinases 
responded differently to anti-EGFR family kinase inhibitors compared with 2D 
cultures.15 Importantly, the authors observed differential sensitivity of 3D cultures 
for monoclonal antibody inhibitors versus the small molecule TKI lapatinib, which 
targets EGFR and its relative HER2. We explore the capacity of the Htc-tide-based 
EGFR assay to report differences in EGFR activity in 2D and 3D cultures of the 
EGFR-overexpressing A431 cell line, derived from an epidermoid carcinoma of the 
vulva. 
3.2 Methods 
3.2.1 Materials 
 Buffers and additives were purchased from Sigma Aldrich (St. Louis, 
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MO), Fisher Scientific (Hampton, NH), or AMRESCO (Solon, OH) unless otherwise 
indicated. Primary antibodies were purchased from Cell Signaling Technology 
(Danvers, MA). Primary rabbit-anti-human antibodies used were anti-EGFR (D38B1, 
#4267), anti-pEGFR (Y1068, #2234), and anti-GAPDH (#5174). Secondary goat anti-
rabbit antibody was from GE (Fairfield, CT). Gels were purchased from BioRad 
(Hercules, CA). The A431 cell line was purchased from the ATCC (Manassas, VA). 
InfluxTM pinocytic loading reagent was from Life Technologies (Carlsbad, CA).  
3.2.2 2D and 3D A431 Cell Culture and Treatment 
 2D A431 cultures were maintained as suggested by the ATCC. Growth 
medium was DMEM supplemented with 10% fetal bovine serum and pen-strep. 3D 
A431 cultures (“spheroids”) were grown in standard polystyrene 96-well tissue 
culture plates modified with an agarose meniscus in each well, as previously 
described.12,16 Briefly, low-melting point agarose was suspended at 1% (w/v) in water, 
then dissolved by maintaining in a 100 ˚C water bath for 30 min. The agarose 
solution was quickly dispensed in 100 µL portions into each well of a 96-well plate. 
The agarose was allowed to set at room temperature for at least 2 h before seeding 
cells. The final agarose gel formed a concave meniscus in each well which facilitates 
spheroid formation. A431 cells were trypsinized, then counted in a hemocytometer 
prior to seeding at a density of 50,000 cells/150 µL. For drug treatment studies, 
spheroids were allowed to coalesce for four days, then treated on the fifth day with 
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50 µL of 4X DMSO (vehicle) or lapatinib in complete DMEM added to each well 
using a multichannel pipette. Spheroids were treated overnight then analyzed the 
next day. 2D A431 cultures were treated in parallel by growing monolayers to 80-
90% confluence, then treating overnight with 1X vehicle or lapatinib. In all cases, the 
final concentration of lapatinib was 60 nM, which is in the range of the reported IC50 
values for lapatinib in vitro and in A431 monolayers.17-19 A convenient value on the 
lower end of this range was chosen in order to maximize the possibility of observing 
differences in response in the two culture systems.  
3.2.3 Pinocytic Loading of A431 Cells 
 Pinocytic loading was performed according to the vendor’s instructions 
and a previously published protocol.20 A431 monolayers were stripped from the 
culture flask using trypsin with EDTA, then counted. Approximately 106 cells were 
pelleted 1 min at 2000 rpm, then resuspended in hypertonic loading medium 
containing 180 µM Htc-tide. The cells were incubated 10 min at 37 ˚C, then pelleted. 
The loading medium was reserved for re-use up to three times. Loaded cells were 
immediately resuspended in 1 mL hypotonic lysis medium (60% serum free DMEM, 
40% water) to lyse pinosomes and release Htc-tide into the cytosol. The cells in 1 mL 
hypotonic medium were quickly added to 2 mL hypotonic medium at 37 ˚C. This 
point was considered time zero in all cases. The cells were aliquoted into two 1.5 mL 
tubes, incubated 90 s, then pelleted by centrifugation (1 min at 2000 rpm). The 
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hypotonic medium was quickly removed and replaced by complete DMEM. The 
cells were either immediately plated for imaging or single cell analysis, or were 
allowed to recover at 37 ˚C until analysis. 3D A431 cultures were loaded as above 
following disaggregation with warm trypsin-EDTA and gentle vortexing. 
Disaggregated spheroids were rinsed with warm media or PBS prior to use to 
remove necrotic debris from the spheroid core.  
3.2.4 Bulk EGFR Assays in Intact Cells 
 2D and 3D cultured A431 cells were loaded with Htc-tide as described 
above, then incubated 50 min at 37 ˚C. The cells were washed 1X with PBS, pelleted, 
then resuspended in cold PBS containing 1X cOmplete protease inhibitor (Roche, 
Penzberg, Germany) and 1X PhosSTOP pan-phosphatase inhibitor (Roche, Penzberg, 
Germany). Cells were immediately lysed with heat (5 min at 100 ˚C). The lysates 
were clarified by centrifugation at 14000 rcf for 15 min in a 4 ˚C centrifuge. Samples 
were stored at -20 ˚C until analysis. 
3.2.5 Microscopy 
 Brightfield and fluorescence microscopy was performed on a Nikon 
Eclipse inverted microscope fitted with an arc lamp and filter sets appropriate to the 
fluorophores used. Images were acquired with a CoolSNAP HQ2 CCD camera 
(Photometrics, Tucson, AZ) and analyzed in ImageJ (http://rsb.info.nih.gov/ij). 
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3.2.6 Western Blotting 
 2D and 3D cultured A431 cells treated as indicated were collected by 
trypsinization, then washed twice with PBS. Cells were lysed by suspending in a 
minimal volume of NP40 lysis buffer supplemented with 1X cOmplete protease 
inhibitor and 1X PhosSTOP, then incubating on ice for 20 min with occasional 
agitation. Lysates were clarified by centrifugation as above then analyzed for total 
protein content by a Bradford assay (BioRad, Hercules, CA). 20-50 µg total 
protein/15 µL was denatured in sample buffer containing bromophenol blue and 2-
mercaptoethanol by boiling at 100 ˚C, then separated by SDS-PAGE. Separated 
denatured proteins were transferred to a PVDF membrane for 1 h at 100 V (4 ˚C). 
The membrane was blocked 30 min in 5% (w/v) bovine serum albumen in TBST 
before incubating overnight with primary antibody at 4 ˚C. Incubation of secondary 
antibody was performed for 1 h at 4 ˚C immediately prior to imaging. Blots were 
developed using Bio-Rad Clarity Western ECL Substrates (catalog #170-5061) and 
imaged using an Alpha Innotech Fluor Chem FC2 imager.  
3.2.7 Capillary Electrophoresis 
 Capillary electrophoretic separations were performed in 30 µm i.d. bare 
silica capillaries. The background electrolyte used was 200 mM boric acid/NaOH, 
pH 9.5, with 2 mM SDS, unless otherwise noted. Detection was performed with 
laser-induced fluorescence as described in the preceding chapter. Standards were 
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loaded hydrodynamically for 10 s. The estimated loading volume, taking into 
account both hydrodynamic loading and spontaneous fluid displacement, was 530 
pL for a 10 s injection.  
3.2.8 Single Cell Analysis  
 Single cell analysis was performed as described in the preceding chapter. 
3.2.9 Data Analysis 
 Electropherograms were processed using custom MATLAB software. 
Software functions included additional data filtering through a low-pass second 
order Chebyshev filter, automated baseline determination, and peak integration. 
Separation efficiencies and peak resolution were calculated based on peak 
parameters derived from Gaussian peak fitting performed using IgorPro. 
3.3 Results and Discussion 
3.3.1 Proposed EGFR Assay in 3D Cultured A431 Cells 
 The proposed workflow for single cell analysis of cells isolated from 3D A431 
cell cultures is represented in Figure 11, and is similarly applicable to primary tumor 
specimens obtained from clinical or research sources. Following treatment of 3D 
culture with the EGFR TKI lapatinib, the spheroid is disaggregated using trypsin-
EDTA to yield a single cell suspension. In the case of clinical specimens, optimized 
protocols appropriate to the tissue would be implemented. The cells are then loaded 
with Htc-tide and incubated to allow phosphorylation by EGFR. For this early work, 
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the cells are loaded using pinocytosis (Figure 12B). Ultimately, Htc-tide will be 
passively loaded to minimize cellular perturbation and resulting experimental 
artifacts. Passive loading may be accomplished by a variety of strategies, discussed 
extensively elsewhere.21-25 Promising possibilities include covalent conjugation of the 
reporter to a lipid or cell-penetrating peptide to drive passive diffusion across the 
outer cellular membrane. Following an appropriate incubation period, the cells are 
lysed and analyzed as discussed in the preceding chapters. Automated serial 
analysis will allow hundreds to thousands of cells to be analyzed in a single 
experiment. 
3.3.2 Pinocytic Loading of A431 Cells with Htc-tide 
 For assay validation, pinocytosis was used to introduce Htc-tide into the 
cytosol of large populations of cells. Briefly, a hypertonic loading solution was 
prepared containing 200 µM Htc-tide. The hypertonic medium consisted of the 
InfluxTM loading reagent (Life Technologies) in DMEM with 5% serum and 50 mM of 
a HEPES buffer. Incubation of cells in the hypertonic solution caused the cells to 
equalize the tonicity across the plasma membrane by taking up packets of the 
surrounding medium into the cytosol. These packets, called pinosomes, were 
encased in plasma membrane; subsequent incubation of the loaded cells in a 
hypotonic solution caused the pinosomes to lyse and released the contents into the 
cytosol, thus initiating the intracellular kinase assay. The cells can then be exchanged 
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into complete medium to recover prior to imaging and/or analysis. Representative 
brightfield and fluorescence microscopy images of A431 cells loaded with Htc-tide 
by pinocytosis are presented in Figure 12A and B, respectively. The cells were co-
stained with propidium iodide (PI), a DNA and RNA-intercalating fluorophore 
excluded by cells with an intact plasma membrane, to indicate dead cells. No 
evidence of co-localization of Htc-tide and PI is observable in Figure 12B, indicating 
that Htc-tide-loaded cells remain viable after pinocytosis.  
 A431 monolayers (2D cultures) were serum-starved overnight and either left 
untreated or stimulated with EGF immediately prior to loading with Htc-tide. CE-
LIF analysis of the cytosolic fraction of bulk homogenates of these cells indicate that 
Htc-tide phosphorylation in intact A431 cells is EGF-dependent (Figure 12C and D). 
Taken together with literature evidence for exceptionally high EGFR expression 
levels in A431 cells, the strong EGF dependence of Htc-tide phosphorylation 
suggests that EGFR is primarily responsible for observed reporter phosphorylation 
under these conditions. 
3.3.3 3D Culture of A431 Cells 
 Generation of 3D A431 cultures, or spheroids, was accomplished as 
outlined in Figure 13. Standard polystyrene 96-well tissue culture plates were 
modified for culture by adding 100 µL of a warm 1% (w/v) agarose solution to each 
well, then allowing the solution to gel at room temperature for at least two hours. As 
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the agarose solidified it formed a deep concave meniscus in the bottom of each well. 
A431 cells are unable to adhere to the agarose surface. Therefore, cells in suspension 
seeded into the wells coalesced into compact spheroids, aided by the geometry of 
the well bottom. A431 cells seeded at 50,000 cells/well-formed spheroids within 24 h. 
The diameter of the spheroids quantified by microscopy gradually decreased over 
the course of 4 days, presumably due increases in spheroid compactness and 
intercellular adhesion over time. Spheroids to be analyzed were treated with drug 
on day 4 and analyzed on day 5 of culture. Prior to analysis either by western 
blotting or peptide reporter assays, spheroids were disaggregated with trypsin-
EDTA and washed to remove the necrotic core. 
3.3.4 Differences in EGFR Activation in 2D and 3D Cultured A431 Cells 
 Relative EGFR expression and autophosphorylation in 2D and 3D A431 
cultures were compared by western blotting (Figure 14A). In keeping with 
published reports of EGFR expression in CRC spheroids, total EGFR expression is 
slightly decreased in the 3D A431 cultures.14 EGFR autophosphorylation at Y1068, a 
proxy for receptor activation, is also lower in the 3D cultures. This observation 
supports the canonical model of spheroid structure, in which only the outermost 
ring of cells are actively proliferating. Given that EGFR is a key player in cell growth 
and proliferation, it is to be expected that its activity will be lower in the quiescent 
inner ring of the spheroid than in the outer proliferative ring. EGFR 
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autophosphorylation is inhibited in both models upon treatment with lapatinib at 60 
nM.  
 Surprisingly, EGFR activity assessed by the intracellular Htc-tide assay is 
higher in the 3D cultured cells (Figure 14B). Treatment with lapatinib reduces Htc-
tide phosphorylation to the levels observed in the 2D cultured cells. The discrepancy 
between the western blotting data and the peptide assay may be due in part to the 
fact that western blotting cannot directly measure kinase activity. Rather, 
phosphorylation at one of the receptor’s autophosphorylation sites (Y1068) is taken 
as a proxy for kinase activity. While this is a common approach to estimating EGFR 
activity, phosphorylation at Y1068 alone provides an incomplete picture of EGFR 
activation. The receptor contains multiple phosphorylation sites which reflect kinase 
activity in complex, poorly-understood ways.26-30 Reports of differential EGFR 
activation in 2D and 3D cultures rarely monitor phosphorylation of more than one 
of these sites, opting rather to probe phosphorylation of downstream proteins 
associated with EGFR signaling.14 A further complication is differential metabolism 
of Htc-tide in the two culture systems (Figure 14C). While the extent of reporter 
metabolism is independent of drug treatment, Htc-tide metabolism is significantly 
higher in the 2D cultured cells. This may be attributable to generally higher 
metabolism rates in actively proliferating cells, which probably comprise a much 
higher percentage of the 2D cultures compared to the 3D cultures given uniform 
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access of the 2D cultured cells to nutrients and oxygen. This dual functionality of the 
reporter may be an interesting avenue for future research.  
3.3.5 Separation Optimization for 4 cm Effective Length CE-LIF System 
 CE-LIF analyses of Htc-tide assays in the preceding sections were performed 
on a conventional single cell microelectrophoresis platform with a capillary effective 
length of 27 cm, using a BGE of 200 mM boric acid/NaOH, pH 9.5, with 2 mM SDS. 
Total separation time on this system under optimized conditions is 2.5 h; this 
significantly limits throughput, particularly for single cell analyses. To enable higher 
throughput analyses comparing Htc-tide phosphorylation in single 2D and 3D 
cultured A431 cells, the separation was re-optimized for compatibility with the 
automated single cell analysis system, which has a capillary effective length of 4 cm. 
Figure 15A shows the dependence of Htc-tide/pHtc-tide resolution on both the 
buffer (boric acid) concentration and additive (SDS). Generally, 200 mM boric acid 
with concentrations of SDS below the CMC (8 mM) gave the best resolution. 
Addition of SDS to the BGE also greatly improves separation reproducibility (data 
not shown), presumably due to decreased protein and lipid adsorption to the 
capillary wall. Optimization of pH (Figure 15B) yielding somewhat puzzling results. 
Separation efficiencies (z-axis) increased with pH up to 9.5, then dropped abruptly. 
Resolution was best a pH 8.5 and pH 10.0, and was found to drop between pH 9.5 
and pH 10.0. Given that differences in resolution were quite small overall and 
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consistently greater than 1.0, pH 9.8 was chosen, despite the lower resolution and 
separation efficiency, for initial testing of single cell analysis. The reason for this is 
that the conditions are only slightly more basic than the initial BGE but resulted in 
slightly longer migration times. This was thought to reduce the likelihood of a major 
change in fragment migration patterns and fragment co-migration with either Htc-
tide or pHtc-tide. Furthermore, repeated comparison of pH 9.5 and pH 9.8 showed 
more reproducible migration times under the pH 9.8 conditions (data not shown). 
The resulting optimized separation is 35 min total, which is a significant 
improvement over the conventional separation. This was thought to be acceptable 
for initial validation of the single cell analysis. However, a more extensive buffer 
optimization will be necessary to further improve separation reproducibility and 
efficiency and to reduce separation time below 10 min. A separation on the order of 
a few minutes or shorter will greatly facilitate high throughput serial analysis. In the 
future, a range of different buffer systems, pH values, and additives will be tested to 
achieve the desired separation.  
3.3.6 EGFR Activity in Single A431 Cells 
 Electropherograms from initial tests of single cell analysis on the high 
throughput system are collected in Figure 16A-H. The standard separation (6A, 6E) 
is reproducible between days. Htc-tide phosphorylation in serum-starved, EGF 
stimulated 2D cultured cells (Figure 16B-D) is in keeping with population data 
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(Figure 2C) and increases with time. Phosphorylation in basal 2D cultured cells is 
lower as expected and is again time-dependent (Figure 16F-H). Htc-tide resistance to 
proteolysis is truly impressive, with a significant amount of Htc-tide and pHtc-tide 
detectable even after 3 h (Figure 16H). These preliminary data demonstrate proof-of-
concept for future high throughput single cell analyses in 2D and 3D cultures.  
3.4 Conclusions and Future Directions  
 The data presented in this chapter lay the foundation for future high-
throughput analysis of EGFR activity in single cells. Htc-tide is differentially 
phosphorylated and metabolized in intact cells from 2D and 3D cell cultures. Htc-
tide phosphorylation decreases upon EGFR inhibition by the selective inhibitor 
lapatinib. The separation component of the assay was successfully shortened by two 
hours, and future work will shorten the total assay time even further. Future work 
will focus on applying this validated assay to biologically relevant systems. 
Analyses in 3D cultured cells will continue to serve as a method development and 
validation platform, particularly as the high throughput analysis workflow is further 
refined. Ultimately, this assay will be applied to EGFR activity measurements in 
single primary cells, including those derived from pancreatic xenografts exhibiting 
elevated expression of EGFR. The ability to assay response to EGFR inhibitors at the 
single cell level will be a valuable tool for probing heterogeneous EGFR activity and 
drug sensitivity in real populations of tumor cells. 
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Figure 11. Proposed workflow for single cell analysis of EGFR activity in response 
to lapatinib treatment in 3D cell cultures and solid tumors. 
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Figure 12. Pinocytic loading of Htc-tide into A431 cells. (A) Brightfield microscopy 
of A431 cells after pinocytic loading and seeding onto CellTak. (B) Composite 
fluorescence microscopy image of Htc-tide-loaded (green) and propidium iodide-
stained (red) A431 cells. (C)-(D) Bulk lysates of A431 cells loaded with Htc-tide after 
serum starving overnight and stimulating with EGF (C) or leaving untreated (D). 
Symbols: * = internal standard; N = Htc-tide; P = pHtc-tide.
A B 
C D 
25 µm 25 µm 
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Figure 13. Schematic of 3D culture technique. 
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Figure 14. Differences in EGFR activity in 2D and 3D A431 cultures. (A) Western 
blot showing decreased EGFR expression and autophosphorylation in 3D cultures 
vs. 2D cultures. Blots are representative of triplicate experiments. (B)-(C) Bulk lysate 
data from 2D and 3D cultured A431 cells loaded with Htc-tide. Htc-tide is 
phosphorylated to a greater extent in 3D cultures (B), but is metabolized to a lesser 
extent (C). N = 3. Blots by Mike Lebhar and Josh Mu. 
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Figure 15. CE separation optimization for high throughput serial analysis. (A) 
Resolution of Htc-tide and pHtc-tide is dependent on the concentration of boric acid 
buffer (pH 9.5) and of SDS. (B) Htc-tide/pHtc-tide resolution and separation 
efficiencies depend strongly on pH in a complex manner. N = 1 
 
A 
B 
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Figure 16. Single cell analysis on the high throughput system on two separate 
days. (A)-(D) Day one, analysis of single A431 cells that had been serum starved and 
stimulated with EGF prior to loading. (A) Standard separation on day one. (E)-(H) 
Day two, analysis of single A431 cells treated with DMSO in complete medium 
(vehicle). (E) Standard separation on day two. Incubation time for each cell is 
indicated on the electropherograms. Symbols: * = Internal Standard; N = Htc-tide; P 
= pHtc-tide; F = Fragment.  
A B 
C D 
E F 
G H 
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CHAPTER 4: A HIGHER THROUGHPUT SITE-DIRECTED COMBINATORIAL 
APPROACH TO KINASE REPORTER OPTIMIZATION 
4.1 Limitations of Kinase Reporter Selectivity 
 The specificity of peptide substrates for tyrosine kinases is constrained by the 
lack of native secondary specificity determinants including spatial and temporal 
localization, defined secondary structure, and auxiliary domains which promote 
protein-peptide binding.1,2 Because the catalytic domain is highly conserved across 
all known tyrosine kinases, few kinases have unique recognition motifs, and a large 
degree of overlap in recognition is found even among functionally distinct 
enzymes.3,4 Tyrosine kinases in intact cells rely on stimulus-specific spatiotemporal 
context and highly selective docking domains to recruit appropriate substrates for 
phosphorylation.5-7 This exquisitely evolved mechanism of specificity is 
exceptionally challenging to mimic synthetically. Nevertheless, many researchers 
have explored rational and semi-rational design of selective peptides.  
4.1.1 Synthetic Approaches to Spatiotemporal Control 
  An elegant approach to intracellular peptide localization involves 
synthetically modifying the peptide with a lipid to encourage membrane 
localization. Lipid modifications that have been reported include myristic 
acid8,cholesterol9, and palmitic acid10. An alternative to lipid targeting is to 
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incorporate a peptidic targeting signal into the overall peptide substrate design. 
These include membrane-crossing sequences11-13, nuclear targeting sequences (e.g. 
TAT)14-16, and mitochondria targeting sequences17-20. Lipid and peptide targeting 
groups are usually covalently tethered to the peptide substrate cargo; if desired, this 
linkage can be engineered to be selectively cleaved following substrate localization. 
For example, a lipid may be employed to localize a peptide substrate proximal to its 
membrane-bound target enzyme and to protect from off-target enzymatic activities, 
followed by release of the substrate cargo in the vicinity of the target enzyme for 
improved access to the enzyme active site. Cleavable linkages that may be employed 
include disulfide linkages, which are cleaved in the reducing environment of the 
cytosol,21,22 photocleavable linkages that release the cargo upon irradiation with a 
specific photon energy, and enzyme-cleavable linkages. 
 Some groups have reported incorporating peptidic docking domains in their 
overall substrate design to facilitate selective binding to the kinase of interest. Small 
protein domains such as SH2 and WW bind, or “dock onto”, specific 
phosphorylated residues within target kinases, thus recruiting their cargo for 
phosphorylation and activity modulation.5,23 Full-length docking domains are too 
large for complete chemical synthesis, but many groups have reported incorporating 
biosynthetic docking domains in genetically engineered peptide biosensors to 
increase selectivity24 or as an integral part of the sensing mechanism.25-27 Fernandes, 
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et al. reported that appending a short peptide derived from an allosteric binding 
domain of a MAPK protein substrate to a short synthetic MAPK peptide substrate 
increased peptide affinity for MAPK 200 fold.28 
 In addition to control of spatial localization, some groups have reported 
methods to exert temporal control over intracellular peptide substrates. This is 
achieved by blocking active sites within the peptide substrate with a stimulus-
responsive functional group. For example, “photocaging” of the substrate 
phosphorylation site shields the peptide from being acted upon by the enzyme 
target. Exposure to the correct wavelength of light releases the protecting group and 
makes the peptide available for phosphorylation. Thus the experimenter is able to 
precisely control the experiment “time zero” and potentially derive kinetic 
information from the experiment.29 
4.1.2 Modification with Unnatural Amino Acids 
 Traditional peptide substrates are limited both in overall size (< 20 a.a.) and in 
composition. Peptide substrates derived from intracellular protein phosphorylation 
sites or from combinatorial motif scans are constructed from among the 20 
proteinogenic amino acids; often, this limited pool of chemical diversity is further 
reduced by omitting side reaction-prone amino acids such as tryptophan and 
cysteine.30 Attempts to discover highly selective substrates of reasonable 
(synthesizable) size from such a limited pool of chemical characteristics have largely 
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failed.31,32 An alternative approach, and one complementary to those discussed in the 
previous section, exploits the exponential increase in chemical diversity accessible 
by synthetically incorporating nonnative and non-proteinogenic amino acids into 
peptide substrates. Rational substitution of nonnative amino acids into promiscuous 
peptide substrates has proven to be an effective, but laborious, method to increase 
substrate specificity of the target kinase over off-target enzymes.33,34 Lawrence and 
colleagues developed a more efficient high-throughput optimization technique in 
which an existing peptide ligand is converted to a scaffold for site-directed 
combinatorial modification by substituting diaminopropionic acid (Dap) at a 
selected site within the original substrate. The Dap residue provides a free primary 
amine which is subsequently acylated with a highly diverse library of synthetic 
carboxylic acids to generate a peptide library containing novel unnatural side chains 
at the selected position. The key to this approach is synthesis of the library on a 
custom cystamine modified resin, allowing DTT-mediated cleavage of the peptide 
library from the resin in kinase assay buffer. The library can then be immediately 
screened for activity, eliminating laborious isolation and purification steps. The 
authors applied this powerful technique to the development of a highly selective 
and potent peptidic inhibitor of PKC (IC50 ≈ 2 nM) capable of discriminating 
between the target kinase and highly homologous isoforms (PKC,).35 
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4.1.3 Site Directed Combinatorial Method for Substrate Optimization 
 The combinatorial optimization scheme developed by Lawrence and 
colleagues for discovery of high-affinity peptidic inhibitors can be modified to 
develop selective tyrosine kinase substrates. Peptide substrates of tyrosine kinases 
are notoriously promiscuous because the high degree of homology among the 
catalytic domains of tyrosine kinases leads to extensive overlap in recognition motifs. 
This chapter outlines a combinatorial optimization campaign, based on the work of 
Lawrence et al, whose purpose is to fine-tune the selectivity of an existing peptide 
substrate for the Epidermal Growth Factor Receptor (EGFR). This substrate “TyrSub” 
(EELEDDYEDDNleEE)36,37 is a previously published sequence pulled from an in vivo 
phosphorylation site and is a substrate for multiple enzymes in addition to EGFR. 
The 6FAM-labeled version of the substrate (“TyrSub-13”, 6FAM-
EELEDDYEDDNleEE-NH2) is efficiently phosphorylated by EGFR in vitro and 
exhibits excellent resistance to proteolytic degradation in cell lysates.38,39 However, 
its susceptibility to off-target kinase activities limits its usefulness as an analytical 
tool in biological matrices; increased selectivity for EGFR would enable improved 
biochemical analyses of EGFR activity in cell lysates and intact cells. 
 4.2 Methods 
 The workflow for the combinatorial optimization of TyrSub is outlined in 
Figure 17. First, a truncated version of the reporter “TyrSub-9” (6FAM-
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LEDDYEDDNle-NH2) was chosen as the scaffold peptide for optimization because it 
is phosphorylated equivalently to TyrSub-13, is similarly stable in cell lysates, and 
can be synthesized more efficiently. The scaffold site for acylation with the 
carboxylic acid library was chosen as described in detail below, followed by 
synthesis of the total scaffold on DTT-cleavable resin. Lysine was chosen to provide 
the free amine for acylation, rather than Dap, because its longer side chain reduces 
the steric barrier to acylation with bulky carboxylic acids at positions proximal to the 
resin. Selective acylation of the scaffold with a structurally-diverse 90-member 
carboxylic acid library yielded a 90-member peptide library with novel, unnatural 
side chain functionalities at the modification site. Cleavage of the peptide library 
with DTT kinase assay buffer was followed by screening for in vitro phosphorylation 
by EGFR and by the off-target kinase Spleen Tyrosine Kinase (Syk). Hits generated 
were synthesized on amide resin, extensively purified, and validated with 
quantitative CE-LIF.  
4.2.1 General Synthetic Methods 
 C-terminal amide peptides were synthesized by standard Fmoc SPPS on 
NovaSyn TGR amide resin (NovaBiochem, EMD Millipore, Billerica, MA); synthesis 
was performed manually in fritted polymer syringes or using a Protein Technologies 
PS3 semi-automated peptide synthesizer. Amino acid building blocks were 
orthogonally protected with base-labile Fmoc and acid-labile tBu protecting groups 
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at the -amino and side chain phenol or carboxylic acid groups, respectively, unless 
otherwise noted. Coupling of sequential amino acids to the resin was effected using 
the HCTU/DIEA/DMF method (Appendix A). Difficult couplings were repeated 
with 2-4 fold increases in reagent excess where economically feasible. Completed 
coupling was verified by a negative Ninhydrin test (AnaSpec, Fremont, CA, 
Appendix A). Fmoc removal was effected as detailed in Appendix A. The 
deprotection solution was supplemented with 0.1M HOBt, a weak organic acid, to 
suppress piperidine-mediated racemization through aspartimide formation. C-
terminal thiol peptides were synthesized on custom cystamine-modified resin, 
described below, using the same protocols as above. 
 N-terminal fluorescein labeling of Fmoc-deprotected peptides with 6-
carboxyfluorescein (6FAM, AnaSpec, Fremont, CA) was accomplished using either 
an HCTU/DIEA/DMF or DIC/HOBt/NMP method (18-24 h, Appendix A). The 
DIC/HOBt/NMP method was preferred for improved coupling efficiencies with 
fewer moles of fluorophore. One to two overnight couplings were generally 
necessary for complete labeling as monitored by Ninhydrin test. Successfully labeled 
peptide resin was treated twice (5-15 min) with deprotection solution to cleave 
fluorescein esters immediately prior to cleavage. N-terminal biotin labeling of 
deprotected peptides was performed by reacting N-terminal deprotected peptide 
resin overnight with 10 molar equivalents each of O-Nitrophenyl ester-protected 
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biotin and HOBt in NMP. Complete labeling was checked by Ninhydrin test and 
repeated couplings performed as needed. Completed peptides were cleaved from 
the resin and isolated using the protocol appropriate to the resin used (Appendix A), 
followed by reconstitution where appropriate in aqueous media.  
4.2.2 Cystamine Resin Preparation and Characterization 
 DTT-cleavable cystamine resin was prepared as described previously.35 
Briefly, PEG-grafted copolymer polystyrene resin beads modified with free 
carboxylic acid functional groups (Tentagel-S-COOH, AnaSpec; loading capacity 0.2 
µmol/mg) were pre-activated 1 h with 5 eq TSTU and 15 eq DIEA dissolved in DMF 
(50 mL/g resin). Following pre-activation, 10 eq cystamine and 20 eq DIEA dissolved 
in an equivalent volume of water were added to the reaction vessel, and the reaction 
allowed to proceed overnight. The resin beads changed color from pale yellow to 
brown, indicating successful coupling. Coupling was terminated after 16-24 h by 
washing 6X with each of the following: distilled water, DMF, and DCM. Successful 
coupling was confirmed by a positive Ninhydrin test. Successfully modified resin 
was then loaded with Fmoc amino acid (10 eq) using HCTU/DIEA/DMF (Appendix 
A). Loading was allowed to proceed overnight, followed by sequential rinsing with 
DMF, IPA, and DCM. Complete loading of resin was verified by a negative 
Ninhydrin test. 
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 Fmoc-amino acid loading of the cystamine resin was determined as follows. 
A standard curve of piperidine-dibenzofulvene (max = 290 nm) was prepared by 
monitoring absorbance as a function of Fmoc-Ala-OH concentration in 30% (v/v) 
piperidine in DMF. Piperidine-dibenzofulvene forms as a result of piperidine-
mediated Fmoc removal from the Fmoc-amino acid. Absorbance measurements at 
290 nm were taken in a quartz cuvette using a Molecular Devices SpectraMax M5 
spectrometer. Three 10 mg portions of vacuum-dried, loaded cystamine resin were 
aliquoted into 1.5 mL polypropylene tubes and treated 5 min with 30% (v/v) 
piperidine in DMF, with gentle shaking, followed by centrifugation to pellet the 
resin. The absorbance at 290 nm of the supernatant was used to back-calculate the 
amount of Fmoc loaded onto the resin, and thus the resin loading capacity in 
µmol/mg. Typical loading capacities were in the range of 0.04 µmol/mg.  
4.2.3 Crude Peptide Purification and Characterization 
 Crude peptide products were purified by RP HPLC on Phenomenex C18 
analytical and/or semi-preparative columns (Torrance, CA) using gradient elution 
on an Agilent HPLC with UV and fluorescence detection modules (Santa Clara, CA). 
High yield peptides requiring little purification were eluted using short gradients 
(2.5-3.3 %/min) from 100% water to 100% acetonitrile (each with 0.1% TFA ion 
pairing reagent). Low yield/difficult peptides were purified using extended 
gradients (1.4-2.0 %/min, water to acetonitrile or methanol) on higher efficiency 
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analytical columns where feasible. Eluted fractions were characterized by soft-
ionization mass spectrometry (MALDI-TOF2 MS or ESI-quadrupole MS) in negative 
ion mode. 
4.2.5 Library Synthesis and Characterization 
 A selection of 90 structurally diverse carboxylic acids was kindly provided by 
Dr. David Lawrence (Appendix C). Stock solutions (0.9 M) were prepared in DMF, 
aliquoted into deep-well solvent-resistant plates, and stored at -20 C until use. The 
library scaffold was synthesized as above on cystamine resin and labeled with 5/6-
FAM at the N-terminus. The modification site lysine was protected with highly acid-
labile Mtt which could be removed with very low concentrations of TFA in DCM, 
leaving the tBu side chain protecting groups in place.  
 Acylation of the library site lysine was effected as follows. First, the Mtt 
protecting group was removed from the peptide scaffold resin by repeated 
treatment with 2% (v/v) TFA in DCM in 5 min increments over the course of 1 h 
until the TFA solution no longer turned yellow. For an unknown reason, the Mtt 
proved very difficult to remove, and the multiple TFA treatments needed almost 
certainly deprotected some of the tBu group as well. The deprotected scaffold 
peptide resin was washed sequentially with DMF, 5% (v/v) DIEA in DMF to 
neutralize TFA remaining, DMF, IPA, and DCM. It was then dried under a stream of 
N2(g) and stored at -20 C until acylation with the library compounds.  
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 For acylation with the library compounds, the dried, deprotected resin (0.5 g) 
was swelled 30 min at a density of 50 mg resin/mL DMF then distributed at 5 
mg/well into a fritted solvent resistant 96-well plate. The DMF was removed by 
vacuum filtration, followed by resuspension in 0.05 mL of fresh activation solution 
(100 eq PyBOP:100 eq HOBt:1000 eq NMM). Acylation was initiated by adding 0.1 
mL of a unique 0.9 M carboxylic acid solution (in DMF) to each well. The plate was 
sealed and gently shaken overnight. Repeated couplings with fresh activation 
solution were necessary for complete acylation as monitored by spot-checking with 
a Ninhydrin test. The acylated peptide library-bound resin was washed sequentially 
3X with DMF, IPA, and DCM and dried 3 min under vacuum. The dried resin was 
stored at -20 C until cleavage. 
 Cleavage of the peptide library first required removal of remaining acid-labile 
side chain protecting groups in 95% TFA/2.5% TIS/2.5% water (2.5 h). Fresh TFA 
needed to be added at intervals over the course of the cleavage because the small 
volume (0.2 mL) of volatile TFA evaporated rapidly (approximately every 45 min). 
The library-bound resin was rinsed sequentially with DMF, IPA, and DCM, dried, 
and stored at -20 C until further use. 
 The resin was treated 30 min with 30% (v/v) piperidine in DMF to cleave any 
esters formed (fluorescein, carboxylic acid, etc.), followed by extensive rinsing with 
DMF, IPA, and DCM and drying 5 min over vacuum. The peptide library was then 
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cleaved from the resin using kinase assay buffer (10 mM DTT in 50 mM Tris, pH 7.5, 
fresh) as follows: 250 µL for 1 h, 125 µL for 1.5 h, 125 µL for 1 h. After each step, the 
cleaved peptide was filtered into a deep-well 96-well plate. The cleaved library was 
aliquoted into 96-well plates and frozen at -20 C until analysis.  
 The purity of each library compound was estimated by semi-quantitative 
MALDI-TOF MS analysis on an AB Sciex 4800 Plus instrument (Framingham, MA) 
using the following matrix: -cyanohydroxycinnamic acid saturated in 50% ACN 
(aq) with 5 mM citric acid and 0.1% TFA. Library compound was spotted 2:1 with 
matrix on a polished steel substrate (AB Sciex). Mass spectra were acquired in both 
positive and negative ion modes. Peaks from each spectrum were exported for 
analysis in MATLAB using the following parameters:  
 mass range: 1200-2000 Da 
 peak density: 1/5 Da 
 S/Nmin: 5 
 Areamin: 100  
 (Peaks/Spot)max: 500 
Peak density was defined as the maximum number of peaks detectable within a 
given mass window. The S/Nmin was defined as the minimum acceptable signal-to-
noise ratio for a detected peak. The Areamin was defined as the minimum acceptable 
area for a detected peak. The (Peaks/Spot)max was defined as the maximum number 
of exported peaks in a given sample. The exported lists of peaks and signal 
intensities were processed with the MATLAB code shown in Appendix B. 
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Nine compounds were selected randomly for quantitative purity analysis 
with LC/MS. Analyses were performed on an Agilent 1200 series instrument with an 
Agilent 6100 single quadrupole spectrometer. The column was a C18 column from 
Grace (Alltima, 3 µm particles, 2.1 X 50 mm; Columbia, MD). Samples were eluted 
with a 6.1%/min gradient of 3% to 95% acetonitrile/water (0.1% formic acid) 
following an isocratic desalting step. Mass spectra were acquired in negative ion 
mode.  
4.2.6 High Yield Synthesis of Asp-Containing Scaffold and Library Hit 
Compounds 
The library scaffold was synthesized on CLEAR amide resin (Peptides International) 
on a microwave synthesizer (Liberty, CEM Corp., Matthews, NC). The sequence 
prepared was: Fmoc-LEDDYEDK(Dde)Nle-(CLEAR resin). Fmoc-amino acids were 
coupled to the resin using HBTU/DIEA in DMF with double couplings at each 
position. Fmoc removal was accomplished using 20% (v/v) piperidine in DMF 
supplemented with 0.1 M HOBt. No evidence of aspartimide formation was 
observed in the intermediate unlabeled product by analytical RP-HPLC-MS. The 
scaffold was N-terminally deprotected and labeled with 6FAM, followed by three 2 
min treatments with deprotection solution to remove FAM esters. Reactive hydroxyl 
groups on the 6FAM label were protected with an acid labile 2-chlorotrityl group (12 
eq 2-chlorotrityl chloride + 12 eq DIEA in DCM, 16 h in a glass vessel). Tritylation of 
the 6FAM label is necessary to prevent reaction of the label with the hydrazine 
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deprotection solution in the next step. The scaffold was then selectively deprotected 
at the library modification site K(Dde) by treating the scaffold-bound resin 3 x 5 min 
with 3% (v/v) hydrazine in DMF. The library hit peptide 4-10F was prepared by 
labeling the deprotected K(NH2) site with N-(3-indolylacetyl)-L-phenylalanine (5 eq) 
using a slight excess of Oxyma and DIC in DMF. After a 10 min preactivation, the 
coupling reaction was allowed to proceed overnight. This was repeated at higher 
reagent excesses as needed for complete coupling as monitored by Ninhydrin test. 
Completed peptides were cleaved from the resin and isolated using the TFA 
cleavage detailed above. Synthesis of the desired product at high purity was verified 
by RP-HPLC-MS and CE-LIF.  
4.2.7 In Vitro Kinase Assays 
 In vitro kinase assays were performed under the optimal conditions for each 
kinase. Kinase buffers were as follows: 
 Buffer A: 5 mM MOPS, pH 7.2; 0.05 mM DTT; 1 mM EGTA; 0.4 mM 
EDTA; 4 mM MgCl2; 10 mM MnCl2; 0.02% (w/v) BSA; 1 mM ATP 
 Buffer B: 50 mM Tris-HCl, pH 7.5; 0.1 mM EGTA; 0.01% (w/v) BSA; 1 
mM DTT; 0.1 mM sodium pervanadate; 50 mM MgCl2; 1 mM ATP 
 Buffer C: 20 mM MOPS, pH 7.2; 1 mM EDTA; 0.1% (w/v) BSA; 10 mM 
MnCl2; 2 mM MgCl2; 5% (v/v) glycerol; 0.1 mM sodium pervanadate; 1 
mM ATP 
 Buffer D: 50 mM Tris-HCl, pH 7.5; 0.5 mM MnCl2; 5 mM MgCl2; 2 mM 
DTT; 1 mM ATP 
 Buffer E: 50 mM Tris-HCl, pH 7.5; 100 mM NaCl; 0.1 mM EDTA; 5 mM 
DTT; 50% (v/v) glycerol 
 Buffer F: 8 mM MOPS, pH 7.0; 0.2 mM EDTA; 4 mM MgCl2; 1 mM ATP 
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 Buffer G: 20 mM MOPS, pH 7.0; 5% (v/v) glycerol; 0.01% (w/v) Brij-35; 
0.1% (v/v) -mercaptoethanol; 0.1% (w/v) BSA 
 Buffer H: 5 mM MOPS, pH 7.2; 1 mM EGTA; 15.3 mM EDTA; 10 mM 
MnCl2; 4 mM MgCl2; 0.025 mM DTT; 8 ng/mL BSA; 1 mM ATP 
 Buffer I: 5 mM MOPS, pH 7.2; 1 mM EGTA; 15.3 mM EDTA; 10 mM 
MgCl2; 0.025 mM DTT; 8 ng/mL BSA; 1 mM ATP 
 
All in vitro kinase assays were performed at 30 C at the indicated enzyme and 
peptide concentrations. Assays were terminated either with an equal or greater 
volume of 0.2 M HCl or by addition of EDTA to a final concentration of 10 mM. 
Assays of EGFR kinase activity were performed in Buffer A using recombinant 
purified EGFR kinase domain (residues 696-end). Spleen Tyrosine Kinase (Syk) 
assays were performed in Buffer B will the full length recombinant protein. 
HER4/ErbB4 tyrosine kinase assays were performed in Buffer C using the 
recombinant catalytic domain (residues 706-991). Abelson tyrosine kinase (Abl) 
assays were performed in Buffer D with recombinant full-length Abl diluted in 
Buffer E. Src tyrosine kinase assays were performed in Buffer F with full length 
recombinant Src diluted in Buffer G. All enzymes were purchased from EMD 
Millipore, aliquoted at working volumes, and stored at -80 C until use. Assays were 
performed in low retention polypropylene microcentrifuge tubes at 10-30 µL total 
volumes. 
 High throughput kinase assays for library compound screening were 
performed in 40 µL-well 96 well polystyrene plates at total assay volumes of 10 µL. 
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Briefly, 2X reaction mixture containing EGFR kinase domain (final concentration: 9 
ng/µL) and Buffer A were pipetted into each well of the 96-well plate, followed by 
assay initiation by addition of 5 µL 1X library compound (final concentration: 1/2X). 
High throughput Syk activity screens were performed in Buffer B to a total assay 
volume of 14 µL with 0.5 ng/µL Syk and 1/2X library compound, as above. Plates 
were sealed and incubated at 30 C for 60 min followed by assay termination by 
addition of an equal volume of 20 mM EDTA. Assays were aliquoted and stored at -
20 C until analysis.  
4.2.8 Capillary Electrophoresis 
 Quantitative capillary electrophoresis analyses were performed on Beckman 
Coulter ProteomeLab PA800 (Pasadena, CA) automated instruments in 30 µm i.d. 
bare silica capillaries pretreated with NaOH and HCl. Detection was performed 
with laser-induced fluorescence using a 488 nm argon ion laser. The optimized 
electrophoretic buffer was 0.3 M boric acid/NaOH, pH 7.5. Analytes were diluted to 
100-250 nM in 1 part electrophoretic buffer to 2 parts water to promote analyte 
stacking and compensate for the high ionic strength of kinase assay samples. 
Separations were carried out at 600 V/cm. 
4.2.9 MALDI-TOF MS 
 Semi-quantitative MALDI-TOF MS analyses were performed on an AB Sciex 
4800 Plus instrument (Framingham, MA) using an -cyanohydroxycinnamic acid 
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matrix (saturated in 50% ACN (aq) with 0.1% TFA and 5 mM citric acid). Spots for 
MALDI ionization were prepared by an air dry method, in which 400-850 nL of 
sample containing 10-13-10-10 mol analyte was spotted onto a patterned steel substrate. 
Before the sample dried, 400-850 nL matrix was spotted on top of the sample and 
allowed to co-crystalize slowly at room temperature in a laminar flow hood. This 
spotting method lead to reproducible, visibly homogeneous spot formation and 
good analyte ionization, provided adequate dilution of concentrated high-salt 
samples had been performed. Ionization was performed with a pulsed UV laser, 
followed by mass analysis by TOF MS in high resolution reflectron mode.  
4.2.10 Homogeneous Luminescence Assays 
 Two high throughput homogeneous (“mix-and-read”) assays were 
investigated as possible screening platforms for detecting phosphorylation of library 
compounds by EGFR and Syk (Figure 18). PerkinElmer’s LANCE and AlphaScreen 
assays are commonly employed in drug discovery laboratories for early-stage 
discovery and validation of clinical kinase inhibitors. Kits for the two assays were 
kindly provided by the vendor. Details of each assay mechanism are provided in the 
discussion sections below. Assays were performed according to vendor instructions. 
Briefly, positive and negative synthetic controls were prepared containing either 
extracellular buffer or Buffer H (for LANCE) or Buffer I (for AlphaScreen) and 
indicated concentrations of biotinylated TyrSub-9 (biotin-LEDDYEDDNle-NH2) or 
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its synthetically phosphorylated analog (biotin-LEDDpYEDDNle-NH2) as negative 
and positive controls, respectively. For LANCE detection, 60 µL of assay sample was 
mixed with 190 µL 1.3X detection mixture (1.3 nM Europium chelate-conjugated 
anti-phosphotyrosine antibody, 47 nM ULight-labeled streptavidin, 1.3X detection 
buffer) in a white opaque plastic 96-well plate. The plate was sealed and shaken 1 h 
at room temperature prior to analysis on a Molecular Devices SpectraMax M5 plate 
reader (Sunnyvale, CA) using optimized parameters. For AlphaScreen detection, 
assay samples were diluted 1:100 in AlphaScreen control buffer; 20 µL of this 
mixture was dispensed into a PerkinElmer ½ Area Plate, followed by addition of 20 
µL 60 µg/mL anti-phosphotyrosine-conjugated acceptor beads. Antibody beads 
were incubated with the assay sample 1 h or overnight at room temperature, 
followed by addition of biotinylated donor beads (20 µL at 60 µg/mL) and a 30 min 
incubation prior to analysis. Plates were read on a specialized EnVision plate reader 
(PerkinElmer, Waltham, MA) kindly provided by Dr. Bill Janzen in the UNC Drug 
Discovery Center. Steps including and following addition of the donor beads were 
carried out in a light-controlled environment to prevent photodegradation of the 
donor beads.  
4.2.11 Library Screen Data Analysis 
 MALDI-TOF spectra of library screening assays were processed using 
MATLAB code modified from a custom program kindly provided by Dr. Ryan 
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Phillips. The code is provided in Appendix B. The input consists of exported peak 
intensities for each MALDI spot, and the corresponding masses, within the mass 
spectra that fall within user defined threshold values. For each spot, corresponding 
to one library peptide or control, MATLAB opens the appropriate file containing a 
matrix of masses and peak intensities and cross-references the mass vector with the 
expected mass of the library peptide, derived from a master file of MALDI spot 
codes and calculated peptide masses. MATLAB applies a mask to the expected mass, 
based on whether the spectra were acquired in negative or positive ion mode, to 
generate the search masses corresponding to the expected ionic species for the 
library peptide and its phosphorylated form. The program also accounts for neutral 
water loss and sodium and potassium adducts. MATLAB searches the mass vector 
for the selected masses within a user-defined tolerance, then simply sums the 
corresponding values in the intensity vector for the library peptide ions and the 
phosphorylated peptide ions. The amount of phosphorylated peptide is calculated 
as a ratio of phosphorylated to total signal and exported. This method was 
employed to quickly screen the library analyses for “hits”—defined as a peptide that 
was phosphorylated better than the control by the target kinase and more poorly 
than the control by the off-target kinase.  
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4.3 Results and Discussion 
4.3.1 Selectivity of the Starting EGFR Peptide  
 The selectivity of 6FAM-TyrSub-9 for EGFR was evaluated using in vitro 
enzyme assays analyzed with quantitative CE-LIF. Assays were performed with 
EGFR, HER4, Syk, Src, and Abl tyrosine kinases as described in the Methods section. 
The results of those experiments are summarized in Figure 19. 6FAM-TyrSub-9 is 
phosphorylated appreciably by each of the kinases tested except Abl. This is not 
surprising given the similarity in consensus sequence for EGFR, Src, and Syk, which 
all prefer highly acidic substrates (Table 4). Measurements in complex biological 
matrices, particularly intact cells, with this peptide would suffer from the ambiguity 
of the protein target, making data analysis difficult. While tyrosine kinase inhibitors 
are available to suppress off-target kinase activities, none of the available tyrosine 
kinase inhibitors is completely selective for its target kinase; indeed, the vast 
majority of tyrosine kinase inhibitors act upon five or more off-target kinases, some 
with comparable affinity to the target kinase.40 Therefore, TyrSub-9 is an excellent 
candidate for combinatorial selectivity optimization.  
4.3.2 Comparison of Potential Library Screening Platforms 
 Three high-throughput phosphopeptide detection platforms (Figure 18) were 
investigated as potential screening assays for the combinatorial peptide optimization 
campaign: LANCE (PerkinElmer), AlphaScreen (PerkinElmer), and MALDI-TOF MS. 
 134 
The three detection schemes were chosen for their sensitivity, amenability to parallel, 
high-throughput analyses, compatibility with available instrumentation, and 
time/cost efficiency. The bases of the detection platforms are described in detail 
below. 
 The LANCE assay is a homogeneous TR-FRET immunoassay that works as 
follows. A biotinylated peptide substrate is phosphorylated by the kinase of interest, 
then mixed with a low concentration of streptavidin labeled with a dye optimized 
for lanthanide-mediated TR-FRET. A Europium chelate-labeled anti-
phosphotyrosine antibody binds only phosphorylated peptide, establishing a FRET 
pair. Stimulation of the Eu chelate at 615 nm within established FRET pairs results in 
excitation of the dye and emission at 655 nm, which can be easily monitored with 
low background using standard fluorescence plate readers. The LANCE assay is 
popular for high-throughput in vitro assays due to its mix-and-read format and 
compatibility with widely-available instrumentation. It is generally restricted to 
simple sample matrices (e.g. not biological) because endogenous fluorophores in 
biological samples can interfere with the TR-FRET and adversely affect sensitivity.  
 The AlphaScreen assay platform is a homogeneous proximity assay similar in 
design to the LANCE assay. Like LANCE, AlphaScreen employs labeled 
streptavidin and anti-phosphotyrosine antibodies to selectively label 
phosphorylated, biotinylated peptide substrate. However, rather than using FRET 
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labels, AlphaScreen uses chemically doped beads. The Donor bead releases singlet 
oxygen (1O2) upon photoactivation at 680 nm. The singlet oxygen diffuses up to 200 
nm to excite the Acceptor beads resulting in broadband emission at 520-620 nm. The 
emission is detected by specialized high sensitivity plate readers such as 
PerkinElmer’s EnVision instruments. The AlphaScreen assay is very sensitive 
because the selective emission pathway is not susceptible to interference from 
endogenous fluorophores, resulting in very low background emission. For this 
reason, AlphaScreen is one of the few high throughput homogeneous assays to be 
successfully adapted to biological matrices.  
 Mass spectrometry is an increasingly popular alternative to luminescence-
based high throughput screening assays. In particular, MALDI-TOF MS is well 
suited to rapid analyses of biomolecules; the soft ionization leads to easy to interpret 
mass spectra. MS is sensitive and highly versatile. Because it is a label-free technique, 
the number of analytes that may be monitored simultaneously is largely limited by 
the range and resolution of the mass analyzer. Sample preparation for MALDI 
involves co-crystallization of the analyte with a small organic matrix compound 
with a strong absorption band at the wavelength of the laser to be employed for 
ionization, usually in the UV. Upon irradiation of the co-crystal, matrix and analyte 
molecules desorb from the MALDI substrate to form a high-energy plume, where 
the gas phase molecules are ionized before being directed into the mass analyzer. 
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Ionization efficiencies vary widely among analytes, so quantitative analyses require 
an internal standard for each species to be quantified. Therefore, semi-quantitative 
analyses are better suited to high-throughput screens where synthesis of an internal 
standard for each compound is not feasible. In this case, semi-quantitative estimates 
of library peptide phosphorylation are sufficient to identify lead compounds for 
secondary quantitative verification. 
4.3.2 Luminescence Assay Validation with Synthetic Standards 
 The luminescence-based commercial assay platforms were tested first as 
library screening assays due to the capability for quantitation and excellent 
compatibility with the assay sample matrix. Biotinylated non-phosphorylated and 
phosphorylated EGFR peptides were synthesized and purified as described in the 
Methods section above. The peptides were reconstituted in a high-salt buffer and 
analyzed by the luminescence assays either in buffer alone or in mock assay 
mixtures comprising all kinase assay components except enzyme. The response of 
the EGFR control peptides was compared to that of the positive control 
phosphorylated peptide LCK-P provided by the vendor. The results of those 
experiments are summarized in Figure 20. Figure 20A shows poor performance of 
the LANCE assay in detecting the positive EGFR control. Compared with the 
commercial positive control, the EGFR positive control is indistinguishable from the 
negative control. The performance of the AlphaScreen platform with the EGFR 
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peptides was superior, with the positive EGFR control showing similar response to 
the commercial positive control, though with less sensitivity at the low range of 
peptide concentration. It is difficult to surmise the reason for poor performance of 
the LANCE assay with the EGFR peptides. The low signal, indicating poor FRET 
efficiency, is possibly due to poor binding of the anti-phosphotyrosine antibody to 
the positive EGFR control, or to the distance between the donor and acceptor of the 
FRET pair being too large for efficient energy transfer. Given the good performance 
of the long-range (200 nm) AlphaScreen immunoassay, the second explanation is 
more likely. 
4.3.3 Effect of N-Terminal Label on Scaffold Phosphorylation by EGFR 
 Given the excellent sensitivity of the AlphaScreen platform with regard to 
synthetic controls, its performance with real assay samples was explored. Detection 
of phosphorylated biotinylated EGFR peptide by AlphaScreen was validated in in 
vitro assays with recombinant EGFR kinase domain (Figure 21). A dose-response of 
AlphaScreen signal versus peptide concentration, compared to synthetically 
phosphorylated control, shows poor phosphorylation of the biotinylated peptide by 
EGFR. This result was unexpected given the excellent phosphorylation kinetics of 
the 6FAM-labeled version of this peptide. However, a comparison of biotinylated 
and 6FAM-labeled peptide phosphorylation by EGFR using MALDI-TOF MS shows 
a significant decrease in affinity of the biotinylated peptide for EGFR (Figure 22). 
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This result can be understood in the context of the preference of EGFR kinase 
domain for highly acidic substrates: 6FAM imparts an additional negative charge at 
physiologic pH, while biotin is uncharged. Furthermore, these data caution against 
the common assumption that the N-terminal labeling of peptide substrates does not 
play a role in enzyme-peptide recognition. Because poor phosphorylation of the 
biotinylated peptide by EGFR precludes use of the AlphaScreen assay as a detection 
platform for the combinatorial peptide optimization campaign, a hybrid approach 
was implemented in which MALDI-TOF MS was employed to first semi-
quantitatively screen the 6FAM-labeled library for lead compounds, followed by 
quantitative validation using CE-LIF. 
4.3.4 MALDI-TOF for Phosphorylation Detection and Effect of Ionization Bias 
 The effect of ionization bias on possible over- or under-estimation of extent of 
phosphorylation in the peptide library screen was evaluated by comparing MALDI-
TOF MS analysis of in vitro EGFR assays with 6FAM-TyrSub-9, to quantitative CE-
LIF of the same samples. CE-LIF analysis under the optimized separation conditions 
provides a bias-free ratio of phosphorylated to total reporter in the EGFR assay 
samples, to which the same parameters derived from MALDI-TOF spectra were 
compared (Figure 23). The head-to-head comparison of the two methods shows that 
MALDI-TOF slightly underestimates phosphorylation of 6FAM-TyrSub-9 compared 
to the CE-LIF values, revealing a small relative decrease in MALDI efficiency of the 
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peptide phosphoform under the analysis conditions used. The addition of two 
negative charges imparted by the phosphoryl moiety probably account for this 
difference. However, since the efficiency differential is small, its effect on assay 
sensitivity is manageable. 
4.3.5 Lysine Scan to Determine Library Site 
 As discussed in detail above, the basis of this combinatorial optimization 
campaign is a semi-rational site-directed coupling of synthetic carboxylic acids to 
the side chain of a lysine residue to generate a library of peptides containing novel, 
structurally diverse non-native amino acids at the chosen modification site. Before a 
full-scale library was prepared, the optimal modification site within the starting 
6FAM-labled EGFR peptide was determined. Potential modification sites were 
identified at the three positions immediately C-terminal to the tyrosyl 
phosphorylation site. A comparison of the recognition motifs of EGFR and other 
tyrosine kinases reveals a nearly universal preference for anionic residues in the Y-N 
(N-terminal) region proximal to the phosphorylation site. In the Y+N region, greater 
diversity in terms of side chain polarity and size suggests that this region is 
preferable for coupling structurally diverse, largely cyclic carboxylic acids 
comprising the carboxylic acid library.  
 One modification site was chosen among the three positions immediately C-
terminal to the tyrosine by evaluating the effect on EGFR-catalyzed phosphorylation 
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of substituting acetylated lysine (K(Ac)) at each site. Lysine acetylation is one of the 
chemically and structurally simplest lysine acylations possible and as such 
represents the minimum perturbation to the starting EGFR peptide. If substitution of 
K(Ac) at a given site is not tolerated by EGFR, then that site is not suitable to provide 
a scaffold for combinatorial optimization. EGFR phosphorylation of the three K(Ac) 
peptides is summarized in Figure 24. All K(Ac) peptides were phosphorylated more 
poorly than the starting peptide, an effect probably based on decreased acidity of the 
sequence. Sites Y+1 and Y+3 affected substrate phosphorylation similarly and to a 
lesser extent than Y+2. Since many of the carboxylic acids in the compound library 
are large, bulky polycyclic compounds, the Y+3 site was chosen for combinatorial 
optimization in order to limit steric hindrance of phosphoryl transfer to the tyrosine. 
Therefore, the library scaffold was synthesized with the sequence: 6FAM-
LEDDYEDK(Mtt)Nle-CONH-(CH2)2-S-S-cystamine resin.  
4.3.6 Library Synthesis and Characterization 
 The peptide library was synthesized as described in detail in the methods 
section above. Following cleavage and isolation of the library in DTT kinase buffer, 
acylation efficiency at the library site was assessed by MALDI-TOF MS (Figure 25). 
MALDI-TOF characterization of the library revealed a major impurity in each library 
peptide, with a mass corresponding to that of the unmodified scaffold minus a 
neutral loss of water. This mass is consistent with internal cyclization of the library 
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site lysine with the adjacent aspartic acid residue, which was made possible by 
deprotection of aspartic and glutamic acid residues during Mtt removal, as 
discussed in depth above in the Methods section. Internal cyclization competed with 
lysine acylation with the carboxylic acid library; the amount of cyclized side product 
detected varied based on acylation kinetics of a given library compound. This was 
further verified by RP-HPLC-MS analysis of selected library peptides (Figure 26). 
Despite the highly variable purity across the peptide library, it was possible to 
screen the library for phosphorylation by target and off-target enzymes because 
universal detection with mass spectrometry allowed global monitoring of both 
desired product and side-product modification by the enzymes. Re-synthesis of the 
peptide library with a more orthogonal protecting group such as ivDde at the 
modification site would greatly improve purities across the library and possibly 
reveal more or different lead compounds for enzymes of interest; however, such an 
effort was not within the scope of this project.  
4.3.7 Library Screening and Data Analysis 
 The peptide library was screened for on-target phosphorylation by EGFR and 
for off-target phosphorylation by Syk, a non-receptor tyrosine kinase known to 
phosphorylate the starting EGFR peptide with similar kinetics to EGFR. Syk is a 
drug target in immune cell-derived cancers and autoimmune diseases such as 
rheumatoid arthritis. MALDI-TOF MS spectra of each library peptide were obtained 
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before and after phosphorylation by EGFR and Syk. The fraction of phosphorylated 
peptide was estimated using MATLAB as discussed in detail above in the Methods 
section. The results of those screens are summarized in Figure 27. The fraction of 
phosphorylated peptide is given normalized to the acetylated control 6FAM-
LEDDYEDK(Ac)Nle-CONH-(CH2)2-SH. In the case of EGFR, no peptide was 
phosphorylated better than the control (normalized value >1). However, the screen 
against Syk produced a hit peptide “4-10F” (Figure 28) that was phosphorylated 
approximated 3-fold better than the control and was not detectably phosphorylated 
by EGFR. While EGFR was the primary target of this screen, the potential hit 
substrate for Syk was pursued for its potential utility in single-cell analysis of 
response to clinical Syk inhibition.  
4.3.8 Library Hit Re-Synthesis and Validation 
 High-yield synthesis of the compound 4-10F proved to be highly challenging. 
Despite replacement of lysine(Mtt) for lysine(ivDde) at the library site, allowing 
fully orthogonal and selective deprotection at that site using hydrazine, persistent 
formation of a racemic side product was detected during quantitative CE-LIF 
validation. The side product is of the same mass as the desired peptide and is 
resolvable from the desired peptide by CE but not by analytical RP-HPLC, strongly 
suggesting that the side product is a -isoform resulting from aspartimide formation. 
In the presence of acid or base, protected aspartic acid residues can cyclize with the 
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amide nitrogen of the peptide backbone, eliminating the side-chain protecting group. 
Nucleophilic opening of the aspartimide ring yields a mixture of - and -peptide 
(Figure 29) that is indistinguishable by mass and difficult to separate using standard 
liquid chromatography. Aspartimide formation is among the best documented side 
reactions in solid phase synthesis of peptides and is commonly mediated by the 
piperidine deprotection reagent used to remove N-terminal Fmoc-residues. 41,42 
Repeated piperidine treatments over the course of a synthesis lead to increases in 
aspartimide formation at each step and make total suppression of aspartimide 
formation extremely challenging.43 Several strategies are available for reduction of 
aspartimide formation in susceptible sequences. The most common is to supplement 
the piperidine deprotection solution with a weak organic acid, most often HOBt, 
which partially suppresses deprotonation of the peptide backbone amide44. 
Alternatively, piperidine can be replaced by a weaker base such as piperazine45, but 
suppression of aspartimide formation is balanced by slow deprotection kinetics and 
possible related side reactions due to long treatment times. Piperidine treatment 
times can be minimized by using microwave synthesis, where deprotection times 
can be as short as 1-2 min. This approach is not suitable for all sequences, as 
microwave synthesis is known to facilitate other common side reactions in SPPS. 
Protection of the aspartic acid side chain with bulky group such as OMpe41 has been 
shown to discourage aspartimide formation, but OMpe-protected aspartic acid is 
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prohibitively expensive for many syntheses, particularly those on a large scale. 
Protection of the backbone amide with an Hmb group has been shown to completely 
eliminate aspartimide formation in most cases46, but Hmb-protected reagents must 
be purchased as expensive dipeptides that are available in a limited range of 
compositions. Minimizing contaminating water in synthesis reagents is particularly 
important for labs located in humid climates, as excess water facilitates aspartimide 
formation. Ensuring that frozen reagents are fully at room temperature before 
opening and sequentially washing resin with solvents of decreasing hydrophilicity 
to exclude excess water will greatly aid in managing aspartimide formation in 
susceptible sequences. Several of these approaches were implemented to mitigate 
aspartimide formation in the synthesis of 4-10F. A combination of careful control of 
water content during synthesis, HOBt supplementation during deprotection, use of 
OMpe-protected aspartic acid, and microwave synthesis was necessary to 
meaningfully decrease the amount of -peptide observed by CE-LIF. However, 
despite extensive purification, an unidentified side product appearing only in CE-
LIF analyses of enzyme assays of the peptide continues to complicate quantitative 
validation of the peptide and limits its present utility for further biochemical studies. 
Future work should include a more detailed structural characterization of the 
peptide and its modification by EGFR and Syk, including nano-LC-MS of assay 
samples. A potential route to achieve superior purification of the reporter at large 
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scale would be supercritical fluid chromatography, a technique popular in industrial 
labs for conducting preparative scale high efficiency, highly selective separations of 
structurally similar compounds that is increasingly being adapted to biomolecule 
separations and can be implemented using standard HPLC pumps.47,48  
 CE-LIF analysis of 4-10F phosphorylation by recombinant Syk (Figure 30) 
shows formation of a time- and ATP-dependent peak that likely is due to 
phosphorylated 4-10F. However, an impurity closely migrating with the major peak 
which is indistinguishable by MS interferes with straightforward interpretation of 
the data. This impurity is probably -peptide whose formation could not be 
completely suppressed despite all previous efforts. Further efforts to purify 4-10F to 
remove -peptide will be necessary, as discussed above.  
4.4 Conclusions and Future Directions 
 This work has laid the groundwork for a future combinatorial campaign to 
generate optimized EGFR substrate(s) by optimizing synthetic parameters and 
validating screening platforms. Future campaigns should follow the optimized 
synthetic guidelines for peptide scaffold preparation and should explore positions 
N-terminal to the phosphorylation site as possible modification sites. Future 
campaigns should also expand selectivity screening to include more receptor and 
non-receptor tyrosine kinases.  
 The library screening platform could be improved further by drawing 
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inspiration from the work of the Mrksich lab at Northwestern University.49,50 
Researchers in that lab have developed a specialized MALDI technique in which 
analytes are immobilized to a gold MALDI substrate using a gold-thiol self-
assembled monolayer (SAM) technique. The analytes are immobilized in a 
background of triethylene glycol-modified alkanethiols which prevent adsorption of 
biomolecules and allows assays to be performed directly on the MALDI substrate. 
Spots can be washed prior to ionization to remove salts, biomolecules, and other 
interferents to maximize ionization efficiency and assay sensitivity. This technique, 
known as SAMDI, would be a particularly interesting addition to the peptide library 
screening workflow, as the library peptides already are functionalized at the C-
terminus with a free thiol that could be used to immobilize the peptide on the 
MALDI substrate. Figure 31 outlines a proposed workflow for such a detection 
scheme. A PEG spacer could be introduced between the cystamine resin linkage and 
the C-terminal amino acid of the library peptide to promote even, dense packing of 
the SAM and to allow the enzyme interaction sites within the peptide to extend 
beyond the background triethylene glycol SAM for easy access to the enzyme active 
site. Use of SAMDI as a screening platform would also enable screening in complex 
biological matrices such as cell lysates, where peptide selectivity could be evaluated 
using selective stimulators and inhibitors of enzyme activity, including 
susceptibility to proteolysis and dephosphorylation.  
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 Generation of selective substrates for tyrosine kinases remains a daunting 
challenge that is unlikely to be completely solved by any one approach. A toolbox of 
well-characterized complementary strategies to improve substrate selectivity is 
highly desirable. Because peptide substrates have traditionally played a limited role 
in analyses of enzyme activity in complex matrices, work to increase substrate 
selectivity has been target focused rather than geared toward comprehensive suites 
of solutions. The combinatorial optimization approach outlined in this work is 
highly versatile and modular and is not limited to the tyrosine kinases used here. 
For these reasons, this technology has the potential to comprise an important part of 
a comprehensive selectivity optimization toolbox
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Table 4 Protein Tyrosine Kinase Consensus Sequences; red: anionic; blue: cationic; 
purple: polar uncharged; grey: hydrophobic; bold: phosphosite; X: any amino acid. 
Kinase Consensus Sequence Reference 
EGFR X-E-E-E-Y-F-X-X-X Ubersax, et al. 2007 
SRC X-E-E-I-Y-E/G-X-F-X Ubersax, et al. 2007 
ABL X-X-X-I/V/L-Y-X-X-P/F-X Ubersax, et al. 2007 
SYK E-D-E-D-Y-E-S-V-G Deng, et al. 2014 
IRK X-X-X-X-Y-M-M-M Ubersax, et al. 2007 
CSK D-E-Q-I-Y-W-Q-I-A Deng, et al. 2014 
LYN D-E-D-I-Y-G-V-L-P Deng, et al. 2014 
JAK D-P-Q-E-Y-I-P-L-P Deng, et al. 2014 
BMX E-E-P-I-Y-I-I-V-P Deng, et al. 2014 
FRK R-D-V-I-Y-I-I-I-P Deng, et al. 2014 
PYK H-P-I-I-Y-pT-I-I-E Deng, et al. 2014 
FES D-E-E-pY-Y-E-I-I-A Deng, et al. 2014 
ACK R-A-F-I-Y-A-I-I-P Deng, et al. 2014 
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Figure 17. Library screening workflow. A) The optimal modification site within the 
starting peptide is selected by monitoring the effect of substituting acetylated lysine 
at various positions and comparing the measured EGFR activity with respect to each 
peptide. B) The library scaffold peptide containing the chosen modification site is 
acylated with a library of 90 unique carboxylic acids in a 96-well synthesis plate, 
followed by cleavage of the 90 library peptides in DTT kinase buffer. C) The 90-
member peptide library is screened for phosphorylation by EGFR using in vitro 
kinase assays.
A B C 
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Figure 18. Summary of library screening platforms. A) LANCE TR-FRET: Eu 
chelate-labeled anti-phosphotyrosine antibody binds phosphorylated peptide with 
N-terminal biotin label, followed by binding of ULight dye labeled streptavidin. 
Excitation at 615 nm stimulates FRET and emission by ULight dye at 655 nm. B) 
AlphaScreen: Donor bead-labeled streptavidin and Acceptor bead labeled anti-
phosphotyrosine bind phosphorylated biotinylated peptide substrates. Excitation of 
the Donor beads at 650 nm stimulates singlet oxygen emission, which stimulates 
broadband emission between 520-620 nm. C) MALDI-TOF MS: Co-crystallization of 
phosphorylated and non-phosphorylated peptides with UV-absorbing matrix is 
followed by desorption of matrix and analytes by irradiation with a pulsed UV laser. 
Desorbed molecules ionize and are directed to the TOF mass analyzer, where 
phosphorylated and non-phosphorylated peptide are detected.
A 
B 
C 
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Figure 19. Time courses of 6FAM-TyrSub-9 phosphorylation by a panel of 
tyrosine kinases. A) 6FAM-TyrSub-9 (10 µM) was incubated with recombinant 
EGFR (4 ng/µL), Syk (2 ng/µL), or HER4 (10 ng/µL) for the indicated times and 
percent phosphorylation quantified by CE-LIF. B) 6FAM-TyrSub-9 (5 µM) was 
incubated with Syk (0.5 ng/µL), Abl (1.6 ng/µL), or Src (1.3 ng/µL) for the indicated 
times and percent phosphorylation quantified by CE-LIF. N = 1. 
A B 
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Figure 20. Comparison of phosphorylated Biotin-TyrSub-9 detection by LANCE 
TR-FRET (A) and AlphaScreen (B) under optimized conditions. AlphaScreen, but 
not LANCE, detects phospho-Biotin-TyrSub-9 comparably to the commercial control. 
N = 1. 
A B 
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Figure 21. AlphaScreen detection of in vitro phosphorylation of Biotin-TyrSub-9 
by EGFR. A small increase in phosphorylation is detectable by AlphaScreen, but 
sensitivity to small changes in phosphorylation is very poor and very little 
phosphorylated peptide is detected overall. N = 1.
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Figure 22. MALDI-TOF MS analysis of in vitro EGFR assays with Biotin-TyrSub-9 
(Biotin-TS9, A) and 6FAM-TyrSub-9 (6FAM-TS9, B). The biotinylated peptide is 
phosphorylated significantly more poorly than the 6FAM-labeled peptide. 
A B 
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Figure 23. Effect of ionization efficiency differential on measurement bias in 
MALDI-TOF MS. Assays of EGFR-catalyzed phosphorylation of 6FAM-TyrSub-9 
were analyzed by MALDI-TOF MS (y-axis) and quantitative CE-LIF (x-axis). 
MALDI-TOF MS underestimates the percentage of phosphorylated peptide in every 
sample in a well-defined linear manner. N = 1
 160 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Site scan to determine optimal library optimization site within the starting EGFR peptide. The starting 
EGFR peptide TyrSub-9 (FAM-LEDDYEDDNle-amide) and three acetylated lysine (K(Ac)) substituted peptides were 
assayed for phosphorylation by recombinant EGFR. Percent phosphorylation was quantified by CE-LIF. N = 1. 
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Figure 25. Results of the MALDI-TOF screen of the EGFR peptide library. The percent intensity is equal to the signal 
collected corresponding to the expected mass for each compound divided by the total signal measured from all species. 
The percent yield is equal to the signal corresponding to the expected mass divided by the signal corresponding to the 
unreacted library scaffold. The values are color coded by intensity according to the key provided. N = 1.  
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Figure 26. RP-HPLC-MS analysis of selected library compounds. The compound code and structure are overlaid on 
each chromatogram. Stars (*) indicate peaks corresponding to correctly synthesized products, determined by ESI-MS. For 
each compound, the top chromatogram is a plot of total ion count vs. time, acquired on an ESI-single quadrupole MS in 
negative ion mode. The bottom chromatogram is a plot of absorbance at 240 nm vs. time.
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Figure 27. Library compound screening by MALDI-TOF MS. Top graph: The library peptides are in general well-
phosphorylated by Syk, with several peptides phosphorylated better than the acetylated lysine control peptide. Bottom 
graph: Acylation at the library modification site is tolerated poorly by EGFR across all compounds. The primary hit for 
Syk (4-10F, structure of acylating reagent shown) is phosphorylated 4X better than the control and is not detectably 
phosphorylated by EGFR. N = 3 except where otherwise indicated. 
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Figure 28. Structure of the Syk screen hit 4-10F. 
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Figure 29. Mechanism of aspartimide formation and resultant racemization.
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Figure 30. Phosphorylation of 4-10F by recombinant Syk. Stacked traces show 
formation of a new peak (*) that is time- and ATP-dependent.
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Figure 31. Proposed workflow for modified library screen with SAMDI. A) 
Structures of 6FAM-TyrSub-9 (top) and the library scaffold with a C-terminal PEG 
spacer between the peptide and the resin linkage. B) Simplified view of peptide 
library synthesis using PEG. 
 
kinase 
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APPENDIX A. PRACTICAL SOLID PHASE PEPTIDE SYNTHESIS 
Solid phase synthesis of short peptides (2-15 residues) using Fmoc chemistry 
is a mature, extensively studied technique that nevertheless requires a considerable 
level of experience to practice successfully and efficiently. The aim of this section is 
to provide a series of both general and specialized synthesis protocols that, borne 
out of trial and error, consultation with collaborators and the literature, and 
experience, have served the author well over the course of this work. It is the 
author’s hope that these protocols will offer practical support to any researcher 
embarking on the journey of solid phase peptide synthesis. 
Overview of Fmoc Solid Phase Peptide Synthesis 
Peptide synthesis at its most basic involves sequential formation of peptide 
bonds (Figure 32) between consecutive amino acids in the peptide sequence. In 
solution phase synthesis, selective bond formation between amino acids is non-
trivial. For many years, synthetic challenges limited the capabilities and popularity 
of peptide synthesis. Merrifield’s 1963 solid phase synthesis of a tetrapeptide 
introduced a novel and, as history has shown, revolutionary concept to the field of 
peptide synthesis.1 Solution phase synthesis of even short amino acid polymers is a 
laborious, lengthy, costly, and inefficient task due to the necessity of isolating and 
characterizing the many peptide intermediates. Merrifield’s introduction of a 
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heterogeneous synthetic medium reduced the problem of isolating intermediates to 
a simple wash step. Later, the introduction of the fluorenylmethyl carbonyl (Fmoc) 
amino protecting group expanded the utility and accessibility of solid phase peptide 
synthesis (SPPS) through milder, safer reaction conditions and online spectroscopic 
reaction monitoring.2 Fmoc SPPS is now the standard peptide synthesis approach in 
industry and academic labs around the world. 
 Fmoc SPPS builds on Merrifield’s original approach of tethering nascent 
peptide chains to porous solid supports by their carboxy termini, constructing the 
peptide from C- to N- from the surface of the support. The carboxy-support linker, 
usually acid labile, performs the dual functions of protecting the peptide C-terminus 
and of conferring the desired C-terminal functionality to the peptide upon cleavage. 
The fundamental advantage of Fmoc chemistry is the orthogonal protection of the 
amino groups with the base labile Fmoc group, allowing the full peptide chain to be 
constructed under basic conditions that have no effect on the peptide-support bond. 
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 Protocol 1. Manual Synthesis of a General Tyrosine Kinase Substrate  
The following protocol will guide the reader through a solid phase synthesis of the 
peptide Ac-DNEYFYV-NH2,3 a general tyrosine kinase substrate derived from the 
protein FLT3. Unless otherwise noted, all reagents were purchased from Fisher 
Scientific (Waltham, MA) or Sigma Aldrich (St. Louis, MO), with the exception of 
Fmoc-amino acids, which were purchased from EMD Millipore (Billerica, MA). 
Supplies 
NovaSyn® TGR Amide resin (NovaBiochem, EMD Millipore, Billerica, MA) or other 
suitable amide resin with moderate loading capacity 
Fmoc-Asp(OtBu)-OH 
Fmoc-Asn(Trt)-OH 
Fmoc-Glu(OtBu)-OH 
Fmoc-Phe-OH 
Fmoc-Val-OH 
Fmoc-Tyr(OtBu)-OH 
HCTU 
0.4 M 4-Methylmorpholine in DMF (ACT) 
20 (v/v)% Piperidine in DMF + 0.1 M HOBt (DEP) 
Acetic anhydride 
Trifluoroacetic acid 
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Triisopropyl silane 
Solvents: DMF, DCM, MeOH, IPA 
Ninhydrin (Kaiser) test kit (AnaSpec, Fremont, CA) 
Protocol 1.1 Peptide Synthesis on the Solid Support 
1. Allow resin and all reagents to reach room temperature before use to 
minimize contamination from moisture. 
2. Weigh desired quantity of resin and transfer to fritted glass synthesis vessel 
or fritted solvent-resistant polymer synthesis syringe. Rinse resin with each of 
the following: MeOH (3X), IPA (3X), DCM (3X), DMF (6X). Allow resin to 
swell in several mL of DMF with gentle agitation for 20-30 min to ensure 
maximum reagent access to resin active sites. 
3. Drain the resin and, if necessary, treat 2X10 min with several mL of DEP 
solution to deblock Fmoc-protected resin active sites. Following DEP 
treatment, resin should be rinsed a minimum of 6X with fresh DMF to ensure 
complete removal of piperidine before proceeding to the next step. 
4. Prepare resin loading solution: 5 eq Fmoc-Val-OH + 4.5 eq HCTU in the 
minimum volume of ACT needed to dissolve the reagents and fully suspend 
resin in a slurry. Whenever HCTU is used to activate Fmoc-amino acids for 
coupling to resin, the Fmoc-amino acid should always be maintained in slight 
excess to avoid side product formation.  
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5. Add coupling solution to resin and allow to react with gentle agitation for 1 h 
at room temperature. 
6. Rinse resin well with DMF and check for complete coupling using the 
Ninhydrin test (see Protocol 1.2). If the Ninhydrin test is positive, repeat steps 
4 and 5 until a negative Ninhydrin test is achieved. 
7. Treat rinsed resin 2X10 min with DEP under gentle agitation, then rinse 
thoroughly to fully remove piperidine. 
8. Repeat steps 4-7 for each subsequent residue, building the peptide from C- to 
N-terminus. 
9. After coupling of the N-terminal aspartic acid and Fmoc-removal at that site, 
rinse the resin thoroughly with DMF. Prepare the acetylation solution by 
mixing ~1 mL acetic anhydride with ~1 mL ACT and add immediately to the 
resin. React 1 h with gentle agitation, then rinse extensively with DMF to 
remove all trace acetic anhydride. Test for complete acetylation using the 
Ninhydrin test, and repeat as necessary. 
Protocol 1.2 Monitoring Coupling Completion with the Ninhydrin Test 
1. In a small test tube, combine ~20 µL of each of three Ninhydrin test 
reagents. The solution should be a very pale yellow. 
2. Using a Pasteur pipette or wide-bore glass capillary, transfer 
approximately 0.5 mg of peptide-bound resin beads to the tube. 
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3. Incubate the test tube in a sand bath between 90-110 ˚C for 5 min. If no 
free primary amines are present, the solution will remain pale yellow to 
brownish. If free primary amines are present, indicating incomplete 
reaction, the beads will turn dark blue to purple. Depending upon the 
amount of resin present, the solution may also turn dark purple-blue. 
Note: The Ninhydrin (Kaiser) test will only detect primary amines. Other tests 
are available to check reaction completion at secondary or tertiary amines. 
Protocol 1.3 Peptide Cleavage from the Resin and Isolation 
1. Rinse peptide-bound resin 6X in each of the following: DMF, IPA (or MeOH), 
DCM. Dry the resin briefly under vacuum or with a gentle jet of N2(g) to 
remove residual solvent.  
2. Prepare the cleavage cocktail: 95% trifluoroacetic acid with 2.5% triisopropyl 
silane and 2.5% water added to scavenge cleaved side chain protecting 
groups. Treat resin 2.5-3 h in the cleavage cocktail with gentle agitation to 
cleave peptide from the resin and to remove OtBu and Trt peptide side-chain 
protecting groups. 
3. Transfer peptide-TFA solution to a solvent-resistant centrifuge tube. Apply a 
gentle stream of N2(g) to agitate the surface of the solution and facilitate TFA 
evaporation. Continue until the solution is blown down to less than 1 mL. 
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4. Add 10-15 mL ice cold diethyl ether to the peptide solution. A precipitate 
should immediately form, indicating that the peptide has been successfully 
isolated from the TFA. Collect the peptide precipitate via centrifugation at 4 
˚C and decant ether. It is good practice to reserve the supernatant, removing 
the ether via evaporation, until the precipitate is successfully characterized as 
the desired product. Allow the peptide precipitate to dry in the hood 
overnight, covered with a Kim wipe to prevent contamination by dust.  
5. Reconstitute the peptide for characterization and purification in the 
appropriate solvent. DMSO/water, 50 mM Tris-HCl (pH 7.5), and 50/50 
acetonitrile/water are common choices, depending upon the subsequent 
characterization step.  
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Protocol 2. Labeling Primary Amines with Carboxyfluorescein 
Reagents 
5- or 6-Carboxyfluorescein (AnaSpec, Fremont, CA) 
Diisopropylcarbodiimide (DIC) 
HOBt or Oxyma 
N-Methylpyrrolidonone (NMP) 
Solvents: DMF, MeOH, DCM 
Protocol 
1. Deprotect the resin-bound primary amine to be labeled using the appropriate 
method. Rinse the resin 6X with DMF. 
2. Prepare a solution of 3 eq carboxyfluorescein, 3.4 eq DIC, and 3.4 eq Oxyma 
in NMP. Allow to preactivate 5-10 min. 
3. Add labeling solution to the resin-bound amine and allow to react 12-18 
hours with gentle agitation. 
4. Rinse the resin well with DMF and check for complete coupling using the 
Ninhydrin test. Repeat coupling as necessary. 
5. Before cleavage, rinse thoroughly with DMF and treat resin 1X 5-10 min with 
20% (v/v) piperidine in DMF with 0.1 M HOBt to remove any fluorescein 
esters. 
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6. Rinse the completed product extensively with DMF, MeOH, and DCM to 
remove residual fluorescein and proceed to cleavage step. 
Protocol 3. Microwave Synthesis of a Difficult Aspartic Acid-Rich Tyrosine Kinase Activity 
Reporter 
This protocol will guide the reader through the difficult, side reaction-prone 
synthesis of the tyrosine kinase activity reporter 6FAM-LEDDYEDDNle-NH2 using 
an automated microwave synthesizer. This aspartic acid-rich sequence is prone to 
racemization through aspartimide formation,4-9 resulting in the formation of 
undesirable beta-peptide side products that are extremely difficult to separate from 
the desired product by HPLC. Aspartimide formation is promoted by the presence 
of excess moisture and by prolonged exposure to reactive bases or acids, particularly 
piperidine. Microwave synthesis significantly decreases the reaction times necessary 
for completion of each synthetic step, thus minimizing exposure times to piperidine 
while allowing all reactions to reach completion. Addition of 0.1 M HOBt to the DEP 
solution has been shown to reduce piperidine-mediated aspartimide formation.10,11  
Reagents 
CLEAR amide resin (Peptides International, Louisville, KY) 
250 mM HBTU in DMF 
1 M Diisopropylethylamine (DIEA) in DMF (ACT) 
20 (v/v)% Piperidine + 0.1 M HOBt in DMF (DEP) 
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0.1 M solutions of Fmoc-amino acids with appropriate side chain protection, in DMF 
 E, Y: OtBu 
 D: OMpe 
Solvents: DMF, MeOH, IPA, DCM 
Protocol 
1. Allow resin and all reagents to reach room temperature before use. This is to 
minimize unnecessary exposure to excess moisture, which promotes 
aspartimide formation. 
2. Rinse resin to remove residual water: 3X MeOH, 3X IPA, 3X DCM, 6X DMF. 
3. Prepare reagents as above and set up the synthesizer as per the 
manufacturer’s instructions. The use of Fmoc-Asp(OMpe)-OH, rather than 
the more common Fmoc-Asp(OtBu)-OH, greatly minimizes aspartimide 
formation due to the increased bulkiness of the OMpe protecting group. 
Because this reagent can be cost-prohibitive, it should only be used in very 
aspartimide-prone sequences and can be coupled manually to reduce reagent 
consumption. 
4. Run the synthesis with the following reaction times: 
5. Label, cleave, isolate, and purify peptide as indicated above in protocols 1.3 
and 1.4. 
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Protocol 4. Synthesis of a Sterically Constrained Tyrosine Kinase Activity Reporter 
Containing L-Htc (7-(S)-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) 
This protocol will guide the reader through the synthesis of the sterically 
constrained tyrosine kinase activity reporter 6FAM-EDDE-Htc-EEV-NH2, a 
phosphatase-resistant EGFR Kinase substrate. 
Reagents 
CLEAR amide (Peptides International, Louisville, KY) or NovaPEG amide resin 
(NovaBiochem, EMD Millipore, Billerica, MA) 
Fmoc-amino acids 
HCTU 
0.4 M NMM in DMF 
20% (v/v) Piperidine in DMF + 0.1 M HOBt 
DIC (AnaSpec, Fremont, CA) 
Oxyma (NovaBiochem, EMD Millipore, Billerica, MA) 
DIEA  
2-Chlorotrityl chloride (NovaBiochem, EMD Millipore, Billerica, MA) 
Fmoc-7-S-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid  
6-FAM (AnaSpec, Fremont, CA) 
TFA  
TIS  
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Protocol 4.1 Synthesis of Htc-Containing Peptide 
1. Allow resin to reach room temperature, rinse 3X MeOH, 3X IPA, 3X DCM, 6X 
DMF, and swell 20-30 min DMF. 
2. Manually load resin with Fmoc-Val-OH, and couple the subsequent 2 
glutamic acids using HCTU and NMM in DMF to catalyze coupling. 
Deprotect the peptide resin with 20 (v/v)% piperidine in DMF with 0.1 M 
HOBt, and rinse thoroughly. 
3. Couple 3 eq Fmoc-Htc(OH)-OH overnight to the deprotected peptide resin 
using 3.4 eq DIC and 3.4 eq Oxyma in DMF, following a 10 min preactivation. 
Rinse thoroughly and check for complete coupling using the Ninhydrin test. 
Repeat coupling as necessary. 
4. This step should be performed in a glass vessel. Rinse resin 6-10X with DCM 
and drain. Prepare the tritylation solution: 2-chlorotrityl chloride (50 eq or 100 
mg, whichever is larger) dissolved in 1-5 mL DCM, depending on resin mass, 
with 1000 eq DIEA. Add to peptide resin and react 2 hours. The resin should 
change color from pale yellow-tan to darker yellow-brown. The 2-chlorotrityl 
group will be cleaved with the other side chain protecting groups in 95% TFA, 
but can also be removed earlier in 1-5% TFA in DCM if desired. To test for 
successful tritylation, rinse the resin thoroughly in DCM, then remove a few 
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beads of resin and treat with TFA. If the trityl group was successfully added 
to the peptide-resin, the TFA will turn yellow and a gas will form.  
5. Deprotect the resin using a 2X20 min treatment with 20 (v/v)% piperidine in 
DMF with 0.1 M HOBt. If desired, perform a secondary amine test (protocol 
4.2) to establish a baseline for positive response. 
6. Couple Fmoc-Glu(OtBu)-OH to the peptide resin overnight using the 
DIC/Oxyma/DMF system. Check for complete coupling using the secondary 
amine test. Repeat coupling as necessary. 
7. Synthesize the rest of the peptide using standard protocols 
(HCTU/NMM/DMF), label and cleave as outlined above.  
Protocol 4.2 Secondary Amine Test 
Reagents 
2% acetaldehyde in DMF 
2% chloranil in DMF 
Protocol 
1. Isolate a few beads of resin using the open end of a Mel-Temp capillary. 
2. Transfer beads to a small test tube containing a 1:1 mixture of the chloranil 
and acetaldehyde solutions. 
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3. Allow to incubate 5 min at room temperature, then inspect the color of the 
beads. Dark blue or green beads indicate the presence of secondary amine. 
Colorless or yellow beads indicate no detected secondary amine. 
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Figure 32. Solid Phase Peptide Synthesis (SPPS) workflow 
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APPENDIX B. MATLAB CODE 
Collaboration with Dr. Ryan Phillips 
function[output] = msbatchp(mass_tol) 
  
% mode = input('MS mode positive or negative?'); 
if exist('mode')~= 1 
 mode = menu('Select MS Mode','Negative','Positive'); 
end 
  
% scaffoldin = input('What is the scaffold molecular weight in Da?')'; 
  
%If no mass tolerance is provided, ask for it. 
if nargin() == 0 
 mass_tol = input('Choose a mass tolerance in Da: '); 
 thresh_in = input('Choose a thresholding value (fraction max value):'); 
end 
  
%Select guide file and data directory 
[f,p] = uigetfile('.txt','Select guide file'); 
filename_guide = strcat(p,f); 
dir_data = uigetdir('c:\Documents and Settings\Abby Turner\My 
Documents\MATLAB\Data','Select data directory'); 
cd(dir_data); 
  
%Import guide spot names and MW info 
guide_raw = importdata(filename_guide); 
spotnames = guide_raw.textdata; 
guideMW = guide_raw.data; 
iscorrect = zeros(1,length(guideMW)); 
pct_yield = zeros(1,length(guideMW)); 
pct_phospho = zeros(1,length(guideMW)); 
  
for i = 1:length(guideMW) %opens a loop for opening and analyzing MASCOT 
files 
 searchterm = strcat('*_',spotnames{i},'_*'); %spot names corresponding to 
samples analyzed (MALDI plate location) 
 [n,~] = size(dir(searchterm)); %opens all files within designated 
directory that contain spot names (MASCOT files) 
 if n~=0 %creates file names and opens all files with appropriate format 
filename 
 data_filename_raw = dir(searchterm); 
 data_filename = data_filename_raw.name;  
 data_raw = importdata(data_filename,'\t',1); 
  
 %extracts columns of data for analysis 
 MW = data_raw.data(:,1); %MW column from MASCOT files 
 Intensity = data_raw.data(:,2); %Corresponding intensities for each MW 
 guideMW(i); %Pulls in guide MW (list of correct target MW per spot) 
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 threshold = thresh_in*(max(Intensity)); 
  
 if mode == 1 %Based on mode, chooses which will be prominent molecular 
ion. 
  MW_molecion(i) = guideMW(i)-1; 
  MW_adduct(i) = guideMW(i)-1; 
 elseif mode == 2 
  MW_molecion(i) = guideMW(i)+1; 
  MW_adduct(i) = guideMW(i); 
 end 
  
 Intensity = Intensity.*(Intensity>threshold); 
  
 %find any traces of correct target in sample 
 MWmask_MW = ((abs((MW)-MW_molecion(i)))<mass_tol); 
 MWmask_waterloss = (((abs((MW)-MW_molecion(i)-18)))<mass_tol); 
 MWmask_sodium = ((abs((MW)-(MW_adduct(i)+22.99)))<mass_tol); 
 MWmask_potassium = ((abs((MW)-(MW_adduct(i)+39.1)))<mass_tol); 
 MWmask = MWmask_MW|MWmask_waterloss|MWmask_sodium|MWmask_potassium; 
  
 %finds any traces of phospho target in sample 
 phosphomask_MW = ((abs((MW)-(MW_molecion(i)+80)))<mass_tol); 
 phosphomask_waterloss = ((abs((MW)-(MW_molecion(i)+80-18)))<mass_tol); 
 phosphomask_sodium = ((abs((MW)-(MW_adduct(i)+80+22.99)))<mass_tol); 
 phosphomask_potassium = ((abs((MW)-(MW_adduct(i)+80+39.1)))<mass_tol); 
 phosphomask = 
phosphomask_MW|phosphomask_waterloss|phosphomask_sodium|phosphomask_potass
ium; 
  
  
 %applies masks to data and sums results 
 maskedMW = MWmask.*MW; 
 maskedInt = MWmask.*Intensity; 
 phosphoInt = phosphomask.*Intensity; 
  
  
 if sum(maskedMW)>=1; 
  pct_yield(i) = sum(maskedInt)/sum(Intensity)*100; %returns percent yield 
  pct_phospho(i) = 
(sum(phosphoInt)/(sum(phosphoInt)+sum(maskedInt)))*100; %returns percent 
phosphorylation 
   
 else 
  pct_yield(i) = 0; 
   
 end 
  
 end 
end 
  
filename_export = strcat(input('Designate a filename for export: 
','s'),'.txt'); 
fid = fopen(filename_export,'w'); 
header = {'Spot' '%Yield' '%Phospho'}; 
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fprintf(fid,'%s\t',header{1,1:end-1}); 
fprintf(fid,'%s\r\n',header{1,end}); 
  
for i = 1:length(spotnames) 
 fprintf(fid,'%s\t',spotnames{i}); 
 % fprintf(fid,'%i\t',iscorrect(i)); 
 % fprintf(fid,'%i\t',pct_intensity(i)); 
 fprintf(fid,'%i\t',pct_yield(i)); 
 % fprintf(fid,'%i\r\n',pct_scaffold(i)); 
 fprintf(fid,'%i\r\n', pct_phospho(i)); 
end 
  
fclose(fid); 
  
  
end 
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APPENDIX C. CARBOXYLIC ACID LIBRARY 
 
Well 
# 
Cmpd 
# 
Chemical Name Chemical Structure 
CAS 
No. 
CAT 
No. 
FW 
Solubility 
(DMF) 
1 1-10H 
2-(4-chloro-3-
nitrobenzoyl)benzoic 
acid 
 
 
 
 
 
   
85-54-1   305.67 good 
2 1-11C 
3-Methylhippuric 
acid 
 
 
 
 
 
   
32,801-
4 
  193.2 excellent 
 188 
3 1-1H 
Trans-2,5-
Difluorocinnamic acid 
 
 
 
  
 
29,034-3   184.14 excellent 
4 5-8E 
2-Methyl-6-nitrobenzoic 
acid 
 
 
 
  
 
15,139-4   181.15 good 
5 1-4E 
(R)-(+)-2-Pyrrolidone-5-
carboxylic acid 
 
 
 
   
 
  42,261-4 129.12 good 
6 1-4F 
2,6-Difluorophenylacetic 
acid 
 
 
 
 
 
  26,448-2 172.13 good 
7 5-9A 
Benzotriazole-5-
carboxylic acid 
 
 
 
   
 
30,423-9   163.14 
poor 
(but 
went in) 
 189 
8 1-8C 
Trans-2-Chloro-6-fluro-
cinnamic acid 
 
 
 
  
 
41,945-1   200.6 excellent 
9 1-8D 
1-phenyl-5-propyl-1H-
pyrazole-4-carboxylic acid 
(Maybridge) 
 
 
 
  
 
116344-
17-3 
230 230.26636 good 
10 2-11D N-Acetyl-L-phenylalanine 
 
 
 
 
   
 
85,745-9   207.23 good 
11 2-1G 
5-Methoxy-1-indanone-3-
acetic acid 
 
 
 
 
 
   
24467-
92-3  
#255282-
1G 
  220.23 good 
12 2-3E 
(S)-(-)-2-Oxo-1,5-
imidazoli-
dinedicarboxylic acid 1-
benzyl ester 
 
 
 
 
 
   
59760-
01-9   
#392308-
1G 
264.24 good 
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13 2-3F (1-Naphthoxy)acetic acid 
 
 
 
   
 
2976-75-
2  
#255416-
1G 
  202.21 good 
14 2-4B 
7-Hydroxycoumarin-4-
acetic acid 
 
 
 
 
   
 
6950-82-
9 
#55157-
500MG 
  220.18 good 
15 2-5H 
3-Fluoro-4-hydroxy-
phenylacetic acid 
 
 
 
  
 
22,451-0   170.14 good 
16 2-7B 
N-(3,5)-Dinitrobenzoyl)-
DL-leucine 
 
 
 
 
 
74928-
54-4  
#251526-
1G 
325.28 good 
17 2-9D 
4,5-Dimethoxy-2-
nitrobenzoic acid 
 
 
 
  
 
4998-07-
6 
#329231-
1G 
  227.18 good 
 191 
18 2-9G 
2,2,3,3-tetramethyl-
cyclopropanecarboxylic 
acid 
 
 
 
   
 
30,156-6   142.2 excellent 
19 6-1D 6-phenoxynicotinic acid 
 
 
 
 
 
   
51362-
38-0 
CC19601-
DA 
Fisher 
215.21 good 
20 3-8B 
2,4-Difluorophenylacetic 
acid 
 
 
 
  
 
26,447-4   172.13 excellent 
21 4-10C 
3-Benzoyl-2-pyridine-
carboxylic acid 
 
 
 
  
 
64362-
32-9 
#422576 
  227.22 good 
22 4-10E 
3-Isoquinolinecarboxylic 
acid hydrate 
 
 
 
 
 
   
33,854-0   173.17 good 
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23 4-10F 
N-(3-Indolylacetyl)-L-
phenylalanine 
 
 
 
 
 
  
 
57105-
50-7  
#345954-
1G 
322.37 okay 
24 4-11B 
7-Methoxy-2-benzofuran-
carboxylic acid 
 
 
 
 
 
   
35,772-3   192.17 good 
25 4-11G Homovanillic acid 
 
 
 
  
 
14,364-2   182.18 good 
26 4-1H 
N,N-Diethyl-3,6-difluoro-
phthalamic acid 
 
 
 
 
   
 
131401-
56-4  
#378291-
1G 
257.24 okay 
27 6-4G 4-Ethoxyphenylacetic acid 
 
 
 
 
 
4919-33-
9 
A12811-2 180.2 excellent 
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28 4-3D 
(S)-(+)-α-Hydroxy-1,3-
dioxo-2-
isoindolinebutyric acid 
 
 
 
 
 
   
40,965-0   249.23 good 
29 4-4E N-Phenylanthranilic acid 
 
 
 
   
 
14,450-9   213.24 low 
30 5-11A 
Trans-1-Acetyl-4-
hydroxy-L-proline 
 
 
 
 
 
44,156-2   173.17 good 
31 5-11H 4-Acetylbenzoic acid 
 
 
 
   
  
17,745-8   164.16 okay 
32 5-1A 
2-(4-
Fluorophenoxy)nicotinic 
acid 
  
54629-
13-9 
  233.198823 good 
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33 5-2A 4-Isopropoxybenzoic acid 
 
 
 
 
 
36,638-2   180.2 good 
34 6-5G 
4-Morpholinomethyl 
benzoic acid 
 
 
 
 
 
   
89-86-1 
AD10940-
1 
221.26 good 
35 5-4A 5-Nitro-2-furoic acid 
 
 
 
 
 
   
15,571-3   157.08 good 
36 5-4B 
1-[5-(trifluoromethyl)-2-
pyridyl]piperidine-4-
carboxylic acid 
 
 
 
 
 
  
 
406476-
31-1 
  274.24 excellent 
37 5-5A 
4-(Diethylamino)benzoic 
acid 
 
 
 
  
 
23,735-3   193.25 excellent 
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38 5-5C 
2-Chloro-4-fluorobenzoic 
acid 
 
 
 
 
 
29,783-6   174.56 good 
39 5-6E 
2,5-Dimethoxybenzoic 
acid 
 
 
 
 
 
25,796-6   182.18 good 
40 5-8G 
Trans-3-(4-
Methylbenzoyl)-acrylic 
acid 
 
 
 
 
 
   
34,601-2   190.2 good 
41 6-11A a-Phenyl-o-toluic acid 
 
 
 
 
   
 
612-35-1 AP3665-7 212.25 excellent 
42 6-11H 
Trans-2,3-
Dimethoxycinnamic acid 
 
 
 
 
 
7345-82-
6 
A27548-4 208.21 good 
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43 6-1C 
3-(4-
Hydroxyphenyl)propionic 
acid 
 
 
 
 
 
501-97-3 
AH5240-
6 
166.18 okay 
44 6-4E 2-Biphenylcarboxylic acid 
 
 
 
 
 
947-84-2 AB3470-2 198.22 good 
45 6-4F 3,5-Dimethylbenzoic acid 
 
 
 
 
 
499-06-9 D149608 150.18 good 
46 6-5F 5-Phenylvaleric acid 
 
 
 
 
 
   
2270-20-
4 
AP3760-2 178.23 good 
47 7-2B 2-hydroxyhippuric acid 
 
 
 
   
 
487-54-7 A13406-6 195.17 excellent 
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48 6-7F 
4-Ethylbiphenyl-4'-
carboxylic acid (4(4-
Ethylphenyl)benzoic acid) 
 
 
 
 
 
   
5731-13-
5 
AC24048-
0050 
Acros 
226.48 good 
49 6-8F 4-Propoxybenzoic acid 
 
 
 
  
 
5438-19-
7 
A36639-0 180.2 excellent 
50 7-4F 
5-fluoroindole-2-
carboxylic acid 
 
 
 
 
 
   
399-76-8 A26512-8 179.45 good 
51 7-1E 2-Methylcinnamic acid 
 
 
 
 
 
   
2373-76-
4 
A43310-1 162.19 good 
52 7-2D 3-benzoylbenzoic acid 
 
 
 
 
 
579-18-0 A26179-3 226.23 excellent 
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53 7-2E Trans-3-Furanacrylic acid 
 
 
 
 
 
81311-
95-7 
A33638-6 138.12 excellent 
54 7-2G 
2,6-dimethoxynicotinic 
acid 
 
 
 
 
   
 
16727-
43-8 
A37271-4 183.16 good 
55 7-4E 
4-fluoro-3-nitrobenzoic 
acid 
 
 
 
  
 
453-71-4 A32904-5 185.11 good 
56 7-5G 
Carbobenzyloxy-l-
glutamine 
 
 
 
 
 
   
2650-64-
8 
A16264-7 280.28 good 
57 7-7G 
(2-pyrimidylthio)acetic 
acid 
 
 
 
 
 
   
88768-
45-0 
A27553-0 170.19 excellent 
 199 
58 8-1C 3-(2-Thienyl)acrylic acid 
 
 
 
 
 
  
 
15690-
25-2 
A13058-3 154.19 good 
59 8-1F 
3-Methyl-2-phenyvaleric 
acid 
 
 
 
  
 
7782-37-
8 
A24790-1 192.26 good 
60 8-4C 
N-p-Tosyl-L-
phenylalanine 
 
 
 
  
 
13505-
32-3 
A39384-3 319.38 excellent 
61 8-6C 
4-(3,4-Dimethoxyphenyl)-
butyric acid 
 
 
 
  
 
13575-
74-1 
A27395-3 224.26 good 
62 7-5A Dicyclohexylacetic acid 
  
 
  
52034-
92-1 
A33384-0 224.35 good 
 200 
63 1-1E 
Trans-2,6-
Difluorocinnamic acid 
 
 
 
     
  
 
  
   
 
29,035-1   184.14 excellent 
64 1-2B 
4-Nitro-3-
pyrazolecarboxylic acid 
 
 
 
 
 
41,484-0   157.09 okay 
65 1-3B 
3-Oxo-1-indancarboxylic 
acid 
 
 
 
   
 
41,077-2   176.17 excellent 
66 1-5H 4-Nitrohippuric acid 
 
 
 
 
 
  
 
23,343-9   224.17 okay 
67 1-7B 
2-Methoxy-4-nitrobenzoic 
acid 
 
 
 
 
 
42,291-6   197.15 good 
 201 
68 1-7C 
2-Bromo-4,5-
dimethoxybenzoic acid 
 
 
 
  
 
44,107-4   261.08 excellent 
69 2-10G Indole-3-carboxylic acid 
 
 
 
   
 
28,473-4   161.16 good 
70 2-11F N-Benzoyl-L-threonine 
 
 
 
   
 
27696-
01-1  
#281093-
1G 
  223.23 good 
71 2-2B 
3-(2-chlorophenyl)-5-
methylisoxazole-4-
carboxylic acid 
 
 
 
    
 
23598-
72-3 
  237.64 good 
72 2-3B 
2-Bromo-5-nitrobenzoic 
acid 
 
 
 
  
 
943-14-6  
#381845-
1G 
  246.02 okay 
 202 
73 2-5E 
3-
(Phenylsulfonyl)propionic 
acid 
 
 
 
 
 
   
25,157-7   214.24 okay 
74 2-9H 6-Methylnicotinic acid 
 
 
 
   
 
#284750-
1G 
  137.14 
poor 
(but 
went in) 
75 3-1C 
4-Hydroxyphenylpyruvic 
acid 
 
 
 
 
 
  
 
11,428-6   180.16 good 
76 3-3C 
5 phenyl-1-H-pyrazole-4-
carboxylic acid 
 
 
 
 
 
633747-
1g 
  188.18 okay 
77 7-5C 
A,a,a-Trifluoro-m-toluic 
acid 
 
 
 
  
 
454-92-2 A18834-4 190.12 good 
 203 
78 7-6E 
2-chloro-5-nitrocinnamic 
acid 
 
 
 
 
 
36015-
19-7 
A30065-9 227.61 excellent 
79 3-7E 
4-(Methylsulfonyl)benzoic 
acid 
 
 
 
 
 
   
13,641-7   200.21 okay 
80 3-8C 3-(p-Toyl)propionic acid 
 
 
 
  
 
11,826-5   164.2 good 
81 4-3B 
2,3,4-Trifluorocinnamic 
acid 
 
 
 
 
 
   
41,838-2   202.13 good 
82 4-4H 4-Fluorocinnamic acid 
 
 
 
 
 
   
459-32-5 
#222720-
1G 
  166.15 good 
 204 
83 4-6C 
2,3-dioxoindoline-7-
carboxylic acid 
 
 
 
 
 
25128-
35-2 
  191.14 
poor 
(but 
went in) 
84 8-1H 
2,4,5-Trimethoxybenzoic 
acid 
 
 
 
  
 
490-64-2 A13889-4 212.2 good 
85 8-4G 4-Pentyloxybenzoic acid 
 
 
 
   
 
15872-
41-0 
A20994-5 208.26 excellent 
86 5-10C 
5-methyl-3-
phenylisoxazole-4-
carboxylic acid 
 
 
 
 
 
   
1136-45-
4 
  203.19 excellent 
87 5-7A 2-Chlorophenylacetic acid 
 
 
 
 
 
19,063-2   170.6 good 
 205 
88 5-7F 2-Fluorophenylacetic acid 
 
 
 
  
 
20,894-9   154.14 excellent 
89 5-8A 
α-Methylhydrocinnamic 
acid 
 
 
 
 
 
39,152-2   164.2 
poor 
(but 
went in) 
90 5-8C 
N-Carbobenzyloxy-L-
isoleucine 
 
 
 
 
 
   
40,853-0   265.31 good 
 
